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Background: Hypertension is one of the most common diseases in the United Kingdom and 
it remains an important risk factor for cardiovascular morbidity and mortality. Dietary 
sodium is an important trigger for hypertension and humans show a heterogeneous blood 
pressure (BP) response to salt intake. The mechanisms for this have not been fully explained, 
with renal sodium handling thought to play a central role. Animal studies have shown that 
dietary salt loading results in Na
+ 
accumulation and lymphangiogenesis in skin mediated by 
vascular endothelial growth factor-C (VEGF-C), both attenuating the rise in BP. This 
represents an additional system for maintaining BP and volume homeostasis in response to 
salt load.  The focus of this thesis is to determine whether these dermal mechanisms exist in 
humans. 
Methods: The technique of measuring skin Na+ and K+ using inductively coupled plasma 
optical emission spectrometry was developed in a pilot study of healthy adults. In a further 
study in healthy adults, the effects of dietary salt modulation on skin Na
+
, the effect of sex 
and the relationship between skin Na
+ 
and haemodynamic parameters and plasma VEGF-C 
were studied. Skin Na
+




 to correct for 
variability in sample hydration. The effect of dietary salt intake on skin gene expression of 
factors that potentially influence BP such as VEGF-C and the hypoxia inducible factor (HIF) 
transcription system was assessed, exploring possible mechanisms linking skin Na
+ 
to 
haemodynamic variables.  
Results: Skin Na+:K+ increased with dietary salt loading and this effect appeared to be greater 




 correlated with 
blood pressure, stroke volume and peripheral vascular resistance in men, but not in women. 
No change was noted in plasma vascular endothelial growth factor-C.  
Conclusions: These findings suggest that the skin may buffer dietary Na+, reducing the 
hemodynamic consequences of increased salt and this may be influenced by sex. Skin Na
+
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Chapter 1     BACKGROUND 
 
1.1     HYPERTENSION 
Blood pressure is a quantitative phenotype with a continuous distribution in human 
populations. Hypertension is defined as systolic blood pressure 140 mmHg or diastolic 
blood pressure  90 mmHg, measured at the brachial artery. It is a common disorder, 
affecting a third of the human population, and its prevalence is increasing worldwide. 
1,2
 
Hypertension represents an important global health challenge, being considered one of the 
foremost modifiable risk factors for stroke, heart failure, ischaemic heart disease and 
chronic kidney disease. 
1,3,4
 Globally, the control of hypertension continues to be inadequate 
despite improved therapies and unhealthy lifestyle factors are thought to be a critical factor. 
5
  Furthermore, cardiovascular risk does not start at the conventional cut-off point 140/90 
mmHg but starts at a systolic blood pressure of 115 mmHg and a diastolic pressure of 75 
mmHg. 
6
 Therefore, understanding and addressing the factors that increase blood pressure 
has important health implications that extends beyond the scope of hypertension.  
1.1.1     Pathophysiology of hypertension 
 
Despite its prevalence, the precise origins of hypertension remain unclear. Hypertension is 
believed to be multifactorial with various pathophysiologic mechanisms. The maintenance of 
a normal blood pressure is dependent on the balance between the cardiac output and 
peripheral vascular resistance.
7
 Hypertension in believed to start with a raised cardiac 
output resulting from extracellular volume expansion, which transforms in time to a raised 
peripheral vascular resistance (PVR), this being determined by the number and contractile 
state of resistance vessels that are less than 150μm in diameter. 
8,9
Previous work suggests 
that there is structural remodelling of these vessels in hypertension, which results in a fixed, 
irreversible, increase in PVR. 
9
 There is also a reduction in the density of arterioles and 
capillaries in the skin and skeletal muscle, termed microvascular rarefaction, which 




Two main forms of hypertension exist. Secondary hypertension is defined as raised blood 
 17 
pressure resulting from a recognisable and potentially correctable cause while in primary or 
essential hypertension, no such cause is identified. In unselected populations, between 1 − 
5% of hypertensives have secondary hypertension, the principal forms of which are listed in 
Table 1. Notably, most of these conditions involve aberrations in body sodium regulation. 
The pathogenesis of essential hypertension remains elusive despite decades of extensive 
research efforts. It is believed to be a complex disorder reflecting interplay between genetic 
susceptibility and environmental triggers, and it is unclear which specific mechanisms are 
involved.  
  
Table 1.1: Causes of secondary hypertension. 12 Disorders in italics involve dysregulation of 
body sodium homeostasis. 
Renal  Endocrine  Drugs 
Renal artery stenosis 
Renal parenchymal 
disease 
Adult Polycystic Kidney 
disease  
Renal tumours 
Liddle’s syndrome  














Oral contraceptive in pill 
Nonsteroidal anti-inflammatory drugs 
Vascular endothelial growth factor 
inhibitors 
Monoamine oxidase inhibitors 
Heavy metals 
 
1.1.2    Central blood pressure and arterial stiffness  
 
Blood pressure measured at the brachial artery (peripheral blood pressure) has played a 
central role in our evaluation and management of cardiovascular disease, but in recent years 
greater emphasis has been placed on the importance of central or aortic blood pressure and 
arterial stiffening. Central blood pressure (CBP) refers to the pressure experienced by the 
large vessels and the heart and has been shown to be a better predictor of cardiovascular 
events than peripheral blood pressure. 
13-15
 This may be because the heart, kidneys and 
 18 
brain are exposed to aortic rather than brachial pressure. 
16
   
 
Stiffness refers to the ability to resist deformation. Arterial stiffness is associated with 
advancing age and is increasingly recognised as a surrogate endpoint for cardiovascular 
disease. 
17
 Stiffening in the large central arteries is positively associated with systolic 
hypertension, coronary artery disease, stroke, heart failure and atrial fibrillation. 
18-21
 Aortic 
stiffening generally results from a complex interplay between factors such as haemodynamic 
forces, calcification, salt intake, glycaemic state and the degeneration of elastin fibres with 
deposition of stiffer collagen. 
22,23
 The large arteries, such as the aorta, provide a conduit for 
circulating blood and buffer arterial pressure changes that occur during the cardiac cycle, 
enabling a constant blood flow to the peripheral vascular beds. During myocardial 
contraction a wave that travels through the aortic trunk and arterial tree is generated. The 
rate which this aortic pressure waves travel is the pulse wave velocity (PWV). Aortic pulse 
wave velocity (aPWV) as measured by carotid-femoral pulse wave velocity, is the gold 
standard measure of arterial stiffness. 
17
.  Carotid-femoral pulse wave velocity is known to 
be independent predictor of cardiovascular events and mortality in the general population. 
24
 An increase of aortic pulse wave velocity of 1 m/s confers an increased cardiovascular risk 
by more than 10%.
25
 The forward going aortic pulse wave gets reflected from the periphery 
and normally returns in diastole, augmenting or increasing systolic pressure in the central 
arteries and maintaining coronary blood flow. The augmentation index (AIx) is a measure of 
pulse wave reflection and quantifies the extent of augmented pressure relative to the 
central pressure. AIx has been shown to predict cardiovascular events in patients with 
hypertension and ischaemic heart disease, as well as all-cause mortality in patients with 
renal impairment. 
17
 CBP, aPWV and AIx can now be determined reliably using non-invasive 









1.2     ROLE OF SODIUM IN HYPERTENSION AND CARDIOVASCULAR DISEASE 
 
Sodium is an alkali metal which serves as an essential nutrient in all animals. It is the 
dominant ion of the extracellular fluid where it functions as an osmotic skeleton, 
maintaining extracellular volume and adequate tissue perfusion. Sodium maintains the 
normal transmembrane electrochemical gradient, transmission of nerve impulses and 
normal cell metabolism. 
26,27
 The terms sodium and salt are often used synonymously, with 
salt comprising of 40% sodium 60% chloride by weight. Over 90% of dietary sodium is 
consumed as salt.  
For the purpose of this thesis: 
Salt refers to sodium chloride 
Na+ refers to both ionised or non-osmotically bound sodium  
Dietary sodium is consumed as salt  
1 mmol sodium = 23 mg sodium 
1 gram of sodium chloride (salt) = 390mg (17 mmol) of sodium 
6 grams of sodium chloride (salt) = 2.3g (100mmol) of sodium  
Excessive dietary sodium, principally as the chloride salt, has long been considered a pivotal 
factor in development of hypertension. 
28
 The average daily sodium intake worldwide in 
2010 estimated at 3.95 g per day, exceeding the maximum UK recommended intake of 2.3 g 
per day. 
29,30
 Essential hypertension is virtually absent in populations with a sodium intake of 
less than 1.2 g per day and tends to occur in populations consuming more than 2.3 g of 
sodium a day, suggesting that the development of hypertension requires a threshold level of 
sodium intake. 
31
  The first scientific report describing a direct relationship between sodium 
intake and hypertension is credited to Dr Lewis Dahl, who showed that mean salt intake 
correlates with the prevalence of hypertension. 
32,33
 Subsequently, numerous 
epidemiological and interventional studies have demonstrated a positive relationship 
between salt intake and blood pressure. The International Study of Salt and BP (INTERSALT) 
study showed that an increase in daily sodium intake of 50 mmol resulted in an increase in 
systolic BP of 5 mmHg over a 30-year period, after adjusting for potentially confounding 
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variables such as BMI and alcohol intake. 
34
 The DASH (Dietary Approaches to Stop 
Hypertension – Sodium) trial showed that a reduction in salt intake resulted in a stepwise 
decrease in BP and this was more pronounced in individuals of African origin, older 
participants and those with hypertension. 
35
 The PURE study, which included 102,216 adults 
from 18 countries, showed increments of 2.11 mmHg in SBP and 0.78 mmHg in DBP for each 
1 g increment in estimated sodium intake. 
36
 
Dietary sodium reduction should theoretically reduce cardiovascular disease by lowering 
blood pressure and this has formed the basis for population wide sodium reduction as a 
means to reduce cardiovascular disease. 
37
 Interventional trials proving this are lacking, but 
observational data from the Trials of Hypertension Prevention (TOHP), which consisted of 
2974 healthy, normotensive individuals, showed a direct linear association between sodium 
intake and cardiovascular events as well as all-cause mortality over a 20 year period. 
38,39
 
Thus, the evidence for reducing population salt intake is strong. Approximately 80% of salt 
consumed is processed and obtained from outside the home and keeping salt intake below 
the recommended targets is challenging. 
28
 The World Health Organisation has proposed salt 
reduction as the key dietary target for 2025 to reduce mortality from cardiovascular disease, 
the main non-communicable diseases. 
40
 The UK salt reduction strategy started in 2003 and 
since then national adult daily sodium intake has fallen from 3.7g in 2001 to 2.9 g in 2014, 













1.2.1       Salt sensitivity of blood pressure  
 
Salt sensitivity of blood pressure (SSBP) is a physiological trait in mammals, including 
humans, by which blood pressure exhibits changes parallel to changes in salt intake. 
42
 
Although most populations, including the UK, have sodium intakes exceeding 2.3 g a day 
most people remain normotensive, suggesting that some individuals are more sensitive to 
salt than others. Acute and chronic salt loading and depletion experiments support this view. 
43,44
 This apparent heterogeneity in blood pressure response to salt has caused controversy 
regarding recommendations to reduce salt intake in the general population. 
42,45
  
SSBP has significant prognostic and therapeutic implications. Weinberger et al showed that 
normotensive individuals who are salt sensitive had a significantly greater increase in systolic 
and diastolic pressure over time than those who were salt resistant, and are more likely to 
develop hypertension in the future. 
46
 This suggests a possible pathophysiological 
connection between SSBP and the development of essential hypertension. SSBP is 
associated with endothelial dysfunction and has been shown to be an independent risk 
factor for left ventricular hypertrophy, renal impairment and cardiovascular events. 
47-49
 SSBP 
is also independently associated with mortality in both normotensive and hypertensive 
individuals. 
50
 Furthermore, women with a history of pre-eclampsia have a tendency for salt-
sensitivity before menopause, which may contribute to their excess cardiovascular risk.
51
 
Thus, it can be seen that the salt sensitivity trait has clinical relevance and implications that 
extends beyond BP. 
1.2.1.1       Determination of salt sensitivity - its challenges and clinical application 
 
The assessment of salt sensitivity of blood pressure is difficult because of the lack of 
universal consensus on definition. 
42
 A large number other studies have been done using a 
variety of dietary approaches, thresholds and measures of BP for defining salt sensitivity. 
42,52
 In these methods of assessment, individual displaying a significant BP response to 
dietary sodium modulation were termed salt sensitive (SS), all those that do not classified as 
salt resistant. (SR). 




 Weinberger et al defined SSBP as a ≥ 10 mmHg increase in mean arterial pressure 
(MAP) after an infusion of 2 L of normal saline over 4 hours, relative to MAP after 1 day of a 
low sodium (10 mmol) diet and administration of frusemide. 
50
 Using this technique in 378 
healthy volunteers, Weinberger et al showed that 26% of normotensive individuals are salt 
sensitive. 
43
 In a study of 198 hypertensives, they showed 73% of blacks were salt sensitive 
compared with 56% of whites 
43
. Factors associated with SSBP include hypertension, 
diabetes mellitus, black race, intrinsic kidney disease and older age. 
54
 Thus the SSBP 
phenotype may be present in a significant proportion of the human population and racial 
variations exist. Recently, ambulatory BP has been used where an increase in 24-hr MAP of ≥ 
4 mmHg with increased salt intake has been introduced as an alternative definition.
55,56
  




There are several limitations for the above definitions and techniques for salt sensitivity. 
Determining salt sensitivity by salt loading and depletion is impractical in routine clinical 
practice, compromising its clinical utility. Although individuals are commonly dichotomised 
as SS or SR, BP responses to sodium manipulation follow a Gaussian distribution and SSBP is 
a continuous, normally distributed quantitative trait. 
43,58
 Defining an individual as SS or SR 
depends on the arbitrarily chosen thresholds for the magnitude of BP changes. Furthermore, 
short term salt loading and depletion studies (days to weeks) may not reflect the long-term 
effects of a particular level of dietary salt intake. The sequence of sodium intake has also 
been a source of controversy. Subjecting individuals to a low sodium intake is believed to 
result in variable degrees of renin-angiotensin-aldosterone system activation. Therefore, 




Salt sensitivity of blood pressure describes a clinical phenotype with a significant prognosis 
for cardiovascular health. Theoretically, reducing salt intake would be more important in salt 
sensitive than for salt resistant water individuals, not only for its benefits for BP control, but 
also for the additional effects on cardiovascular risk. 
42
 An understanding of the underlying 
mechanisms for differential BP response to a salt load and reliable biomarkers for the SSBP 
phenotype are currently lacking. Trials evaluating the relative efficacy of antihypertensives in 
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salt sensitive hypertensives are also inadequate. Thus, SSBP may be relevant, but its clinical 
applications are still uncertain. 
1.2.2     How sodium modulates blood pressure 
 
1.2.2.1     Traditional paradigms - the two-compartment model for body water and sodium 
 
Total body water (TBW) has traditionally been divided into two compartments, intracellular 
fluid (ICF) and extracellular fluid (ECF), with the latter consisting of the intravascular and 
interstitial spaces. Total body sodium (TBNa) has been divided similarly. The interstitium is 
the space located between the capillary walls and cells, being further subdivided according 
to body site and tissue type(see Figure 1.1). 
59,60
 The intravascular and interstitial spaces are 
considered to be in a state of equilibrium, in which fluids with nearly constant osmolyte 
concentrations surround the body cells. This conventional model, the ‘equilibrium theory’, 
derives from Claude Bernard’s 19
th
 century paradigm of a “milieu interieur”, which 
introduced the physiological concept of homeostasis. 
61,62
 In the two-compartment model, 
sodium ions act as the principal extracellular osmoles, holding water in the extracellular 
space. 
63
 Conversely potassium ions retain water within cells with this balance being 




- ATPase pump in the cell membrane. In this model, sodium 
accumulation is primarily extracellular and inevitably leads to commensurate water 
retention, such that accumulation of 140 mmol of sodium must inevitably lead 1 litre of 
water in the extracellular fluid, thus maintaining iso-osmolality. 
63,64
 Extracellular sodium 
content is maintained within narrow limits to prevent perturbations in fluid balance, and 
multiple physiological systems operate to maintain extracellular sodium levels. 
63
 
The mechanisms by which sodium influences blood pressure are not fully understood. In the 
classical Guytonian model, increased salt intake leads to a corresponding expansion in 
extracellular volume. This leads to an increase in plasma volume, venous return and cardiac 
output, which is turn causes a rise in systemic blood pressure. 
65
 This increase in 
extracellular volume can be counterbalanced by pressure natriuresis carried out by the 
kidneys. 
66
 The kidney is therefore believed to be the main organ regulating the 
haemodynamic response to salt intake. 
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Figure 1.1: Body fluid compartments. In the average male, intracellular fluid and 
extracellular fluid domains consist of about 57% and 43% of total body water respectively. 
The ECF compartment is further subdivided into interstitial fluid, lymph, plasma, bone and 
connective tissue, adipose tissue, and transcellular water. Percentages are percent of TBW. 
Taken from Bave et al. 60 
 
















1.2.2.2     The role of the kidney in salt sensitivity 
 
The kidney has traditionally been considered to be at the centre of BP control, with blunted 
renal sodium excretion thought to result in a rise in BP via an increase in extracellular 
volume (Figure 1.2).  This is supported by physiological and genetic observations. 
67,68
 
Systemic blood pressure determines renal perfusion, which can directly regulate sodium 
reabsorption in the proximal tubule. In the Guytonian model, this acute pressure natriuresis 
response is a uniquely powerful means of BP around a set point (Figure 1.2).This implies that 
a mismatch between renal perfusion pressure and sodium excretion could cause BP to rise in 
the face of dietary salt intake. 
69
 Renal sodium absorption per se is increased in hypertensive 
individuals and differs across ethnic groups. It is likely that genetic polymorphisms 
contribute to this phenomenon via effects on sodium transporters in the kidney, NKCC2 and 
ENaC, and regulatory molecules of the renin-angiotensin aldosterone system. 
70-72
 Further 
compelling evidence for the central role of the kidney in hypertension comes from cross 
transplantation studies between normotensive and hypertensive rat strains showing how 
normotensive recipients develop hypertension after receiving kidneys from hypertensive 
donors. 
73
 Thus, a wealth of evidence supports the traditional nephrocentric view of 
hypertension and salt sensitivity in humans. Despite this, specific renal mechanisms in the 
















Figure 1.2: The nephrocentric model of salt sensitivity. Renal responses to salt loading in salt 
resistant (dotted red line) and salt sensitive (green line) individuals. The traditionally held view is 
that renal sodium excretion rises rapidly and to match an increase in sodium intake, so that BP 
changes only minimally. In salt sensitive individuals is believed that renal sodium excretion is 
impaired, resulting in an increase in extracellular fluid volume and blood pressure. (Taken from 




1.2.2.3     Other mediators of salt sensitivity 
 
Several natriuretic and anti-natriuretic neuro-hormonal systems have been implicated in salt 
sensitivity. 
 
The renin-angiotensin-aldosterone system (RAAS): The RAAS is the principal volume-
regulatory effector in mammals and a major regulator of blood pressure within the human 
body. 
76
It is sensitive to changes in salt intake. 
77
 Short-term salt loading and depletion 
studies by Macgregor and Weinberger showed that individuals who are salt sensitive display 
a blunted renin, aldosterone and angiotensin-2 response to salt depletion. 
78,79
 This is 
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believed to be due to the excessive BP response to salt loading, as preventing the expected 
decrease in aldosterone and angiotensin-2 that accompanies salt loading prevents the 
expected natriuresis. 
80
 Thus, the blunted RAAS system is a phenotypic characteristic of SSBP. 
 
The sympathetic nervous system: Studies in rats and humans have shown that the pressor 
response to salt is associated with increased plasma and urine catecholamine levels. 
81
 In 
hypertensive humans plasma catecholamines decrease more in those who are salt resistant 
compared to those who are salt sensitive, and this is likely to contribute to the difference in 
haemodynamic response. 
82-84
 Salt sensitive hypertensive humans are also known to have a 
greater pressor response to exogenous norepinephrine than salt resistant hypertensives, 




Atrial natriuretic peptides (ANPs): These are peptide hormones that are synthesised, stored 
and released by atrial myocytes in response to atrial distension, angiotensin 2, endothelin 
and sympathetic stimulation. The salt sensitive sub-strain of spontaneously hypertensive rats 
(SHR) fail to respond to volume expansion during salt loading with an increase in ANP, 
compared with salt resistant SHR controls. 
86
 Low levels of circulating N-terminal ANP have 
been shown to predict SSBP in the Framingham Offspring cohort. 
87
 However, the opposite 
has also been observed. 
88
 The available evidence suggests that ANP may play a pathogenic 
role in some cases of SSBP.   
 
The endothelin system: Endothelins are vasoactive peptides that are known to modulate  
vascular function, fluid-electrolyte homeostasis, cardiac function, and neuronal function. 
89
 
Urinary endothelin displays a circadian rhythm and correlates negatively with BP and 
positively with Na
+ 
excretion during salt loading. Humans with SSBP have low levels of 





Nitric oxide (NO): Dietary salt loading increases the excretion of NO metabolites in salt 
resistant individuals while the opposite is seen in humans who are salt sensitive. It is 
believed that an endogenous inhibitor of NO may play a role in SSBP. 
91
 Differences in NO 
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production may exist in salt sensitive and salt resistant individuals. Black SS appear to have a 
greater BP reduction with intravenous L-arginine compared to SR controls. This  apparent 
deficit in NO production by those with the SSBP triggered may explain their endothelial 





1.2.2.4     Genetics of salt sensitivity in humans  
 
Several lines of evidence support a genetic basis for SSBP. BP changes with dietary salt 
modulation has been found to have a higher correlation between monozygotic twins 
compared with sibling pairs.
92
 Investigators in the GenSalt study, a dietary salt modulation 
population study in 1906 rural Chinese, observed that 22-33% of the BP changes occurring in 
response to a change in response salt intake could be attributed to genetic effects. 
93
 The 
higher prevalence of SSBP in people of blacks compared with Caucasians suggests a genetic 
influence on this trait. It has been postulated that people of African origin evolved in an 
environment low in sodium and genetic mechanisms aimed at retaining sodium evolved. 
94
 
However, the exact genetic factors contributing to salt sensitivity in blacks is still unclear.  
Studies searching for candidate genes for SSBP have focussed on traditional pathways 
believed to mediate SSBP, as described in 1.2.2.1 - 1.2.2.3. These include genes for 
angiotensin converting enzyme (ACE), angiotensinogen (AGT), angiotensin II type 1 receptor, 
epithelial sodium channel (ENaC) , 11-beta hydroxy steroid dehydrogenase (11-BHSD), alpha 
and beta adrenoceptors, endothelial nitric oxide synthase and adducin. 
95
 These studies have 
shown association between these candidate genes and the SSBP trait, but have been 
plagued by several methodological challenges such as study size and lack of replication 
across multiple studies. 
42
   
Mendelian syndromes of hypertension have been considered important for the 
understanding the genetic basis for SSBP and essential hypertension. 
96
 In keeping with the 
nephrocentric model SSBP, mendelian hypertension results from mutations leading to 
sodium retention while mendelian hypotension results from mutations causing renal sodium 
loss. 
42
 Mutations in the aldosterone synthase/11β-hydroxysteroid dehydrogenase, 




. However, these syndromes are rare, accounting for less 
than 1% of the prevalence of essential hypertension, and their relationship to salt sensitivity 
in the general population is still unclear. Furthermore, individuals with these mutations were 
not formally assessed for the SSBP trait. 
75
  
More recently genome wide association studies (GWAS) have been used to identify single-
nucleotide polymorphisms associated with SSBP.  These have identified genes that influence 
BP variability but, to date, statistically significant associations have yet to be found and 
confirmed that meet genome-wide significance thresholds. 
42,98
 In summary, SSBP appears 
to be an inherited trait but our knowledge of genetic mechanisms for the general population 
remains incomplete.  
1.2.2.5     Relevance of other ions   
 
In addition to sodium, dietary chloride also appears to play an important role in the 
pathogenesis of primary hypertension. 
99
 The concentrations of sodium (135 – 145 mmol/l) 
and chloride (95 – 106 mmol/l) are predominant in the serum and are the main constituents 
of serum osmolarity. The chloride component of salt may determine the volume expansion 
leading to the rise in BP; neither of these findings is seen if sodium is given with another 
anion, such as citrate, or chloride with another cation such as ammonium. 
100,101
 The reasons 
for these observations are not clear, though most of our dietary salt intake comes in the 
form of sodium chloride. A growing body of evidence supports the relative importance of 
transmembrane Cl
-
 fluxes via chloride channels in the maintenance of cell volume, 




Potassium intake is also known to be a factor in hypertension associated with salt intake, 
with previous evidence suggesting that dietary potassium modulates salt sensitivity. 
104
. 
Possible mechanisms include potassium-induced effects on vascular tone and renal sodium 
retention. 
31
 Population studies have shown an inverse relationship between dietary 
potassium and blood pressure. 
31
 In addition to the adverse effects of low dietary potassium 
intake, the ratio of dietary sodium–to-potassium intake based on urine sodium-to-potassium 
ratio can also independently influence blood pressure. 
105
 A higher sodium-to-potassium 




mechanisms for these observations are unclear and could be related to the influence of 
dietary potassium on renal sodium reabsorption. 
105
   
 
 
1.2.3     Novel paradigms 
 
1.2.3.1     Rethinking the mechanisms for salt sensitivity 
 
In the classical model a defect in renal sodium excretion is the basis for salt sensitivity, and 
humans who are salt-resistant are protected from salt-induced BP rises because they can 
rapidly excrete a salt load without retaining sodium. 
107
 Several studies in animals and 
humans oppose this view. Short term salt loading studies have shown that the amount of 
body sodium retained by healthy salt-resistant rats and humans is comparable, or in fact 
higher, than those who are salt-sensitive normotensives of hypertensives (Figure 1.3). 
108-115
 
In salt loading experiments in lasting 4 weeks, Titze et al showed that salt resistant rats 
accumulated greater levels of total body sodium than salt sensitive rats, without showing 
the same rise in BP 
116
 In a short-term salt loading experiment in healthy normotensive 
humans in a metabolic ward, Heer et al observed the retention of very large amounts of 
body sodium (1704 ± 309.8 mmol) without a significant increase in BP. 
117
 Thus, salt resistant 
individuals undergo sodium retention without a BP rise during acute salt loading. These 
observations oppose the view that salt-sensitivity is simply due to a deficit in renal excretion 
of excess sodium.  
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Figure 1.3: Results of salt loading studies in normotensive African-Americans. Schmidlin et al 
measured cumulative sodium retention and mean arterial pressure before and after increasing 
dietary sodium intake from 30 mmol to 250 mmol per day. Salt-resistant and salt-sensitive subjects 
have comparable degrees of sodium accumulation despite having different haemodynamic 
responses. (Taken from Schmidlin et al. 111) 
 
 
Contrary to the traditionally held view, salt-resistant subjects experienced substantial 
increases in blood volume with short-term salt loading (days to weeks).  
110,111,117,118
 In 
healthy normotensive subjects acute salt loading results in increases in blood volume, stroke 
volume and cardiac output that is comparable to salt-sensitive subjects, even though salt 
resistant subjects do not have an increase in blood pressure. 
110,111,119-121
 Studies in heathy 
and hypertensive humans revealed that salt-resistant subjects compensate for the increase 
in cardiac output during salt loading via concomitant vasodilation and decrease in peripheral 
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vascular resistance (PVR) 
111,118,121,122
 The mechanisms for this are unclear. 
 
These findings contradict the view that increasing salt intake in salt-resistant individuals does 
not increase BP because they are able to rapidly excrete excess sodium and avoid expansion 
of blood volume. Instead, salt-resistance may be explained by the ability to respond to a salt 
load with compensatory vasodilation.
75
 This raises questions regarding pathophysiology of 
salt sensitivity the possibility of alternative mechanisms that underlie the normal response 
to salt intake.  
 
 
1.2.3.2     A `three-compartment model’ of body sodium 
 
As described in 1.2.2.1, in the classical paradigm an increase in salt intake leads to increased 
sodium accumulation in the extracellular space with a corresponding increase in 
extracellular volume. However, more long term studies looking at sodium balance in humans 
have shown that large amounts of sodium can accumulate without being paralleled by 
commensurate water retention, termed non-osmotic water retention. 
117,123-125
 Under close 
monitoring, the excretion of sodium via urine, stool and sweat did not match the amount of 
sodium ingested. 
117,123
 Recently the Mars 500 study, a long-term study that simulated a 
space flight to Mars in healthy males, investigated sodium metabolism at constant salt intake 
under controlled conditions for 105 and 250 days. 
125
 This study showed that sodium is 
rhythmically stored and released completely independent from salt intake. At a constant salt 
intake, a circaseptan variability in sodium excretion was observed. There was considerable 
variability in day-to-day 24-hr sodium excretion with fluctuations in aldosterone, cortisol, 
and cortisone with a periodicity of 1 week. It was observed that BP, body weight and 
extracellular water were not coupled to urine sodium excretion as expected, and the 
rhythmical accumulation and release of total body sodium was independent of salt intake 
(Fig 1.4). 
125







Figure 1.4: Observations from the Mars 105 and 250 long-term studies in sodium metabolism. (A) 
Changes in systolic blood pressure (SBP) and urinary aldosterone, cortisol, cortisone, and 
cortisol/cortisone excretion at varying levels of sodium intake. (B)In the longer study, subjects 
were re-exposed to a high salt intake of 12 g per day salt for consecutive weeks after being on 6 g 
per day. SBP increased. Body weight increased initially before during the transition but then 
returned to baseline. Extracellular water (measured using impedance) increased and then 
decreased. Aldosterone excretion had an expected sustained decrease while total body sodium 




These observations supporting the existence non-osmotic storage of excess sodium (sodium 
accumulation without commensurate water retention) in an additional third compartment. 
Several lines of evidence suggest this additional compartment is the interstitium. In 
cartilage, chondrocytes are known to be subjected to relatively higher sodium 
concentrations of 250 - 350 mmol/l, which is much higher than the mean serum sodium 
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concentration of 140 mmol/l, suggesting that extracellular sodium concentration is not 
uniform and may reach high levels in the interstitium. 
126,127









radioisotopes and deuterium into human tissues, showed 





 This would suggest that the interstitium can accumulate excess sodium 
in the face of positive sodium balance without equilibrating with extracellular fluid or 
plasma. 
  
In 1909, Wahlgren measured the chloride content of skin, intestine, liver, muscle, lungs, 
skeletal bone, brain and blood in salt-loaded dogs. He observed that one-third of total body 
chloride was stored in the skin but could not measure sodium. 
129
 This led Cannon to 
suggest, in 1929, that the skin and connective tissues could serve as a reservoir for sodium 
chloride during times of dietary excess. 
61
 Subsequent salt loading experiments in rats have 
supported this view, showing skin sodium concentrations can rise to 180 - 190 mmol/l 
without the expected rise in skin water content, indicating water-free sodium retention and 
hypertonicity. 
130
 These studies revealed that glycosaminoglycan polymerisation enables 
osmotically inactive sodium storage in the skin, serving as an important mechanism for 
buffering volume and blood pressure changes with salt intake. 
130-134
 Titze et al found that 
osmotically inactive sodium storage in salt resistant rats was three-fold higher than in salt 
sensitive rats, as determined by the relationship between body sodium and body water. 
116
They concluded that salt sensitivity is associated with a reduced capacity for osmotically-
inactive sodium storage and that such sodium storage serves as an important mechanism for 
buffering volume and blood pressure changes with salt intake.  
In summary, this novel evidence opposes the traditional views that salt intake leads to a 
corresponding expansion in extracellular volume, extracellular sodium is tightly regulated 
and that intravascular and interstitial sodium are a state of equilibrium. It can be seen that 
the interstitium, particularly the skin, functions as a reservoir for sodium and constitutes a 
local hypertonic environment which is not readily equilibrated with plasma. Sodium 
accumulation in the interstitial space may have implications for salt sensitivity.  
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1.2.3.3     The role of glycosaminoglycans in sodium homeostasis 
 
The interstitium consists of a framework of fibres of which collagen is predominant, a gel 
phase of glycosaminoglycans and a solution of electrolytes and proteins. The relative 
composition of these constituents varies considerably between tissues. 
135
 
Glycosaminoglycans (GAGs) are unbranched polyanionic polysaccharide chains of variable 
length consisting of repeating disaccharide units. 
136,137
 There are five types identified: 
hyaluronan, chondroitin sulphate, dermatan sulphate, heparan sulphate and keratan 
sulphate. With the exception of hyaluronan, all GAGs are covalently bound to core protein 
backbones, forming proteoglycans (Fig 1.5). 
138
 GAGs are highly negatively charged at 
physiological pH because of their carboxyl and sulphate groups. 
139
 The cation binding 
capacity of GAGs is mainly dependent on the degree of sulfatation and the resulting osmotic 
pressure contributes to the hydration of the interstitium. 
135,140
 GAGs may also play an 
important role in enabling osmotically inactive skin Na
+
 
in the interstitium and sodium 
homeostasis.   
 
Farber was the first to propose sodium binds to GAGs , describing how chondroitin sulphate 





Ivanova et al first described this process occurring in the skin, observing an increase in skin 
Na
+
 and sulphated GAGs in salt loaded albino Wister rats. 
131
 More recently, Titze et al found 
that skin Na
+
 concentration in rat skin increased from 152mmol/l to 180 mmol/l with 8 
weeks of salt loading, with parallel increase in GAG content. 
130
 Conversely, they found that a 
low salt diet resulted in lower skin Na
+





 Dietary salt intake is therefore directly linked to polymerization and 
sulfatation of glycosaminoglycans in the interstitium, providing an additional storage 
capacity for sodium. Recently, Fischereder et al showed that skin GAGs content correlated 
with Na
+
 concentration in renal transplant donors and recipients, suggesting that skin Na
+ 




There are several limitations of the above studies. They quantified GAGs using gene 
expression of enzymes involved in GAG chain elongation such as chondroitin synthase and 
xylosyltransferase, due to the technical challenges of analysing GAGs. 
130,142,143
 It is believed 
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that sodium is bound to GAGs without being osmotically active through their high negative 
charge density, but this remains to be proven. 
130
 The exact nature of GAG-Na
+ 
interactions 
are unclear - this is believed to be electrostatic such that and GAGs and Na
+
 are in a state of 
incomplete ionisation. 
141,144
 Nevertheless, GAGs appear to mediate an important 




Figure 1.5: An illustration of proteoglycans and glycosaminoglycans. Proteoglycans are the major 
structural components of the interstitium and they consist of multiple glycosaminoglycans (GAGs) 
attached to a linking protein. GAGs have fixed negative charges in the form of carboxyl (COO−) and 
sulfate (SO3−) groups. The polyanionic nature of the GAG network forms the basis for electrostatic 











1.2.3.4     Tissue macrophages influence sodium balance, interstitial volume and blood 
pressure 
 
In recent years it has become apparent that cells of the innate and adaptive immune system 
play a role in hypertension and cardiovascular disease. 
146
 Macrophages, together with 
dendritic cells, monocytes and bone marrow precursor cells form the mononuclear 
phagocytotic system and are present in every peripheral tissue of the body. 
147
 Macrophages 
serve diverse and essential functions in development, homeostasis, tissue repair and 
immunity. 
148
 Macrophages appear to recognize NaCl-induced hypertonicity as a chemotactic 
stimulus and migrate in the direction of high salt concentration. 
149
 Macrophage 
transcriptional and translational expression profiles are influenced transcriptional by 




Recently, further work in rat skin by Jen Titze’s group showed that macrophages mediate an 
additional adaptive mechanism that functions during periods of high salt intake (Figure 1.6). 
133,134
 In their rat model high salt intake increased skin Na
+
 concentration and the resultant 
hypertonicity caused recruitment of macrophages, which activated tonicity-responsive 
enhancer binding protein (TonEBP). TonEBP binds to the vascular endothelial growth factor C 
(VEGF-C) gene and increases its expression. By mediating VEGF-C, the macrophage response 
restructured the interstitial lymphatic network which enabled drainage of water and 
electrolytes into the systemic circulation. VEGF-C also and induced expression of endothelial 
nitric oxide synthase (eNOS) which causes vasodilation via nitric oxide (NO) production. 
These processes appeared to buffer the haemodynamic response to salt loading. 
133
 VEGF-C 
inhibition using soluble VEGFR3 and macrophage-inhibition using clodronate liposomes 
resulted increased in skin electrolyte and water content, decreased eNOS expression and 
elevated MAP in response to a high salt diet. 
133
 More recent work in mice has also 
confirmed that antagonism of VEGF-C and TonEBP via genetic deletion results a greater rise 
in MAP with salt loading, correlating with the rise in Cl
-
 but not Na
+  152
. This may suggest a 
central role for Cl
-
 in salt-sensitive hypertension that has yet to be elucidated.  
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Figure 1.6: A novel extra-renal mechanism for buffering dietary salt. Under normal conditions Na+ 
binds to negatively charged GAGs in the dermal interstitium, without commensurate water, 
allowing high concentrations of Na+ to accumulate in the skin. During salt loading, the Na+ binding 
capacity of GAGs is exceeded and interstitial hypertonicity develops, leading to an influx of 
macrophages, which release an osmosensitive transcription factor (TonEBP). This induces the 
secretion of VEGF-C in an autocrine manner, leading to lymphangiogenesis. The enhanced 
lymphatic network increases Na+ transport back into the circulation, for eventual removal by the 
kidneys, preventing a blood pressure rise with salt loading (Image Adapted from Marvar et al 
courtesy of Gökçen Ackali)153. 
 
In summary, macrophages exert a homeostatic function in the skin via TonEBP and VEGF-C, 
regulating clearance of osmotically inactive stored salt via cutaneous lymphatic vessels. The 
interstitium, including the lymphatics, acts as a third separate and locally regulated 
compartment. This appears to constitute an extra-renal mechanism controlling blood 
pressure during high salt intake, mediating a vasodilatory response. Incorporating this model 
into the traditional paradigm of sodium homeostasis, the skin may act as a buffer as well as 
a reservoir for sodium, while the kidney controls sodium excretion and reabsorption, 
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controlling serum osmolality and total body water. It is conceivable that people predisposed 
to salt-sensitive hypertension have defects in the pathway described above and these 
individuals are less effective at buffering the increase in volume resulting from salt intake, 
resulting in a rise in BP. Future challenges include ascertaining how different 
antihypertensive agents affect the distribution of sodium and water between the 
subcutaneous lymphatic system and the intravascular space and how this system interacts 
with other organs that modulate BP like the kidney and brain. 
 
 
1.2.3.4.1     VEGF-C and its role in BP control 
 
Vascular endothelial growth factor (VEGF) was initially discovered as a tumour-derived 





members of the VEGF family have been identified so far (Figure 1.7). The effects of VEGF are 
mediated by tyrosine kinase receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-2 is 
expressed on endothelial cells and activation by VEGF stimulates to release NO release by 
endothelial cells. VEGFR-3 is expressed on lymphatic vessels and mediates 
lymphangiogenesis in response to VEGF-C and VEGF-D
154,155
 The activation of VEGFR-1 and 
VEGFR-2 receptors by VEGF C this may be relevant to sodium homeostasis and BP regulation, 
as discussed previously.  
Figure 1.7: The different types of VEGF and VEGF-receptors in humans. 
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Evidence for a role for VEGF in BP control in humans comes from the use of VEGF inhibitors 
in the treatment of various malignancies. 
156
 Bevacizumab is a recombinant humanized 
monoclonal antibody that binds to circulating VEGF-A and prevents its association with 
endothelial receptors. 
155
 It was the first FDA-approved VEGF pathway inhibitor intended for 
systemic use in various cancer types, including breast, colorectal, renal, and lung cancer. 
Hypertension and proteinuria were described as side-effects in up to 36% of patients and 
this was attributed to endothelial dysfunction and podocyte dysregulation, via its 
interactions with VEGFR-2 receptors. 
157
  A recent study in rats using sunitinib, a multi-
targeted tyrosine kinase receptor inhibitor which would affect VEGF-A and VEGF-C, showed 
that sunitinib caused a rise in BP that was exacerbated by a high salt diet. In this study 
macrophage infiltration  and lymphangiogenesis  was increased by high salt intake  but the 
lymphangiogenesis was not significantly impaired by sunitinib,  suggesting that salt 
sensitivity with this class of drug may involve other mechanisms. 
158
 Direct evidence for 
VEGF-C involvement in BP control is lacking.   In a cross-over study in patients with chronic 
kidney disease (CKD) plasma VEGF-C was significantly higher following a high-salt diet (200 
mmol Na
+
 a day) for compared to a low salt (50 mmol a day), suggesting VEGF-C was 
induced by high salt intake. 
159
This was not observed in healthy volunteers. 
159
 Further 
studies are required to substantiate the clinical and therapeutic relevance of VEGF-C in 
regulating sodium homeostasis and BP in humans.  
1.2.4     Dietary sodium and arterial stiffness 
 
Several lines of evidence suggest a relationship between arterial stiffness and salt intake. A 
previous observational study in two Chinese populations, showed the age-related rise in 
aortic PWV was blunted in the population with a lower salt intake. 
160
 Humans with salt-
sensitivity have increased arterial stiffness compared with salt-resistant subjects with the 
same BP levels. 
161
 A recent meta-analysis of 11 randomized controlled trials of salt 
restriction and arterial stiffness showed that average reduction in sodium intake of 89.3 
mmol/day was associated with a 2.84% (95% CI: 0.51–5.08) reduction in PWV. 
162
 These 
studies were done in hypertensives and normotensives using applanation tonometry, 
doppler transducer and pressure transducer techniques to measure PWV. 
163-173
 The length 
of dietary intervention ranged from 1 to 6 weeks. The improvement in PWV with dietary salt 
 41 
reduction was independent of baseline BP and BP change between interventions. 
162
 The 
maximum benefit from salt intake restriction was seen expected for hypertensive patients 
on antihypertensive drug treatment. 
163-173
  in one study,  the reduction in PWV was 
observed the greater in black compared with white and Asian hypertensive patients, with 




The pathomechanics of dietary sodium’s influence on arterial stiffness is unclear. In addition 
to its effects on BP, sodium may directly affect arterial wall components. In hypertensive 
rats, high sodium intake leads to cardiac hypertrophy, fibrosis, hypertrophy of large arteries 
and enhanced extracellular matrix. 
174
 Et-taoil et al showed that high sodium intake and 
indapamide therapy decreased and increased aortic hyaluronan content respectively in a rat 
model. 
175
 They showed that the reduction in systemic arterial compliance with indapamide 
was associated with increased media thickness and reduced aortic hyaluronan content and 
these changes occurred under stable BP conditions. The hypothesised that the RAAS system 




Pressure may also affect arterial wall sodium and GAG content. Hollander et al examined the 




 and sulfated GAGs at constant 
sodium intake 
177
. They found that in the aortic hypertensive segments created by 
coarctation, sodium and chloride concentrations were 18.2% and 25% higher than in control 
respectively. They noted that sulfated GAGs increased by 27 - 35% in the coarcted dogs. The 
authors concluded that the increase in pressure on the coarcted aortas induced an increase 
in sulfated GAG synthesis, and the rise in sodium content was a consequence. It is possible 
that a similar Na
+
-GAGs relationship exists in the vascular interstitium and the skin.  
 
Evidence from human studies show that moderate dietary sodium intake reduces arterial 
stiffness independent of BP. Considering arterial stiffness as a predictor of cardiovascular 
and all-cause mortality, this adds to the value of dietary salt reduction in the reducing 
cardiovascular disease.  Animal experiment suggest possible relationship between dietary 
sodium, shear stress and arterial wall constitution, but the link between sodium intake and 
arterial stiffness remains unexplained. 
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1.3     SKIN ELECTROLYTES IN HUMANS  
 
1.3.1     Skin structure and physiology 
 
In humans, the skin is the largest organ in the body, constituting 6% of body weight and 
incorporating blood flow of up to 60% of cardiac output. 
178
 The skin incorporates all major 
support systems such as blood vessels, lymphatics muscle and nerves. The skin consists of 2 
tissue layers: the epidermis, the external layer consisting of non-stratified epithelial cells and 
the dermis, which consists mainly of connective tissue (See Figure 1.7). 
178
 The epidermis is 
approximately 50–200 µm thick and acts as a physical barrier against micro-organisms and 
water loss. 
179
 The dermis is a tough, flexible and very elastic layer between 1.5 and 3 mm 
thick, arranged into two sub-layers: the papillary dermis and the reticular dermis. Despite its 
greater volume, the dermis is relatively acellular compared with the epidermis and consists 
of fibroblasts, blood vessels, lymphatics and nerves interspersed in an extracellular matrix. 
Most of the functionality in the dermis is dependent on its extracellular matrix, which is 
composed of macromolecules such as collagen, elastin and proteoglycans, the most 





















Figure 1.7: Skin structure with relative thickness of epidermis and dermis. Proteoglycans are most 






   
1.3.2     The skin as a depot for NaCl in humans 
 
Studies in rodents suggests the skin functions as a reservoir for sodium and a buffer for 
dietary salt. 
116,130,131
  A review of the literature shows a paucity of information on skin 
sodium concentrations in humans, with most studies done between 50 - 90 years ago. 
181-
188
Most of these studies included skin K
+ 
analysis.  Skin Cl
-
 measurement may have started 
earlier and relied on different quantification techniques. 
129,189
  Table 1.2 summarises 10 




 and their methods. In table 1.2 elemental 









. The exact 
relevance of skin electrolytes was not understood but the skin was considered as depot for 
sodium, chloride and water. 
186,190,191









factors could account for this. Essential elements are often distributed heterogeneously in 
solid biological tissue structures and their quantification would depend on the sensitivity of 






 were measured using 
precipitation techniques, which would have had variable sensitivity, until flame photometry 
was available in the 1940s. 
193
 A number of studies used skin samples taken post-mortem, 
which could have had elemental shifts secondary to tissue autolysis
181,182,186,194,195
 6 studies 
analysed full-thickness skin biopsies. 
143,181-184,186,195
 It can be seen that analysis of epidermis 
tissue alone yielded higher potassium values, suggesting an anatomical variation in skin 
potassium distribution. 
185,187,188
In 1928 Urbach conducted salt loading experiments in a 
small number of humans, which involved the administration of oral NaCl 10g daily over a 
period of 1 week. 
183,190
 He observed the sodium chloride content of human skin increased 
by 15 – 20%. This finding and earlier work by Wahlgren in dogs lead him to conclude that the 
skin was a repository for sodium chloride in 1928. 
129,190
No similar studies on humans have 
been published since.  
 
  More recently 2 studies analysed human skin Na
+
 using modern techniques.  Kopp et al used 
human cadaveric lower limb specimens with atomic spectrometry after ashing the 
specimens. They obtained sodium concentrations of significant variability. 
195
 However, they 
did not perform skin biopsies on live patients. Very recently, Fischereder et al measured skin 
Na
+
 in renal transplant donors and recipients under general anaesthetic,  using inductively 
coupled plasma optical emission spectrometry. 
143





significant variability and did not publish their sample preparation methods.  
 
The skin has long been considered a depot for sodium, chloride and water, although the 
influence of this on BP was not previously studied. 
190,191
The literature on human skin Na
+ 
measured with direct chemical analysis has yielded a wide range of values with several 
limitations. None of the above studies looked at the relationship between skin Na
+
 and 
blood pressure, sex or age. Based on current evidence a universally accepted normal range 
for skin electrolytes in lacking. 
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Table 1.2 - Previous studies assessing skin Na+ and K+ content. 143,181-184,186,195 
Study  Study Size Source Local 
anaesthetic 
Analysis method Na+ (wet) mg/g Na+ (dry) mg/g K+ (wet) mg/g K+ (dry) mg/g % Water  
Brown 1926 10 Epidermis & dermis (Chest and waist) 
Cadavers 
Nil Precipitation with 
BaCl2 
- 3.60 ± 0.37  - 2.39 ± 0.51  
Brown 1927 27 Epidermis & dermis (Chest and waist) 
Cadavers 
Nil  Precipitation with 
BaCl2 
1.58 ± 0.20 - 0.91 ± 0.24 - 63.5 ± 3.7 
Urbach 1928 26 Epidermis & dermis (Various regions) 
Healthy volunteers 
Nil Precipitation with 
BaCl2 
0.95 – 1.39 - - -  
Cornbleet 1942 10 Epidermis & dermis (Various regions) 
Healthy volunteers 
Nil Calorimetric method 
(Yoshimatsu) 
- 3.50 ± 0.02 - 2.47 ± 0.04  
Suntzeff 1945 18 Epidermis (Mastectomies & limb 
amputations) 
Nil Flame photometry 1.22 ± 0.02 - 3.22 ± 0.03 -  
Eisele 1945 18 Epidermis and dermis (Mastectomies        
& limb amputations 
Nil  Butler-Tuthill 
method 
2.14 ± 0.18 7.56 ± 1.03 0.64 ± 0.13 2.28 ± 0.50 70.8 ± 20.1 
Zheutlin 1950 12 Epidermis (Mastectomies) Nil Flame photometry 1.06 ± 0.19 3.07 ± 0.58 3.15 ± 0.30 9.07 ± 1.13 65.1± 3.1 
Hodgeson 1960 45 Epidermis (Various regions)          
Healthy volunteers 
Procaine 0.5% Flame photometry 2.00 ± 0.44 5.63 ± 1.34 1.37 ± 0.28 3.84 ± 0.84  
Hodgeson 1960 20 Epidermis (Various regions)          
Patients under GA 
Nil Flame photometry 1.83 ± 0.49 5.23 ± 1.33 2.07 ± 0.57 6.03 ± 2.07  
Kopp 2011 21 Epidermis & dermis (Limb amputations) Nil Atomic spectrometry 1.77 ± 0.37 - - -  
Fischereder 2017 21 Epidermis & dermis (Abdomen) 
Healthy kidney donors 
Nil ICP-OES - 6.57 ± 4.03 - 1.76 ± 1.09  
Fischereder 2017 27 Epidermis & dermis (Abdomen) 
Dialysis patients 
Nil ICP-OES - 7.05 ± 3.34 - 1.92 ± 0.98  
                        
                       Values are mean ± SD 
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1.3.3     Sodium MRI of the skin 
 
Traditional methods for estimating tissue sodium in humans are invasive and rely on tissue 
biopsies or administration of a radioactive or stable isotope. For over 30 years the use of 
23Na-MRI spectroscopy has enabled the non-invasive assessment of sodium concentrations 
in human tissue in vivo. 196 Recently 23Na-MRI spectroscopy has been used in human skin. 
195,197-204 Sodium (23Na ) possesses a quadrupolar nucleus with 3/2 spin, yielding the second 
strongest nuclear magnetic resonance signal after protons (1H) in biological tissue 205.          
23Na-MRI spectroscopy is able to simultaneously measure proton and sodium signal 
intensity, giving a measure of the ratio of sodium to water in vivo. This technique was first 
developed in the skin by Kopp et al, who used a 3 tesla magnetic resonance (MR) system to 
assess  the sodium : water ratio in calf skin and muscle, which was quantified in mmol/l. 195. 
Using 23Na-MRI, several this group revealed several trends in skin and muscle sodium 
storage. In a study of 56 normotensives and 57 hypertensives, Kopp et al showed that skin 
and muscle sodium storage increased with age and was higher in men than women (Figure 
1.8). 197 Skin Na+ and water accumulation paralleled increased systolic blood pressure while 
the age-dependent increases in muscle Na+ content in men was not associated with increase 
in water content, indicating water-free Na+ storage(Figure 1.8). 197 When skin and muscle 
content was controlled for age, patients with refractory hypertension had increased tissue 
Na+ content compared with controls, suggesting a link between tissue Na+ and essential 
hypertension. 195 A subsequent study in 38 subjects again showed higher skin Na+ in men 












Figure 1.8: Trends in skin and muscle Na+ and water and determined with 23Na MRI. Na+ and water 
content in relation to age. A: Muscle Na+ detected by 23Na-MRI in women (n=44) and men (n=69) with 
or without the diagnosis of hypertension. An additional analysis of muscle water content was 
performed in 25 women and 35 men in this study group. B:23Na-MRI analysis of skin Na+ and 1H-MRI 




23Na-MRI in haemodialysis patients showed that a dialysis session reduced skin Na+ by 19% 
and patients with higher serum VEGF-C levels showed better dialytic Na+ removal. 198 In their 
27 healthy controls there was an age-related rise in skin Na+ which corresponded with a 
decline in serum VEGF-C. The authors concluded that skin Na+ stores can be mobilised by 
haemodialysis and VEGF-C facilitates Na+ flow between the interstitium and systemic 
circulation in humans, supporting earlier work in rodents. 133,198 In a small study of 9 heart 
failure patients, diuretic treatment with frusemide was observed to reduce skin Na by 34%, 
suggesting that diuretic treatment can mobilize skin Na+ stores.  Recently, Schneider et al 
showed that skin sodium content positively correlated with systolic BP and was an strong, 
independent predictor of left ventricular mass (LVM) in patients with mild chronic kidney 
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disease (Figure 1.9). 204 The relationship between left ventricular mass skin Na+ was 
unaffected by BP, leading the authors to conclude that sodium had BP-independent effects 
on the myocardium and skin Na+ could reflect Na+ accumulation in the myocardium, which 
could have detrimental effects. 204 
Figure 1.9: Relationship between skin Na and left ventricular mass. LVM was measured with 1.5 
tesla MRI in 89 participants with mild renal impairment (mean eGFR 51 ml/min per 1.73 m2. This 
was independent of sex, height, SBP and body hydration as measured by bioimpedence. 204 
 
                                    
23Na-MRI has revealed relationships between skin Na+ and age, sex, BP and LVM, making it a 
potential biomarker for cardiovascular disease. 204 There are several limitations this 
technique for quantifying skin Na+ using this method. MRI sensitivity for sodium is 9.2% of 
the sensitivity to protons and therefore the signal to noise ratio is much higher for sodium. 
205 Variability in Na+ signal intensity may be seen between in different tissues and 
discordance may occur between MRI Na+ measurements and direct chemical 
measurements. 205-207 Thus, 23Na MRI is unlikely to provide an exact quantification of tissue 
sodium and values need to be interpreted with caution. It is unclear whether Na+ bound to 
GAGs and ionised Na+, as well as intracellular and extracellular sodium are detected 
differently by 23Na MRI. This could lead to a discordance between direct chemical 
measurements and 23Na MRI measurements. In summary despite its limitations 23Na MRI 
has provided important insights into the relevance of skin Na+ in humans.   
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1.3.4     Dermal sodium distribution 
  
There is a paucity of data describing electrolyte distributions in the skin. Microstructural 
analysis of sodium distribution in rodents has shown that sodium is concentrated under the 
keratinocyte layer. 208 Electron probe analysis and more recently, 7-tesla  23Na-MRI have 
revealed a similar accumulation of sodium, below the epidermis, in the papillary dermis. 
199,209  Mechanisms proposed for this ‘band’ of  high sodium concentration in the skin 
include active sodium transport, combined with cutaneous blood capillary loops, creating a 
functional kidney-like countercurrent system for concentration of sodium chloride under the 
skin. 208  Two functions of this apparent dermal sodium barrier have been proposed. It is 
possible that it acts as physiological fluid barrier with high osmolality inside or directly under 
the epidermis. 208,209 Jantsch et al showed that skin Na+ accumulation occurs during 
cutaneous bacterial infections and endogenously boosts antimicrobial capacity in humans 
and in mice. 210 This suggests that the dermal sodium functions as an antimicrobial barrier.  
Further work is needed to explain the exact mechanisms that generate and maintain this 
apparent pattern of sodium distribution skin, as well as the distribution of other elements 


















1.4     DERMAL CONTROL OF BP IN HUMANS 
 
The focus of hypertension research has traditionally been the kidney, brain, heart and blood 
vessels. Emerging evidence In humans suggests that the skin modulates BP via regulation of 
cutaneous blood flow and salt metabolism. 211 Blood flow in the skin is dynamic and 
mediates thermoregulation, ranging from as low as 1% rising from to as high as 60-70% in 
erythroderma and heat stress. 211,212 Mechanisms such as sympathetic neural control of skin 
blood flow are believed control cutaneous vasodilation that occurs with heat stress. 212 The 
skin is a rich source of nitric oxide, containing ten times the levels in the circulation. 213 On 
this background several new mechanisms linking the skin to BP have been recently 
identified.  
 
Ultraviolet A irradiation of the skin has been observed to induce NO release, reducing 
systemic BP. 214,215 Human skin contains photo-labile NO derivatives like nitrite and S-nitroso 
thiols, which after UVA irradiation, decompose and lead to the formation of vasoactive NO. 
214 This process of photo-relaxation, as described by Furchgott, may account for the 
latitudinal and seasonal variations of BP and CVD. 211 
 
The hypoxia inducible factor (HIF) transcription system, acting via the heterodimeric 
transcription factors HIF-1α and HIF-2α, plays a central role in the cellular response to 
hypoxia. 216 Recent evidence suggests that the HIF-1α: HIF-2α ratio in the skin affects MAP in 
via regulation of nitric oxide synthase 2(NOS 2), a key regulator of vascular tone. 217 HIF-1α 
and HIF-2a act antagonistically - HIF-1a promotes nitric oxide production by keratinocytes via 
NOS 2 while HIF-2α promotes keratinocyte arginase expression and urea production. 218 HIF-
1α also up-regulates VEGF A, which influences NO via VEGFR2 receptors, influencing 
vascular tone. 219,220 Cowburn et al recently showed that mice with keratinocyte HIF-1α 
deletion had increased vascular tone and elevated systemic BP. Conversely, deletion of HIF-
2α activity in keratinocytes resulted in increased skin NO levels and reduced systemic BP. 217 
In accordance with this, they showed decreased epidermal expression of HIF-1α and 
increased epidermal HIF-2α expression in hypertensive humans correlated significantly with 
increased mean blood pressure. These findings provide a novel mechanism for systemic BP 
regulation by the skin. Recent evidence suggest that HIF metabolism may also be influenced 
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by dietary salt. In the renal medulla dietary salt suppresses HIF prolyl-hydroxylase 2 (PHD2), 
which degrades HIF-1α and HIF-2α,increasing natriuresis221,222 It would be plausible that if a 
similar mechanism exists in the skin, high salt intake could alter levels of HIF isomers, 
potentially influencing PVR. 217 This would need to be explored in further work.  
 
As described in in 1.2.3.1 - 1.3.3, the skin appears to buffer dietary salt and rodent models, 
dermal Na+ accumulation in response to acute salt loading protects against a BP rise. The 
role of GAGs and macrophages in this process are described in 1.2.3.3 and 1.2.3.4 
respectively. Cross sectional data in humans show that long-term, higher skin sodium 
storage is associated with higher BP. The mechanisms for this association are yet unknown 
and may explain BP differences between the sexes and the increase in BP with age. 
 
Capillary rarefaction is the reduction in the density of capillaries and has been observed in 
the skin of hypertensives using video microscopy. 11,223-227 Capillary rarefaction is believed to 
be structural in origin, associated with either impaired angiogenesis or capillary attrition, or 
functional, associated with impaired recruitment of non-perfused capillaries. 224 The 
mechanisms by which capillary rarefaction is thought to lead to hypertension is subject to 
debate. Capillaries do not have vascular smooth muscle and cannot increase resistance to 
blood flow by vasoconstriction.  It has been suggested that capillaries can contribute to 
peripheral vascular resistance by virtue of their narrow calibre or reduction in the number, 
leading to an increase in resistance in the remaining capillaries. 223,224,228 Prasad et al showed 
a negative correlation between capillary density in the forearm and SBP in patients with 
essential hypertension. 223 He et al showed that in hypertensive humans a modest reduction 
in salt intake improves dermal capillary density as assessed by capillaroscopy. 11 This trend 
was seen across different racial groups and suggests that salt intake is linked to 
microvascular rarefaction. Mechanisms whereby salt affects the microcirculation remain 
unclear. A reduction in capillary reserve may have deleterious effects on organs affected by 
hypertension such as the brain and heart, though there is a paucity of data linking 
microvascular rarefaction to clinical outcomes. Recently, in the Maastricht study skin 
capillary density independently associated with albuminuria, suggesting a role for capillary 
rarefaction in albuminuria and microvascular damage.   
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Thus, the evidence for BP regulation in the skin is growing with the promise of novel 
pathways and cutaneous therapeutic targets. 
 
 
1.5     SEX DIFFERENCES IN RESPONSE TO DIETARY SALT 
 
Studies in animals and humans have consistently shown sex differences in hypertension,  
with females having lower blood pressure than males across a variety of species and animal 
models. 229-231 Studies on the impact of biological sex on the haemodynamic effects of 
dietary salt are sparse and controversial. 45 Kojima et al reported in a dietary salt modulation 
study of 174 Japanese essential hypertensives that women were sensitive while men were 
not. 232 Overlack et al reported greater SSBP in women in dietary salt modulation study of 
163 white, non-obese normotensive subjects. 44 In the GenSalt study in 1906 Chinese, 
women exhibited larger changes in blood pressure than men in response to changes from 
low-to-high or high-to-low salt intake. 58 It should be noted only the GenSalt study controlled 
dietary salt intake with respect to body weight, which is a potential confounder in sex-
comparisons 58 In a study by Weinberger et al in 374 normotensive, where SSBP was 
determined differently (salt loading with an infusion of 2 L of normal saline over 4 hours and 
salt depletion with a low sodium (10 mmol) diet and frusemide), sex differences in SSBP 
were not observed. 50 In contrast, in rodent studies of salt sensitivity, male Dahl salt sensitive 
rats had a higher BP and more than female Dahl salt sensitive rats in response to a high 
sodium diet, suggesting that the males were more salt sensitive than females. 233 This was 
attributed to testosterone-dependent hypertension and upregulation of intrarenal 
angiotensinogen in males.    
 
Several putative factors have been proposed to contribute SSBP in females.  SSBP tends to 
me more marked in post-menopausal women, but  it is not known if this observation may be 
attributable to ageing  or differences in sex hormones. Shulman et al showed an increase in 
SSBP in the absence of a BP rise in 40 normotensive women following surgical hysterectomy, 
supporting the latter. 234A relationship between ovarian hormones and SSBP via differential 
effects on renal sodium absorption has been suggested.  In a study by Pechere-Bertschi et al 
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in 35 healthy normotensive women not on the oral contraceptive pill, dietary salt 
moderation had similar effects on blood pressure during the luteal and follicular phases of 
the menstrual cycle. 235 This occurred despite renal blood flow being significantly greater 
during the luteal phase. In a further study by this group, the effects of modern low dose 
oestrogen and progesterone-only contraceptive treatment was studied in 27 normotensive 
women.  The use of oral contraceptives but not associated with an increase in SSBP in 
response to dietary salt modulation. 236 
 
In summary sex differences in SSBP have been suggested but further studies are needed to 
confirm this and explain the underlying pathomechanics. Differences in skin sodium storage 
as determined by 23Na-MRI spectroscopy may allude to extra-renal mechanisms that could 




























1.6      SUMMARY 
 
 
The relationship between dietary sodium and BP and the underlying mechanisms explaining 
the heterogeneity in response to salt intake are poorly understood. In the last 15 years we 
have witnessed a renaissance in our understanding of sodium physiology and how humans 
handle dietary sodium, with a paradigm shift away from the traditional nephrocentric view 
that pressure natriuresis exclusively determines salt sensitivity. Emerging novel data on the 
storage of sodium in the interstitium and the study of possible differences in such storage 
between SS and SR individuals has highlighted the relevance of interstitial electrolytes and 
the roles played by GAGs, the lymphatics and cells of the mononuclear phagocytotic system.  
Sodium distribution the skin may facilitate water conservation and cutaneous antimicrobial 
defence. The use of magnetic resonance imaging techniques to measure such interstitial 
sodium storage has led to an appreciation of trends and differences in interstitial sodium 
storage in humans and may also lead to the development of a radiological marker for the 
SSBP phenotype.  The skin is now emerging as a potentially important site of extra-renal 
sodium homeostasis and BP regulation. 
 
There are several areas of uncertainty.  The function of skin as a buffer for dietary salt has 
not been proven by 23Na MRI, which has not been used to measure changes in skin Na+ with 
dietary salt modulation. 23Na magnetic resonance imaging (MRI) studies in humans have 
shown a direct relationship between skin Na+ and BP, but the mechanisms underlying this 
are unknown. 197,204 It is unknown if age and sex differences in the capacity to store skin Na+ 
could explain the observed tendency for SSBP in women and older individuals. 197,204 
Although MRI data were confirmed by direct ashing of human cadaveric samples, they have 
not yet been confirmed by direct chemical analysis of skin electrolytes in humans. 195 It is 
unclear if other factors other than GAGs, such as sodium transporters, influence the storage 






1.7     HYPOTHESES    
 
The principle hypothesis is that the skin functions as a buffer for dietary sodium and 
modulates its haemodynamic effects.  
 
This hypothesis was interrogated in 2 clinical studies and related experiments, discussed in 
Chapters 2 - 6 respectively. Their main hypotheses are summarised below:  
 
1. In humans the skin acts as a reservoir to buffer increases in body sodium and the 
degree of change in skin sodium with dietary salt loading relates to the BP change.  
 
2. Increased sodium intake leads to a rise in plasma VEGF-C and the degree of change 
determines the haemodynamic response to dietary salt loading. 
 
3. Levels of sodium in the skin are positively associated with plasma VEGF-C levels.  
 
4. Dietary salt loading leads to changes in skin capillary density in healthy humans. 
 
5. Increased salt intake in humans lead to changes in dermal expression of 
glycosaminoglycans, Ton-EBP and VEGF-C in humans. 
 
6. The hypoxia inducible factor (HIF) transcription system in the skin is altered by 
dietary salt loading and relates to associated BP changes. 
 







1.8     AIMS 
 
The above hypotheses were tested in 6 studies, described in detail in Chapters 2 - 6 
respectively. Firstly, the feasibility of measuring skin Na+and K+ concentrations using ICP-OES 
was assessed using skin samples obtained from the tissue bank and skin biopsies in healthy 
volunteers. Next, the techniques developed in skin elemental analysis were used to study 
changes in skin electrolytes alongside haemodynamic and biochemical measurements in 
another group of healthy volunteers within a double-blind, randomized, crossover study 
comparing high and low dietary salt intakes. Within this group capillaroscopy was used to 
measure changes in skin capillary concentration and skin changes gene expression with salt 
loading were investigated. Finally, the feasibility of determining skin elemental distribution 
patterns and underlying molecular mechanisms was assessed.  
 
  Study 1 (Chapter 2): To measure skin electrolyte concentrations in skin samples obtained   
under general anaesthesia to assess the effects of local anaesthetic on skin Na+, K+ and 
water content. 
 
Study 2 (Chapter 3):  To assess the feasibility of measuring skin elemental concentrations in 
skin biopsy samples taken from healthy volunteers and to observe the naturally occurring 
inter-individual variation.  
 
Study 3 (Chapter 4):  To measure skin Na+ and K+ in 48 healthy volunteers and observe the 
effects of varying salt intake on skin electrolytes and plasma VEGF-C. Furthermore, to study 
the correlation between skin sodium, blood pressure, other hemodynamic variables and 
plasma VEGF-C.  
 
Study 4 (Chapter 4):  To measure changes in skin capillary concentrations with varying salt 
intake in a sub-set of participants in Study 3. 
 
Study 5 (Chapter 5): To measure changes in dermal gene expression for glycosaminoglycans, 
Ton-EBP, VEGF-C and hypoxia inducible factor isomers with dietary salt loading in a sub-set 
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of participants in Study 3. 
 
Study 6 (Chapter 6): To assess the feasibility of studying skin sodium distribution profiles 
using scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM-EDX), 

























Chapter 2     METHODS DEVELOPMENT 
 
2.1     INTRODUCTION 
 
The quantification of the essential elements Na+ and K+ in human skin forms a central tenet 
of this thesis. An equally important consideration was the avoidance of elemental 
contamination, defined as the inadvertent addition of target analytes to samples during 
sample collection, transportation or analysis. 237 Skin elemental analysis was done in the 
following stages: 
 
. Skin biopsies were taken from volunteers under local anaesthetic in the EMIT unit 
. Storage of skin samples in cryovials at −80°C    
. Division of skin samples under microscopy  
. Skin elemental analysis by Inductively Coupled Plasma/Optical Emission 
Spectrometry (ICP-OES) at the MRC Elsie Widdowson Laboratory 
 
Elemental contamination could have occurred at all stages, including the use of local 
anaesthetic (lidocaine hydrochloride), which contains Na+. The methods for skin Na+ and K+ 
analysis and assessment of elemental contamination were developed concurrently during 
the following studies:  
 
1. Gelatine analysis - gelatine samples were used to simulate skin samples to 
determine if Na+ and K+ contamination occurred during division and handling prior to 
elemental analysis. 
 
2. Tissue Bank skin analysis - this study assessed the feasibility of measuring Na+ and K+ 
in human skin using ICP-OES. Skin elemental concentrations were measured in 17 
skin samples obtained under general anaesthesia to assess the effects of local 
anaesthetic on skin Na+, K+ and water content. Due to the large size of samples, skin 
samples were divided prior to analysis by ICP-OES. 
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3. VARSITY methods study - a pilot study in 48 healthy humans assessing the feasibility 
of measuring skin elemental concentrations in healthy subjects and the naturally 
occurring inter-individual variation.  
 
4. VARSITY study - a study in 48 healthy humans looking at the effects of varying salt 
intake on skin Na+ and K+. During this study, Na+-free lignocaine was developed and 
trialled.  Skin samples were divided prior to analysis by ICP-OES, with one portion 
used for elemental analysis and the other retained for other experiments later.  
 
In this chapter methods used for skin elemental analysis and the measures taken to avoid 
contamination are described. Description of routine measurements are given in relevant 
experimental chapters.  Detailed descriptions of the VARSITY methods and VARSITY studies 























2.2     SKIN BIOPSY TECHNIQUE 
 
Skin biopsies were carried out using sterile technique in a closed, temperature-controlled 
room (23 ± 2°C). An area of skin was selected on the lower back and cleaned using 2% 
chlorhexidine gluconate solution (ChloraPrepTM), which was confirmed by ICP-OES analysis 
not to contain Na+ or K+. The skin was injected with lignocaine hydrochloride local 
anaesthetic (Xylocaine 1% with 2% adrenaline, AstraZeneca). This has a significant Na+ 
content (116mmol/l) and no K+ content as measured with ion-sensitive electrodes (Siemens 
Dimension RXL auto analyser) at the Cambridge Core Biochemical Assay Laboratory. In view 
of this, injections were carried out at a depth of approximately 11mm into the 
subcutaneous layer to avoid introducing lignocaine Na+ and water into the dermis (Figure 
2.1). A single full-thickness skin punch biopsy was taken with disposable punch skin biopsy 
needles (Miltex™) of 4-5mm width.  Any attached subcutaneous tissue was immediately 
removed by macroscopic dissection using a blade Bard-ParkerTM surgical blade. Skin tissue 
handled with sterile forceps and immediately placed in a 2ml cryovial (Thermoscientific). All 
surgical instruments were sterilised and autoclaved prior to use. In the VARSITY methods 
study the cryovial was then placed on ice before being stored at −80°C until analysis. For the 















Figure 2.1: Illustration of skin biopsy procedure showing injection of local anaesthetic 






















2.3     SKIN ELEMENTAL ANALYSIS  
 
2.3.1     Inductively Coupled Plasma/Optical Emission Spectrometry (ICP-OES) 
 
ICP-OES is a sensitive, powerful analytical tool for the determination of trace elements in a 
variety of sample matrices, including biological tissue. 238,239 Its high sensitivity allows 
elemental analysis in small tissue samples. ICP-OES has been used in Forensic Science for 
over 30 years for trace element analysis of evidential human tissue. 240 Very recently ICP-
OES has been used successfully to measure skin Na+ and K+ in human skin. 143 This technique 
was available at the MRC Elsie Widdowson Laboratory, where it was previously used for 
trace element analysis in human and animal tissue. 241,242 Skin samples require acid 
digestion and homogenisation to allow elemental analysis, and ICP-OES has the capacity to 
handle samples of extreme pH. For these reasons ICP-OES was chosen for skin elemental 
analysis undertaken in this thesis. 
 
The major components and layout of an ICP-OES system are illustrated below in Figure 2.2. 
With this technique, the analyte is transported into the instrument as a stream of liquid. 
Within the instrument the liquid is converted into an aerosol through nebulisation. The 
aerosol is then injected into argon plasma at a temperature of 10 000K in aerosol form, 
allowing analyte elements to be liberated as free atoms and ions in the gaseous state. 
239,243Collisional excitation within the plasma confers additional energy to the atoms, 
promoting them to excited states.  The excited state species can then relax to the ground 
state by the emitting photons. These photons have characteristic wavelengths which can be 
used to identify the elements from which they originated. The total number of photons is 
directly proportional to the concentration of the originating element in the sample, and this 
way elemental concentration is measured. 239 The main advantage of this technique over 
other alternatives originates from its efficient and reproducible vaporisation, atomisation, 
excitation and ionisation for a wide range of elements and sample matrices.  This is mainly 
due to the high temperature of the argon plasma, which is much higher than the maximum 








2.3.2     Sample preparation 
 
Skin samples were analysed by ICP-OES in liquid form, as explained above. To achieve this, 
samples were freeze dried and underwent cold acid digestion at the MRC Elsie Widdowson 
Laboratory. The steps and techniques used for skin preparation for analysis by ICP-OES are 
summarised below in Figure 2.3. Environmental elemental contamination during sample 
preparation is a potential problem in all laboratories, with the main contributor being dust 
and atmospheric particulates. 237 The MRC Elsie Widdowson Laboratory specialises in trace 
element analysis and had precautionary measures already in place to reduce environmental 
elemental contamination. This included the use of clean room environment for sample 





2.3.2.1     Freeze-drying 
Elemental concentrations measured in solid biological tissue are calculated from the 
detected elemental output divided by the weight of sample, as opposed to volume, in the 
case of biological fluids. This presents a challenge as the weight of a sample varies with 
degree of hydration. The weight of tissue when it obtained is termed tissue wet weight. The 
weight of tissue after water is removed by a drying technique is termed dry weight. 
Elemental measurements per wet weight of tissue may have potential inaccuracies 
introduced by changes in sample hydration during sample processing, which is why previous 
studies in humans and rats have expressed skin Na+ and K+ concentrations per unit dry 
weight. 134,182,184,186-188,244,245 Tissue drying has been carried out using different methods, 
including dry ashing, oven drying and freeze-drying. Freeze drying was used for as it 
available and in use at the MRC Elsie Widdowson Laboratory.  
 
Freeze-drying is a process by which water is removed from frozen tissue by sublimation at a 
low temperature and under vacuum. A vacuum is needed as sublimation can only occur 
when the partial pressure of the water vapour exceeds that of the atmosphere. Freeze 
drying facilitated acid digestion and the measurement of sample water content. The skin 
samples were weighed in a pre-weight polypropylene vial using an electrobalance to 
determine their wet weights and then freeze-dried overnight in a Mini Lyotrap system (LTE 
scientific, Greenfield, Oldham, UK) until they reached a constant weight (dry weight). This 
took up to 48 hours. The vials were re-weighed after drying to determine water content, as 
the difference between wet weight and dry weight.  
 
 
2.3.2.2     Sample acid digestion 
Freeze-dried skin samples were digested directly in the vial by adding a digestion solution 
containing 1:1 (volume for volume) mixture of 69% HNO3 and 40% H2O2. The volume of the 
digestion solution was adjusted to the sample dry weight to ensure complete digestion - a 
skin sample of 7mg dry weight required 150 μL of digestion solution. Samples were vortexed 
thoroughly to provide a homogeneous matrix for digestion. Following this, the samples 
were incubated overnight at room temperature followed by a second incubation overnight 
in a water bath at 40⁰C. More digestion solution was added if the solution was not clear and 
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the incubation at 40⁰C repeated.  All samples were digested to completeness before being 
diluted 1:40 with ultra-high purity (UHP) water containing strontium (Sr, 1ppm final 
concentration). Digestion blank controls were prepared alongside the skin samples as empty 
vials and analysed collectively with the digested skin samples.  
 
 











2.3.3     ICP-OES settings 
 
 
The skin elemental concentrations of Na+ and K+ were determined using a Jobin Yvon Horiba 
– ULTIMA 2C ICP-OES system equipped with a concentric PFA micro-flow nebuliser with 
sample flow rate 0-2ml/min, a 50ml glass cyclonic spray chamber and a radial torch with an 
3mm internal diameter (i.d.) alumina injector. Sample solutions were introduced from an 
auto-sampler (Jobin Yvon Horiba AS500) using a sample probe with 0.25mm i.d. sample 
tubing and 0.38mm i.d. pump tubing (orange/green). Instrument operating conditions are 
listed in Table 2.1. Strontium, added during sample preparation, was measured alongside 
Na+ and K+ to control for possible error in sample dilutions and uptake. Peak profiles were 
used to measure individual elements as described in table 2.2. A series of external 
calibration standards were prepared from 1000 ppm commercial stock solutions in 2% HNO3 
(Na, Fluka Tracepure; K, Perkin-Elmer Pureplus), with final concentrations per element 
ranging from 0 to 15 ppm in a diluent matched to the digested solution (final concentration 
0.86% HNO3, 1ppm Sr). The Na+ and K+ concentrations were calculated against the linear 
regression obtained from the calibration standards.  Drift check solutions and blank (diluent) 
solutions were measured after every block of approximately 6 samples to monitor 
contamination during the ICP-OES analysis process. Blank solutions contained ultra-pure 
water (Arium
 
Pro Ultrapure Water Systems, Sartorius) in place of sample digests.  
Table 2.1: Running conditions used for ICP-OES. 
 
       Analytical Conditions Na:K 
RF power (W) 1000 
Plasma gas (L min-1) 12 
Sheath gas (L min-1) 2 
Auxiliary gas (L min-1) 0.0 
Speed pump (rates min-1) 10 
Nebulizer gas flow rate (L/min-1) 0.73 
Nebulizer pressure (bar) 2.75 
Number of replicates 3 
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Table 2.2: Peak profile measurement parameters 
 
Element Na K Sr 
Wavelength (nm) 588.995 766.490 346.446 
Number of points 21 11 9 
Integration time (s) 0.5 0.5 0.5 
Increments (nm) 0.001 0.002 0.002 
Photomultiplicator tube voltage (V) 911 990        750 
Photomultiplicator tube gain (%) 100 100 100 
Points used 5 5 5 
Number of replicates 3 3 3 
Calculation mode Gauss Gauss Gauss 
 
2.3.4     Assessment of Matrix effect 
 
In analytical chemistry, matrix refers to the components of a sample other than the analyte. 
246 Matrix effect is defined as the combined effect of all components of the sample on the 
measurement of the analyte. 246It represents the quantification of sample interference on 
the measurement of Na+ and K+ through our method. This effect will be different depending 
on the method, sample, analyte and technique of analysis. Matrix effects are primarily 
caused by the disturbance of the ion beam path through the ion optics and the mass 
spectrometer by the high concentration of the matrix element.  To measure matrix effect, a 
pooled sample was created from the skin digest samples and aliquoted and spiked with Na+ 
and K+ with final concentrations per element ranging from 0 to 15 ppm and maintaining a 
sample dilution of 1:40. The slopes of the linear regressions obtained for each element are 
compared with the slopes of the external calibration linear regression in diluent described 
above and a correction factor calculated.  
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2.3.5     Expression of skin elemental concentrations and water content 
 
Skin Na+ and K+ were quantified by ICP-OES in milligrams. Concentrations were calculated 
for each sample by dividing the measured Na+ and K+ by the weight of the sample. The 
sample wet weight was used to obtain skin Na+wet and K+Wet in mg/g. The sample dry weight 
was used to obtain skin Na+Dry and K+Dry in mg/g. Water content was taken as the weight loss 
with freeze drying - the difference between wet weight and dry weight (in milligrams). This 
was expressed as a percentage of wet weight to give percentage water content (% water). 
The ratio of Na+ and K+ to water were used as an estimate of osmotically inactive storage of 
these elements in the skin. This ratio was calculated as follows: 
1. Na+Dry and K+Dry were converted from mg/g to mmol/g and the total amount of 
Na+ and K+ in each sample was calculated in mmol. 
2. The sample water content (in grams) was converted to volume of water using 
the formula: 1ml = 1mg of water.  
3. The total amount Na+ and K+ in each sample was divided by the volume of water 
and the ratio of Na+ and K+ to water expressed as mmol/l. 
 
2.3.6     Assessment of drying consistency 
 
The consistency of freeze drying over a range of skin sample weights is unknown. If water 
removal is less efficient in larger samples, their recorded dry weights would be higher than 
their true dry weights. Consequently, skin elemental concentrations expressed per 
milligrams of dry weight would be underestimated in in these samples. To assess if this was 
present sample wet weights were plotted against percentage weight loss with freeze drying 




2.4     GELATINE ANALYSIS 
 
2.4.1     Introduction 
 
In the Tissue Bank skin analysis and the VARSITY study it was necessary to halve skin 
samples divided before elemental analysis by ICP-OES. In this experiment, the 
contamination of skin samples with Na+ and K+ during this procedure was assessed. Gelatine 
samples were used to simulate skin samples undergoing the same procedures to assess Na+ 
and K+ contamination.  Gelatine is a mixture of peptides and proteins produced by partial 
hydrolysis of collagen extracted from the skin, bones and connective tissues of animals such 
as cattle, chicken, pigs and fish. 247  It is a viscoelastic substance, mainly composed of 
carbon, hydrogen, nitrogen and oxygen. It is also known to contain Na+ and K+ within its 
matrix. 248,249 Gelatine therefore shares similar properties to skin and was deemed a suitable 
substrate to assess elemental contamination in skin samples. During this experiment, 
elemental contamination from 2ml cryovials (Thermoscientific) used to store skin samples 
was also assessed, as the use of solutions containing Na+ and K+ during their manufacture 
was unknown. 
 
2.4.2     Aims 
 
1. Assess if the procedures involved in dividing skin samples prior to elemental analysis 
in the introduced Na+ and K+ contamination and variability.  
 
2. Determine whether storage of samples in cryovials introduced contamination. 
 
2.4.3     Methods  
 
An initial analysis of 10 pieces of gelatine from several regions of a 4 x 2 cm gelatine block 
was carried out at the MRC Elsie Widdowson laboratory to determine Na+ and K+ content. 
Subsequently, all procedures planned for skin samples were carried out on the same 
gelatine block at the EMIT unit, as shown in Figure 2.4. Firstly 5 mm punch biopsies were 
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carried out using sterile technique. 10 x 5mm punch-biopsy samples were removed with 
sterile non-toothed forceps and a blade Bard-ParkerTM surgical blade. Sterile gloves were 
used when handling the samples. Samples were placed in cryovials, snap-frozen in liquid 
nitrogen and kept in a- 80 °C freezer for 72 hours. The samples were individually removed 
and placed on a tray containing dry ice covered in aluminium foil. Dry ice was used to keep 
samples frozen and reduce moisture loss. Each sample was halved longitudinally with a 
scalpel under an 10x microscopic view. One half was placed in a new cryovial and the other 
half was placed in the original cryovial. Samples placed back in the original cryovial were 
labelled Group 1 (G1) and those placed in a new cryovial were labelled Group 2 (G2). All 
samples were placed on dry ice before being stored in a - 80 °C freezer for 48 hours. The 
gelatine samples were transported to MRC Elsie Widdowson laboratory analysis by ICP-OES 
analysis as previously described in 2.2. The procedures for sample preparation for ICP-OES 
as outlined in 2.3.2 and 2.3.3 were carried out. Differences in dry weight values for Na+ and 
K+ (Na+Dry and K+Dry) between Groups 1 & 2 were used to determine if there was any 
contamination and variability introduced by sample division. During sample preparation 4 
empty 2ml cryovials had ultra-pure water (Arium
®
Pro Ultrapure Water Systems, Sartorius) 
added in place of sample digests to determine Na+ and K+
 
content in empty cryovials.  
 





2.4.4     Results 
 
Gelatine elemental concentrations and water content are shown in Table 2.3. Results are 
expressed as mean ± standard deviation. 2 samples were rejected (1 from each group) due 
these samples being dropped during handling and were likely to have incurred 
environmental contamination. The results for the remaining 9 samples per group are shown 
in table 2.3. No significant difference was noted between the 2 groups for Na+Dry (3.64 ± 0.68 
vs.3.66 ± 0.58 mg/g; p = 0.95) and K+Dry (0.05 ± 0.00 vs. 0.05 ± 0.00 mg/g; p=0.81). Water 
content was similar in both groups (90.6 ± 1.1 % vs. 90.1 ± 1.5 %, p=0.42). Concentrations of 




Table 2.3: Elemental concentrations for gelatine samples for Group 1 (G1) and Group 2  (G2). 
 
Samples G1 G2 P for difference 
Na+Wet, mg/g 0.34 ± 0.04 0.35 ± 0.04  0.22 
Na+Dry, mg/g 3.64 ± 0.68 3.66 ± 0.58 0.95 
K+Wet, mg/g 0.01 ± 0.00 0.01 ± 0.00 0.69 
K+Dry, mg/g 0.05 ± 0.00 0.05 ± 0.00 0.81 













2.4.5     Discussion 
 
The data suggests that Na+ and K+ contamination did not occur during the dividing of 
samples prior to elemental analysis. Moreover, the results show low standard deviations for 
Na+ and K+, suggesting that contamination during the procedures for sample handling and 
instrumentation was unlikely.  There was also no detectable Na+ and K+ contamination from 
the cryovials used to store samples. There were several limitations of this experiment that 
would have affected the ability to generalise the findings for human skin samples.  Firstly, 
local anaesthetic injections were not used as injecting lignocaine into gelatine samples was 
not possible. Secondly, the water content of gelatine was high (>90%) compared to human 
skin. 182,186,187 Furthermore, the homogeneity of Na+ and K+ distribution in gelatine was 
unknown and may have been different from human skin. In conclusion, the findings of this 
experiment suggest that the procedures involved in dividing skin samples prior to elemental 
analysis and the storage of samples in cryovials did not introduced Na+ and K+ contamination 
and variability. It was therefore deemed appropriate to use these procedures when 













2.5     ANALYSIS OF TISSUE BANK SKIN  
 
2.5.1     Introduction 
 
Skin biopsies in this thesis were taken with lignocaine local anaesthetic, as described in 2.2. 
Although Injections were carried out deep into the subcutaneous layer, there was still a risk 
of Na+ and water contamination of biopsy tissue. The purpose of this study was to evaluate 
skin electrolyte and water content without the influence of local anaesthetic injection in to 
the skin and the feasibility of measuring skin Na+ and K+ with ICP-OES using the techniques 
described in 2.3. 
 
 
2.5.2     Aims 
 
The primary aim of this study was to evaluate the Na+ and K+ concentrations and water 
content in healthy human skin without the influence of local anaesthetic. A further aim was 
to assess the feasibility of skin elemental analysis with ICP-OES. 
 
2.5.3     Methods 
 
2.5.3.1     Samples 
We obtained healthy skin specimens from the Cambridge University Hospitals NHS 
Foundation Trust Human Research Tissue Bank. The skin samples were all healthy breast 
reduction surgical resections obtained from 17 women under general anaesthesia. The skin 
specimens were previously collected during surgery and placed on a small piece of foil and 
the plunged into liquid nitrogen for a up to 10 seconds. Once frozen each sample was placed 
into a pre-cooled cryovial and then stored at - 80 °C. All tissue acquisition procedures and 
experimental protocols were approved by Cambridge University Hospitals Human Research 
Tissue Bank, under the generic ethics approval (11/EE/0011). Only data on age and sex was 
provided under this ethics approval. 
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2.5.3.2     Sample processing and analysis 
 
The skin samples were large in comparison to punch biopsy samples obtained from the 
VARSITY Methods and VARSITY studies, and this would have led to longer cold acid digestion 
times. For this reason, samples were divided using the techniques described with gelatine 
samples in 2.4.3. Each sample was halved longitudinally with a scalpel under 10x 
microscopic view, as described in 2.4.3, to ensure even splitting of the epidermis and dermis. 
Samples were cut on aluminium foil over dry ice to keep them frozen and avoid loss of 
moisture. Samples were then sent on dry ice to the MRC Elsie Widdowson laboratory to 
determine Na+ and K+ content by ICP-OES analysis as previously described in 2.2. The 
procedures for sample preparation for ICP-OES were carried out as outlined in 2.3.2 and 
2.3.3. 
 
2.5.3.3     Expression of skin elemental concentrations 
Skin Na+ and K+ concentrations and water content were calculated and expressed as 
described in 2.3.5.  
 
2.5.3.4     Assessment of drying consistency 
This was assessed as described in 2.3.6. 
 
2.5.4     Results 
Samples from 17 women were analysed for Na+ and K+ concentrations and water content. 
Results are expressed as mean ± standard deviation in Table 2.4. Mean age was 43.4 ± 15.9 
with range 19 - 72. Mean Na+ concentration was 2.25 ± 0.23 mg/g of wet skin and 6.35 ± 
1.75 mg/g of dry skin. Mean K+ concentration was 0.57 ± 0.17 mg/g of wet skin and 1.56 ± 
0.50 mg/g of dry skin. The mean water content was 62.9 ± 6.5 %. Measured water content 
was not correlated with sample wet weights, suggesting that freeze drying removed water 





Table 2.4: Results for skin elemental and water content in Tissue Bank samples.  
 
  
Variable Mean ± SD 
Age, years 
 
43.4 ± 15.9 
Wet weight, g 
 
60 ± 3 
Dry weight, g 
 
20 ± 10 
Skin Na+Wet, mg/g 
 
2.25 ± 0.23 
Skin Na+Dry, mg/g 
 
6.35 ± 1.75 
Skin Na+: water, mmol/l 
 
156.2 ± 8.8 
Skin K+Wet, mg/g 
 
0.57 ± 0.17 
Skin K+Dry, mg/g 
 
1.56 ± 0.50 
Skin K+: water, mmol/l 
 
23.4 ± 7.7 
Water content, % 
 










Figure 2.4: Effects of sample wet weights on % water content. 
 





















2.5.5     Discussion 
 
The main aim of this study was to measure skin Na+ and K+ and water content without the 
influence of local anaesthetic. The values for skin Na+ and K+ per unit wet and dry weight fall 
within published ranges (Chapter 2.3). Tissue Bank samples had a water content of 62.9 ± 
6.5 %, which is similar to previously published values in human skin. 182,187 Skin Na+ to water 
ratio was 156.2 ± 8.8 mmol/l while K+ to water ratio was 23.4 ± 7.7 mmol/l. In these absence 
of serum Na+ and K+ concentrations these values suggest storage of these elements in the 
skin without commensurate water accumulation.  The freeze-drying technique did not 
appear to be affected by sample wet weights.  
 
There are several weaknesses of this analysis. The skin samples were not collected 
prospectively, and it was not possible to ensure that Na+ containing substances were used 
during the surgical procedure or collection. The samples were only from women and this 
could have affected their generalisability for men. The measurements of Na+ and K+ to water 
ratios did not differentiate between extracellular and intracellular Na+ and K+ and could not 
be compared with the serum concentrations. Despite these limitations, the results skin Na+ 
and K+ and water content measured with modern techniques are similar to previously 
published values and will inform later work. 
 
 
2.5.6    Conclusions 
 










2.6     DEVELOPMENT OF SODIUM FREE LIDOCAINE SOLUTION  
 
2.6.1     Introduction 
 
Xylocaine 1% with 2% adrenaline (AstraZeneca) is the conventional form of local anaesthetic 
used in Addenbrookes Hospital. It contains the excipients sodium metabisulphate, sodium 
hydroxide and sodium chloride, as confirmed by AstraZeneca. These excipients are added to 
increase the osmolality and pH of Xylocaine, which minimises the risk of tissue reaction and 
improves tolerability during tissues injection. 250,251 Sodium metabisulphate is also used to 
prevent oxidation and improve the shelf life of the solution. The sodium content of Xylocaine 
is a potential source of contamination during skin elemental analysis in human volunteers. It 
was therefore necessary to create an alternative Na+ free anaesthetic. Dextrose, which has 
previously been used as an excipient for lidocaine solutions, was chosen as substitute for the 
above Na+-based excipients. 252 Commercially available lidocaine local anaesthetic solutions 
have pH of around 3.5-7.0. 253 In designing a lidocaine/dextrose solution, the pH would also 
have to be similar for tolerability. 
2.6.2      Aims 
 
1. To develop a Na+-free lidocaine/dextrose solution with suitable osmolality 
and pH for use in the VARSITY main study. 
 










2.6.3     Methods 
 
 
Conventional lidocaine (Xylocaine 1% with 2% adrenaline, AstraZeneca) was analysed at the 
Addenbrookes Core Assay Biochemistry lab (CBAL) for Na+ and K+ using an ion selective 
electrode (Siemens Dimension RXL auto-analyser). The osmolality of Xylocaine 1% was 
measured using method of freezing point depression with an Advance Micro-Osmometer 
model 3300 (Advanced Instruments, Norwood, USA). Tayside Pharmaceuticals, a MHRA-
approved Pharmaceutical company in Dundee, made up solutions of lidocaine 1% and 
dextrose as an alternative excipient at different concentrations (2.5%, 5% and 10%). Ultra-
pure water was used to make up lidocaine solutions and precautions were taken to avoid 
introducing sodium during the manufacturing process. The osmolality of these different 
lidocaine/dextrose solutions were measured and plotted against dextrose concentrations to 
determine the concentration of dextrose that would have a similar osmolality to 
conventional lidocaine. Lidocaine 1% was subsequently produced with this concentration of 
dextrose and tested for osmolality at the CBAL and pH at Tayside Pharmaceuticals.  Due to 
technical challenges adrenaline was not included in the solution. Na+ and K+ concentrations 















2.6.4     Results 
 
The osmolality of Xylocaine 1% with 2% adrenaline (AstraZeneca) was measured as 277 
mOsm/kg. Osmolalities for lidocaine 1% and dextrose solutions at different dextrose 
concentrations are shown in Table 2.5. Osmolality had a linear relationship with dextrose 
concentration (Figure 4.5). Using dextrose 3.5% gave a similar osmolality to Xylocaine. 
Lidocaine 1% with dextrose 3.5% was produced by Tayside Pharmaceuticals. This was found 
to have an osmolality of 269 mOsm/kg and pH of was 5.0. 12 vials of lidocaine 1% with 
dextrose 3.5% were analysed by ICP-OES and were found to have Na+ and K+ concentrations 
of less than 0.1 mmol/l.  
 
Table 2.5: Results for osmolalities at different concentrations of dextrose.  
 







Figure 2.5: Linear plot of osmolality values for lidocaine and dextrose solutions at different 
dextrose concentrations.  
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2.6.5     Discussion 
 
Lidocaine 1% and dextrose 3.5% has been shown to have a similar osmolality and pH as 
conventional lidocaine. This Na+ free lidocaine was manufactured in time for the last 16 
volunteers for VARSITY study. A concentration of < 0.1 mmol/l for Na+ and K+ was regarded as 
negligible for the purpose of avoiding elemental contamination. The use of lidocaine 1% and 
dextrose 3.5% would avoid Na+ contamination of skin, but not water contamination, which 





















Chapter 3     VARSITY METHODS PILOT STUDY 
3.1.    INTRODUCTION 
 
 
The recent discovery of novel mechanisms in the skin for buffering dietary salt in rodent 
models has highlighted the relevance of skin electrolytes. 133,134,152 At the commencement of 
this work the available data on skin electrolyte content in humans was sparse with significant 
heterogeneity and limitations, as shown in Table 1.2 in 3.2. 181-188 In the last 7 years, 23Na-MRI 
measurements have revealed relationships between skin Na+ and age, sex, BP and LVM, 
making it a potential biomarker for cardiovascular disease. 197,204 Direct chemical 
measurements of human skin have not evaluated the relationship between skin electrolytes 
and these variables. 181-188,197,204  To interrogate the hypotheses of this thesis outlined in 1.7, a 
reliable technique for skin elemental quantification and an evaluation of the normal variation 
in healthy humans was essential. On this background, VARSITY Methods was conducted as a 
pilot observational cross-sectional study to assess the feasibility of measuring skin Na+ and K+ 
concentrations in healthy subjects and the naturally occurring inter-individual variation. This 
study was meant to inform the analysis of Na+ and K+ content of skin samples in the main 
VARSITY study, which assessed the effects of dietary salt on skin Na+. As described in 2.6, the 
use local anaesthetic for skin biopsies was associated with the risk of sodium contamination. 
To assess whether contamination occurred, skin Na+ values obtained from VARSITY methods 












3.2    AIMS 
 
1. The primary aim of this study was to assess the feasibility of measuring skin Na+ and K+ 
concentrations in healthy subjects define the usual concentrations of sodium and potassium 
in the skin of healthy adult humans. 
 
2. The secondary aim was to examine the naturally occurring variations in skin Na+ and its 
relationship with putative factors such as age, sex, BMI, BSA and BP.  
 

















 3.3    METHODS 
 
3.3.1     Study design & protocol 
 
VARSITY Methods was a single-centre observational, cross-sectional study. Participants 
attended a single study visit, having refrained from caffeine, alcohol, strenuous exercise and 
the application of moisturiser or fake tan to their lower back for the previous 6 hours. Height 
and weight were assessed and, after a minimum of 5 minutes rest, seated brachial blood 
pressure was recorded. Body surface area (BSA) was calculated using the Du Bois formula 
254: BSA = 0.007184 x Weight(kg)0.425 x Height(cm)0.725.Twenty millilitres of blood were drawn 
into three EDTA tubes and a clotted tube. For each participant a single EDTA sample was 
centrifuged at 4°C (3200 rpm for 15 minutes) and the serum separated and stored at - 80°C 
prior to analysis for VEGF-C.  
 
3.3.2     Subjects 
 
Participants were healthy individuals aged between 18 to 70 years at the time of screening. 
Exclusion criteria included hypertension (sustained blood pressure >140/90mmHg), current 
use of antihypertensive drugs, diuretics or salt supplements, renal impairment, heart failure 
or pregnancy. Participants were recruited from Cambridge using adverts placed through the 
university and hospital common areas as well as sending letters to their general 
practitioners. We set a recruitment target of 48 participants, stratified by screening age as 














18 to 30 16 
31 to 50 16 




3.3.3     Haemodynamic assessments 
 
In all participants, brachial blood pressure was measured using a validated semi-automated 
oscillometric device (HEM-705CP, Omron Corporation) after 5 minutes of rest in seated 
position. BP was measured in the non-dominant arm in triplicate, with approximately a 1- 
minute interval between readings.  The average of three readings was recorded in use for 
analysis. Further readings were taken if there was a difference of > 5 mmHg was observed 
between the 2nd and 3rd readings.   
  
 
3.3.4     Biochemical measurements 
 
Serum and 24-hr urine electrolytes (Na+, K+ and creatinine), plasma renin and aldosterone 
were measured in an accredited laboratory (Cambridge University Hospitals Department of 
Clinical Biochemistry). Estimated glomerular filtration rate was measured using the 
Modification of Diet in Renal Disease (MDRD) formula. 255 Plasma VEGF-C measurement was 
carried out at the Addenbrookes Core Biochemical Assay Laboratory (CBAL) using a validated 
sandwich ELISA (MesoScaleTM, Rockville, USA), in which a VEGF-C-specific antibody was used 
to bind the serum VEGF-C. Reproducibility of the assay was checked by the team at CBAL by 
running quality control samples at the beginning and end of each batch. 
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3.3.5     Skin biopsy procedure 
 
As described in 2.2, full-thickness skin punch biopsies (4mm diameter) were carried out over 
the lower back region using 2 – 4 ml of local anaesthetic (Xylocaine 1% with 2% adrenaline, 
AstraZeneca) in all participants. The skin was cleaned using 2% chlorhexidine gluconate 
solution. Skin tissue was handled with forceps and immediately placed in a cryovial in ice 
before being stored at − 80°C until analysis.  
 
3.3.6     Skin elemental analysis 
Whole skin samples were then sent on dry ice to the MRC Elsie Widdowson laboratory to 
determine Na+, K+ and water content by ICP-OES analysis as previously described in 2.2. The 
procedures for sample preparation for ICP-OES were carried out as outlined in 2.3.2 and 
2.3.3.  
 
3.3.7    Expression of skin elemental concentrations 
Skin Na+ and K+ concentrations and water content were calculated and expressed as 
described in 2.3.5.  
 
3.3.8     Assessment of drying consistency  
 
This was assessed as described in 2.3.6. 
 
3.3.9    Statistical analysis 
 
Statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA). Graph-Pad 
Prism 7.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to construct graphs and 
figures. Results are expressed as means ± SD unless otherwise stated. Differences in skin Na+ 
were examined in different tertiles of age using ANOVA analysis. Post hoc test were 
performed using the Bonferonni algorithm. Correlation coefficients between skin Na+and 
putative parameters such as age, sex, body mass index (BMI), body surface area (BSA) and 
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BP were calculated using Pearson’s method for normally distributed variables and 
Spearman’s method for non-normally distributed variables. Multiple regression analysis was 
then performed to examine the parameters that independently influence skin Na+ and K+. 
The unpaired 2-tailed Student’s t-test was used to compare normally distributed skin 
biochemical parameters between sexes and between VARSITY methods and Tissue Bank. 
The Mann Whitney test was used to compare non-normal distributed data. Test for 




















3.4     RESULTS 
3.4.1     Subjects and exclusions  
 
48 healthy participants were recruited over a 2-year period from 2011 to 2013, with 16 
recruited in each age category specified in table 3.1. Skin samples were analysed for all 48 
participants in 5 batches. After reviewing results for skin analysis for both VARSITY main and 
VARSITY methods 11 participants were excluded. 8 were excluded because of an analytical 
problem with the ICP-OES instrument during analysis of the 2nd batch, resulting in a dramatic 
shift in sensitivity. This was determined by the trace element analysis teams at the MRC Elsie 
Widdowson Laboratory after reviewing skin electrolyte values from both studies. This was 
attributed to a drop in ICP-OES argon pressure during the analysis. 3 further participants 
were excluded because of low sample wet weights (< 0.01 g), leading to variability in the 
freeze-drying process and elemental analysis, as discussed further in 4.5.1.2.   
 
3.4.2     Baseline characteristics 
 
The baseline characteristics for the remaining 37 participants used in the analysis are 
summarised in Table 3.2, with values shown for the whole group and participants divided 
into tertiles of age. Mean age was 39 ± 16 years and 18 were men.36 out of 37 participants 
were Caucasian, in keeping with the demographics of the Cambridge region. The mean 24-
hour sodium excretion of 117.1 ± 45.9 mmol, approximating to a salt intake of 7g a day. This 
is below the UK average daily sodium intake, recently estimated at 130 mmol. 256 No 
participants were current smokers. 3 women were on hormone replacement therapy and 6 
were on contraceptive treatment. As seen in Table 3.2 the expected age-related rise in blood 
pressure and decline in renal function was observed. 257,258 VEGF-C displayed a high 
variability using our ELISA assay and mean plasma concentration was 106.4 ± 107.9 pg/ml, 





Table 3.2: Baseline demographic data for Varsity Methods. Data is presented for the whole 
population and tertiles of age.    
 
Variables 
 Age tertile  
All subjects 1 2 3 P for 
difference* 
n 37 12 12 13  
Age  39 ± 16 22 37 58 < 0.001 
BMI, kg/m2 23.5 ± 3.0 22.6 ± 3.4 24.2 ± 3.1 23.6 ± 2.5 0.41 
BSA, m2 1.81 ± 0.18 1.81 ± 0.16 1.88 ± 0.19 1.74 ± 0.16 0.15 
Gender (M/F) 18/19 6/6 7/5 5/8 0.94 
Seated SBP, mmHg 124 ± 12 121 ± 11 121 ± 9 132 ± 12 0.02 
Seated DBP, mmHg 78 ± 9 75 ± 9 75 ± 6 83 ± 10 0.04 
MAP, mmHg 90 ± 10 90 ± 9 90 ± 7 99 ± 10 0.02 
Serum Na, mmol l-1 139.4 ± 2.1 139.4 ± 2.0 138.8 ± 1.8 140.1 ± 2.3 0.29 
GFR, ml/min/1.72m2 95.6 ± 19.2 107.3 ± 18.9 94.6 ± 19.4 84.8 ± 12.6 0.01 
Renin, mU/l 20.1 ± 11.0 20.8 ± 8.3 24.0 ± 14.9 15.9 ± 7.9 0.18 
Aldosterone, pmol/l  268.2 ± 185.1 330.5 ± 222.1 253.2 ± 161.4 224.5 ± 
165.9 
0.35 
VEGF-C pg/ml 106.4 ± 107.9 80.8 ± 71.7 131.6 ± 177.0 111.3 ± 58.3 0.58 
 24-Urinary Na+, mmol  117.1 ± 45.9 102.0 ± 31.0 128.0 ± 61.4 97.4 ± 26.2 0.39 
Data presented as mean ± SD. Difference between age groups was analysed using one-way Anova 










3.4.3     Assessment of drying consistency 
Measured water content did not correlate with sample wet weights (Figure 3.1), suggesting 
that overall, freeze drying removed water consistently in this sample set. This suggested that 
Na+Dry and K+Dry could be used in the analysis. 
 
 




3.4.4     Skin biochemical variables 
 
Results for skin biochemical analyses are shown in Table 3.3 with values shown for the whole 
group and participants divided into tertiles of age. Mean Na+ concentration was 2.15 ± 0.27 
mg/g of wet skin and 5.69 ± 1.30 mg/g of dry skin. Mean K+ concentration was 0.69 ± 0.18 
mg/g of wet skin and 1.82 ± 0.52 mg/g of dry skin. The mean skin water content was 60.9 ± 
8.2 %. The ratio of Na+ to water in skin was higher in the skin than in serum (157.6 ± 41.6 vs. 
139.4 ± 2.1 mmol/l ,  p = 0.01) and more variable (range 118.6 - 236.1 mmol/l). No difference 
was noted in skin electrolytes or water content between the different tertiles of age.  Sex 





Table 3.3: Skin biochemical parameters for Varsity Methods. Data is presented for the whole 
population and tertiles of age. 
 
  Age Tertile  
All subjects 1 2 3 P for difference*  
n 37 12 12 13  
Age  43 22 37 58 < 0.001 
NaWet mg g-1 2.15 ± 0.27 2.09 ± 0.30 2.15 ± 0.26 2.19 ± 0.28 0.69 
NaDry mg g-1  5.69 ± 1.30 5.47 ± 1.37 6.06 ± 1.40 5.57 ± 1.17 0.50 
Na/H2O mmol l-
1  
157.6 ± 41.6 158.9 ± 59.0 149.9 ± 24.3 163.6 ± 36.8 0.72 
KWet mg g-1 0.69 ± 0.18 0.73 ± 0.17 0.71 ± 0.19 0.64 ± 0.19 0.42 
KDry mg g-1 1.82 ± 0.52 1.88 ± 0.41 1.97 ± 0.57 1.62 ± 0.54 0.22 
% water 60.9 ± 8.2 62.9 ± 6.4 61.0 ± 9.9 58.8 ± 8.0 0.47 
Data presented as mean ± SD. Difference between age groups was analysed using one-way Anova 
with post-hoc Bonferonni algorithm. P value < 0.05 taken to be significant 
 
Table 3.4: Skin biochemical parameters for Varsity methods according to sex. 
 
  Age Tertile  
All subjects 1 2 3 P for difference*  
n 37 12 12 13  
Age  43 22 37 58 < 0.001 
NaWet mg g-1 2.15 ± 0.27 2.09 ± 0.30 2.15 ± 0.26 2.19 ± 0.28 0.69 
NaDry mg g-1  5.69 ± 1.30 5.47 ± 1.37 6.06 ± 1.40 5.57 ± 1.17 0.50 
Na/H2O 
mmol l-1  
157.6 ± 41.6 158.9 ± 59.0 149.9 ± 24.3 163.6 ± 36.8 0.72 
KWet mg g-1 0.69 ± 0.18 0.73 ± 0.17 0.71 ± 0.19 0.64 ± 0.19 0.42 
KDry mg g-1 1.82 ± 0.52 1.88 ± 0.41 1.97 ± 0.57 1.62 ± 0.54 0.22 
% water 60.9 ± 8.2 62.9 ± 6.4 61.0 ± 9.9 58.8 ± 8.0 0.47 
Data presented as mean ± SD. Difference between age groups was analysed using one-way Anova 
with post-hoc Bonferonni algorithm. P value < 0.05 taken to be significant 
  
Women had lower skin K+Wet and skin K+Dry and a trend for lower skin Na+Wet and skin Na+Dry 
compared to men. No significant correlations were seen between Na+Wet or Na+Dry and 
putative parameters such age, BMI, BSA, SBP, DBP or MAP (Table 3.5 and 3.6). A significant 
correlation was seen between skin Na+Wet and K+Wet (r = 0.47, p = 0.003) as seen in Figure 3.2.   
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Variable Correlation Coefficient  Significance 
Age, years 0.16 0.34 
BMI, Kg/m2 - 0.19 0.28 
BSA, m2 - 0.04 0.83 
SBP, mmHg - 0.22 0.19 
DBP, mmHg - 0.29 0.09 
MAP, mmHg - 0.27 0.11 
Renin, mU/l - 0.07 0.67 
Aldosterone, pmol/l - 0.04 0.83 
VEGF-C pg/ml - 0.04 0.84 
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Data presented as mean ± SD. Correlation and significance was determined using the Pearson’s 
correlation test.  
 




Variable Correlation Coefficient  Significance 
Age, years 0.01 0.97 
BMI, Kg/m2 0.10 0.55 
BSA, m2 0.23 0.17 
SBP, mmHg 0.06 0.74 
DBP, mmHg 0.12 0.47 
MAP, mmHg 0.10 0.57 
Renin, mU/l 0.03 0.87 
Aldosterone, pmol/l 0.01 0.98 
VEGF-C, pg/ml 0.10 0.57 


















3.4.5     Comparison with Tissue Bank samples 
 
Comparison between skin biochemical parameters for VARSITY methods and Tissue Bank 
samples is shown in Table 3.7. There was no significant difference in Skin Na+Dry or Skin 
Na+Wet between both sets of samples. Levels of skin K+ per unit wet weight (K+Wet) was lower 
in the Tissue Bank samples (0.57 ± 0.17 mg/g vs 0.69 ± 0.76 mg/g; p = 0.02). There was no 
significant difference skin K+ per unit wet dry weight. Tissue Bank samples were significantly 
larger than Varsity methods samples (0.062 ± 0.0026 mg vs. 0.023 ± 0.009 mg, p < 0.001). 
The measured water content was similar between both sample sets (62.3 ± 6.5 % vs. 60.9 ± 
8.3 %, p = 0.29).   
 
Table 3.7: Skin biochemical parameters Tissue Bank skin samples compared with Varsity Methods  
 
 Varsity methods  Tissue Bank P for difference  
n 17 37  
Age  43 ± 16 39 ± 16 0.38 
Gender (M/F) 0/17 18/19 - 
Skin NaWet mg g-1 2.25 ± 0.23 2.15 ± 0.27 0.18 
Skin NaDry mg g-1  6.35 ± 1.76 5.69 ± 1.30 0.17 
Skin Na (mmol/l) 156.2 ± 8.8 157.6 ± 41.6 0.89 
Skin KWet mg g-1 0.57 ± 0.17 0.69 ± 0.76 0.02 
Skin KDry mg g-1 1.56 ± 0.50 1.82 ± 0.52 0.10 
Wet weight g 0.062 ± 0.026 0.023 ± 0.009 < 0.001 
% water 62.3 ± 6.5 60.9 ± 8.3 0.29 
Data presented as mean ± SD. Difference between groups was analysed using the unpaired t test with 
normally distributed data and the Mann-Whitney U test for non-normal data. P value < 0.05 taken to 








3.5     DISCUSSION 
 
The Varsity methods study showed that human skin Na+ and K+ can be quantified in healthy 
humans using skin biopsies and ICP-OES. No significant associations were seen between skin 
Na+ and age, BP or other putative parameters. The use of local anaesthetic did not appear to 
affect skin Na+ and water content.  
Table 3.8 shows all studies of that analysed Na+ or K+ in full thickness skin, with data from 
Varsity methods included for comparison. It can be seen that the values for skin Na+, K+ and 
water content are within the range of values for previous direct chemical measurements in 
full thickness human skin done more than 70 years ago. 181-184,186 These studies used 
precipitation techniques to quantify skin electrolyes, which would have had greater 
variability and less sensitivity than ICP-OES. Recently, during the course of this work, 2 
further studies on skin Na+ analysis using modern techniques were published. 143,195 Kopp et 
all used atomic spectroscopy to measure wet skin Na+ in cadaveric calf skin. Their values for 
wet skin Na+ appeared lower than in VARSITY methods, though cadaveric tissue could have 
had elemental shifts secondary to tissue autolysis. 194 Fischereder et al used ICP-OES to 
measure skin Na+ and K+ in abdominal skin obtained from 27 kidney transplant recipients on 
haemodialysis and 21 healthy donors under general anaesthetic. 143 This group used a 
similar technique for skin elemental analysis but used a pressure digestion system instead of 
freeze drying. Their values for skin Na+ Dry were similar to Varsity methods, but with higher 
variability. Fischereder et al analysed skin Na+ Wet in their 48 patients and their values 












      Table 3.8: Previous studies assessing skin Na+ and K+ content in full thickness skin samples with data from 
VARSITY methods included for comparisons. 143,181-184,186,195 














% Water  
Brown 1926 10 Epidermis & dermis 




- 3.60 ± 0.37  - 2.39 ± 0.51  
Brown 1927 27 Epidermis & dermis 
Chest and waist 
Cadavers 
Nil  Precipitation 
with BaCl2 
1.58 ± 0.20 - 0.91 ± 0.24 - 63.5 ± 3.7 
Urbach 1928 26 Epidermis & dermis 
Various regions 
Healthy volunteers 
Nil Precipitation 0.95 – 1.39 - - -  






- 3.50 ± 0.02 - 2.47 ± 0.04  
Eisele 1945 18 Epidermis and dermis 
Mastectomies        
Limb amputations 
Nil  Butler-Tuthill 
method 
2.14 ± 0.18 7.56 ± 1.03 0.64 ± 0.13 2.28 ± 0.50 70.8 ± 20.1 





1.77 ± 0.37 - - -  
VARSITY 
methods 
37 Epidermis & dermis  
Lower back 
Yes ICP-OES 2.15 ± 0.27 6.11 ± 1.17 0.57 ± 0.17 2.06 ± 0.52 62.4 ± 9.0 
Fischereder 
2017 
21 Epidermis & dermis 
Abdomen 
Healthy kidney donors 
Nil ICP-OES - 6.57 ± 4.03 - 1.76 ± 1.09  
Fischereder 
2017 
27 Epidermis & dermis 
Abdomen 
Dialysis patients 
Nil ICP-OES - 7.05 ± 3.34 - 1.92 ± 0.98  
 
Elemental measurements per wet weight of tissue may have potential inaccuracies 
introduced by changes in sample hydration during sample processing, which is why previous 
animal studies expressed skin Na+ and K+ concentrations per unit dry weight after samples 
underwent dry ashing. 134,244,245 There is no definite consensus on how skin electrolyte 
concentrations should be expressed. For the purpose of making comparisons to previous 
studies and evaluating the normal variation in healthy subjects, skin Na+ and K+ in this study 
were expressed in terms wet and dry weight.   
The use of lidocaine 1% local anaesthetic for skin biopsies was a potential source of sodium 
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and water contamination for VARSITY methods. Comparison with Tissue Bank samples 
showed no significant difference is skin Na+ or water content (Table 3.7). This suggests no 
significant sodium and water contamination for VARSITY methods. Furthermore, previous 
studies which did not use local anaesthetic and had similar skin Na+ values (Table 3.8).  
23Na-MRI studies assessing in human skin in-vivo showed a variation of skin Na+ storage with 
age and sex and a positive correlation between skin Na+ and SBP. 195,197,198,204 This has not 
been shown by this study or other previous studies that involved direct chemical 
measurements of skin Na+.143,181-184,186,195,197,204 Skin Na+ quantification with 23Na-MRI has 
yielded values ranging from 10-40 mmol/l of water. 195,197,198,204 In VARSITY methods mean 
Na+:water ratio was higher at 157.6 mmol/l (range 118.6 - 236.1 mmol/l). This indicates a 
difference in sensitivity between both techniques for quantifying skin Na+, whereby 23Na 
MRI may quantify Na+ in ionised form and bound to GAGs differently, as suggested by 
previous 23Na MRI studies in cartilage. 259 It is also not known if skin sodium follows a 
topographical variation. This could be of relevance as it may explain some of the differences 
between 23Na MRI analysis of calf skin and the analysis of back skin in VARSITY methods, as 
well as previous studies that looked at skin from various regions (Table 3.8).   
 
Skin K +appeared to be lower in women than in men (Table 3.4) and lower in the Tissue Bank 
breast skin samples compared to VARSITY methods (Table 3.7). The reasons for these 
observations is unclear and previous studies did not evaluate sex specific differences in skin 
K +.181,182,184,186-188The epidermis has a significant K+ content and this difference could be 
explained by the epidermis being thinner in women. 188,260 Structural differences between 
lower back and breast skin could potentially explain differences in skin K + content. There 
was a trend for lower skin Na+ in women in VARSITY methods, in keeping with the findings in 
23Na MRI studies which showed lower Na+ skin storage in women. The reasons for this are 
unclear. Men have a thicker epidermis and dermis at all ages and may have higher levels of 
dermal glycosaminoglycans, leading to sex-specific difference in skin Na+ storage 261,262 
 
As shown above the values obtained for skin mean Na+: water ratio show a higher ratio than 
plasma, which may be in keeping with the existence of non-osmotic sodium storage in the 
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skin as observed in previous rat studies. 132,133,244,245 In this study, the mean skin Na+ 
concentration was 2.15 mg/g of wet weight. If skin sodium follows a uniform distribution, in 
a 70 kg human with skin constituting 6 % of body wet weight, this translates into a total Na+ 
content of approximately 8.6 g on a basal salt intake of 7g a day. This approximates to 
around 10 - 14 % of total body sodium. 263 
 
Skin Na+ positively correlated with skin K+ per wet weight of skin (Figure 3.1) This finding was 
noted recently by Fischereder et al and could reflect the balance of intracellular and 
extracellular cations in the skin.143 Further work is needed to understand the relevance the 
mechanisms underpinning this relationship. 
There are several limitations to this pilot study.  VARSITY methods had a small study size and 
data from 11 participants were retrospectively excluded because of analytical issues, and 
this would limit the generalisability of its findings and the ability to detect significant 
relationships between skin Na+ and other parameters. Our skin biopsies were small and 
taken from the lower back, and we had no means of ascertaining if they were representative 
of the whole skin or if skin Na+ varies with region and time.  
 
3.6     CONCLUSIONS 
 
This pilot study has shown the feasibility of skin elemental analysis with ICP-OES using the 
techniques described. The sex differences in skin electrolytes observed were further 










Chapter 4     VARSITY STUDY 
4.1    INTRODUCTION 
 
Large population studies suggest that excessive dietary sodium, principally as the chloride 
salt, is an important trigger for hypertension. 34,36 The mechanisms for this relationship are 
still debated. 42,45 Recent observations oppose the traditional view that body sodium 
balance functions as a two-compartment model, supporting the existence of non-osmotic 
sodium retention in a third compartment. In support of this, studies in rat models have 
shown that the skin is capable of osmotically inactive Na+ storage, via glycosaminoglycans, 
serving as an important mechanism for buffering volume and blood pressure changes with 
salt intake. 131,133,134 High salt intake in rats also stimulates tonicity-responsive enhancer 
binding protein (TonEBP;NFAT5) secretion by mononuclear phagocyte system (MPS) cells, 
which mediates vascular endothelial growth factor C (VEGF-C) expression. This results in 
enhanced interstitial lymphatic drainage and increased expression of endothelial nitric oxide 
synthase (eNOS), which buffers the hemodynamic response to salt loading. 133,134 However, 
the relevance of these mechanisms in humans is unclear.  
 
Previous studies have not examined the relationship between dietary salt, skin Na+and 
blood pressure. A few studies have examined VEGF-C in humans, with plasma VEGF-C being 
shown to be higher in hypertensives compared to normotensives and a trend for decline in 
circulating VEGF-C with age. 133,198 Recent 23Na magnetic resonance imaging (MRI) studies in 
humans have shown a direct relationship between skin Na+ and BP, as well as age and sex 
differences in the capacity to store skin Na+.197,204 Although MRI data were confirmed by 
direct ashing of human cadaveric samples, they have not yet been confirmed by direct 
chemical analysis of skin electrolytes in humans. 195 Moreover,23Na MRI has not been used 
to measure changes in skin Na+ with dietary salt modulation.   
 
The ability to taste salt, or salt taste sensitivity, is believed to be a primary determinant of 
salt intake. The threshold for detect the taste of salt has been observed to be greater in 
subjects with hypertension and diabetes, and positively correlated with age and BP. 264,265 
Mechanisms for these observations are unclear. The transduction of the taste of salt is 
believed to occur via specific apical amiloride -sensitive (ENaC) sodium channels in the 
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lingual epithelium and factors such as aldosterone secretion and dietary salt depletion are 
known to modulate this process. 266-268 It is unknown if VEGF-C influences the ability to taste 
salt. 
 
Capillary rarefaction is the reduction in the density of capillaries and has been observed in 
the skin of hypertensives using video microscopy, and is believed to influence systemic BP 
and target organ damage 11,224,225 Salt intake has been shown to influence skin capillary 
rarefaction in subjects with mild hypertension, with a negative correlation seen between 
skin capillary density and urine sodium excretion. 11 The relevance of skin capillary 
rarefaction and the effect of dietary salt modulation on skin capillary density in healthy 
subjects is uncertain.  
 
On this background the VARSITY study was a double-blind, randomized, crossover study in 
healthy subjects comparing the effects of a high and low dietary salt intake on skin 
electrolytes, haemodynamic and biochemical variables, including plasma VEGF C. Therefore, 
the work in this chapter sought to determine if the mechanisms described in rodent skin 
models function in humans. Furthermore, the VARSITY study assessed changes in skin 



















Skin Na+ and plasma VEGF-C increase with dietary salt loading and the degree of BP change 
relates to the change in these parameters - individuals with a greater rise in skin Na+ and 




. Skin Na+ is positively associated with plasma VEGF-C levels, blood pressure and  
 other hemodynamic variables.  
. The ability to taste sodium is positively associated with plasma VEGF-C levels.  
. Skin capillary density decreases with dietary salt loading and correlates with  




































To study the change in skin Na+ with an increased dietary salt intake by direct chemical 




To study the following: 
 
1. The change in the following variables with dietary salt modulation: 
⁃ Plasma VEGF-C and sFLT-4 (soluble receptor for VEGF-C) 
⁃ Plasma renin and aldosterone 
⁃ Blood pressure (clinic and ambulatory) 
⁃ Cardiac output (CO) and peripheral vascular resistance (PVR)  
⁃ Arterial stiffness (as measured with pulse wave velocity and augmentation index) 
⁃ Heart rate variability (a measure of autonomic nervous system activity) 
⁃ Ability to taste salt 
⁃ Skin capillary density 
 
2 The correlation between skin sodium, blood pressure, other hemodynamic variables 
and plasma VEGF-C. 
3 The relationship between the ability to taste sodium and plasma VEGF-C levels.  









4.4    METHODS 
 
4.4.1    Study design and protocol 
 
The VARSITY study was a 4-week single-centre, double-blind, randomized, crossover study as 
depicted in 4.1.  Volunteers were screened and placed on a 4g low salt diet (equivalent to 70 
mmol of sodium/day) at visit 1 to standardize the background sodium intake. Participants 
were outpatients and given a printed booklet provided by practicing dietitians on how to 
maintain a low salt diet, with email and telephone advice offered throughout the duration of 
the study. Baseline salt consumption was assessed by checking 24-hour urinary sodium 
excretion (UNaV) up to 3 days after visit 1.  
 
Figure 4.1 Illustration of the VARSITY study’s 4-week double blind crossover design. Participants 
had a 7-day run in on a 4g low salt diet before being asked to take either 200 mmol slow sodium or 
placebo tablets for 7 days. This was followed by a 7-day washout period before they received the 






Participants with high baseline salt intakes were given further advice on dietary salt 
restriction. After a 1-week run-in period on a low-sodium diet, participants then received at 
200 mmol/day of slow sodium tablets (HK Pharma, UK) for 7 days or an equal number of 
placebo tablets (99.25 % lactose, 0.75 % magnesium stearate; Rayonex, UK) during weeks 2 
and 4. The order of treatment was randomised. Study compliance was assessed by checking 
24-hour UNaV within 48 hours of visits 2, 3, and 4, with participants and investigators 
blinded to the results.  Medication compliance was assessed by participants returning used 
tablet bottles. Each participant was seen at approximately the same time at each study visit 
in a temperature-controlled study room. Weight was measured at every visit using the same 
calibrated scales, with one layer of clothing and no shoes.  Participants were required to 
refrain from caffeine, alcohol, strenuous exercise and the application of moisturizer or fake 
tan to their lower back for 6 hours prior to study visits. At each visit, seated brachial BP was 
recorded after a minimum of 5 minutes rest. After a further 10 minutes rest in supine 
position, brachial BP, CO, stroke volume (SV), pulse wave analysis, aortic pulse wave velocity 
and heart rate variability were taken.  
Ambulatory blood pressure monitoring (ABPM) was carried out with the 24-hour UNaV 
collections within 48 hours of visits 2, 3, and 4. Venepuncture and venous blood samples 
were collected in a standard 4.7 ml serum gel tube for electrolytes, a 2.6 ml EDTA tube for 
plasma renin and aldosterone and a 4.7 ml EDTA tube for plasma VEGF-C and sFLT-4. At each 
visit, the participants’ ability to taste salt was tested with salt solutions of different 




4.4.1.1     Study blinding and randomisation 
 
The order in which the participants received placebo or slow sodium tablets was 
determined with automated randomisation computer program (Microsoft excel version 
14.0). This was conducted by Dr Kaisa Mäki-Petäjä from the EMIT unit before the start of the 
study, who labelled the order of placebo and slow sodium tablets in pre-prepared bottles. I 
was blinded to the randomisation and tablet preparation. The randomisation code was kept 
by Dr Kaisa Mäki-Petäjä and used by her for unblinding following skin elemental analysis and 
analysis of haemodynamic and biochemical variables. 
 
4.4.2     Subjects 
 
Participants were healthy individuals aged between 18 and 50 years and recruited by 
advertisement. Exclusion criteria included hypertension (sustained blood pressure>140/90 
mm Hg), current use of antihypertensive drugs, diuretics, salt supplements, renal 
impairment, or pregnancy. All participants gave informed consent prior to study 
participation. Ethical approval for the study was obtained from a National Research Ethics 
Committee (REC Reference: 11/H0304/003) and was performed according to Good Clinical 











4.4.3     Haemodynamic assessments 
 
4.4.3.1     Blood pressure 
 
4.4.3.1.1     Clinic blood pressure 
 
In all participants, brachial blood pressure was measured using a validated semi-automated 
oscillometric device (HEM-705CP, Omron Corporation) after 5 minutes of rest in seated 
position BP was measured in the non-dominant arm in triplicate, with approximately a 1- 
minute interval between readings.  The average of three readings was recorded in use for 
analysis. Further readings were taken if there was a difference of > 5 mmHg was observed 
between the 2nd and 3rd readings. After 10 minutes rest in supine position, brachial blood 
pressure was taken in an identical manner. 
  
 
4.4.3.1.2     Ambulatory blood pressure 
 
Ambulatory blood pressure monitoring (ABPM) was carried out within 48 hours of each visit 
using Mobil-O-Graph® (IEM, USA). The ABPM device was placed on the non-dominant arm. 
Ambulatory BP recordings were analysed with the Mobil-O-Graph® system software 
package. A total of 40 readings were taken in a 24-hour period - 30 during the day (0800 - 
2159 hrs) and 10 at night (2200 - 0759 hrs). ABPM Recordings were rejected if less than 30 
readings were recorded. 
 
 4.4.3.2     Central haemodynamic measurements     
 
4.4.3.2.1     Pulse wave analysis and arterial wave reflections 
 
Radial artery waveforms were measured using a high-fidelity micromanometer (SPC- 301; 
Millar Instruments) from the wrist of the non-dominant arm with the participant lying 
supine after a further five minutes of rest, as previously described. 269 Pulse wave analysis 
was carried out using SphygmoCor software (AtCor Medical, Sydney) was used to calculate 
augmentation index (AIx), the difference in pressure between the first and second systolic 
peaks of the pulse wave, expressed as a percentage of the pulse pressure. AIx 
 107 
measurements with an operator index of below 80% were rejected. Heart rate was recorded 
during measurement of the radial artery waveform and central mean arterial pressure 
(MAP) was obtained as the value given by the software derived from integration of the 
waveform, as previously described. 269 The equipment used for pulse wave analysis and a 
typical SphygmoCor software output are shown in Figures 4.2 and 4.3 respectively.  
 



















4.4.3.2.2     Aortic pulse wave velocity 
 
Carotid-femoral aortic pulse wave velocity (aPWV) was measured using the SphygmoCor 
system (AtCor Medical, Sydney). Subjects had at least 15 minutes rest before supine blood 
pressure was measured in triplicate and the mean was entered into the SphygmoCor 
software. Electrocardiogram (ECG) electrodes were attached to each subject to enable 
gating of arterial waveforms when they were recorded. Sequentially recording of ECG-gated 
carotid and femoral artery waveforms was then performed using applanation tonometry, as 
described previously. 269 Waveforms were gated to the ECG R wave. Measurements were 
made in triplicate. The path-length for the determination of aPWV was measured as the 
surface distance between the suprasternal notch and femoral site minus the distance 
between the suprasternal notch and point of maximum carotid pulsation, which was marked 
in the skin. This measurement was made using a tape measure and entered into the 
software. aPWV was calculated by the SphygmoCor software, dividing the surface distance 
by the by the wave transit time. The mean of 2 aPWV readings was taken and accepted if the 
SD was less than ± 0.5 m/s. The method used to calculate aPWV is illustrated in Figure 4.4.  
 109 
 
Pulse wave analysis and arterial wave reflections and aortic pulse wave velocity were 
performed by myself after I received training from Dr Kaisa Mäki-Petäjä and Jean Smith and 
Jean Woodcock Smith. I performed measurements independently after I was able to achieve 
AIx measurements with an operator index of below 80% and aPWV readings with SD of less 





















4.4.3.3     Cardiac output 
 
Cardiac output (CO) and stroke volume (SV) were determined by a non-invasive, inert gas 
rebreathing technique with the InnoCorTM gas analyser system (Innovision, Odense, 
Denmark) as shown in Figures 4.6 and 4.7. In this technique, the concentration of an 
absorbed gas (nitrous oxide, N2O) and a non-absorbed gas (sulphur hexafluoride, SF6) using 
a photoacoustic multi-gas analyser. The difference in absorption of the two gases is 
proportional to pulmonary blood flow, and hence cardiac output. This technique has 
previously been validated against thermodilution and direct Fick methods for measurement 
of pulmonary blood flow and cardiac output. 270-274 CO and SV were analysed after central 
haemodynamic measurements were taken. While resting in supine position, subjects 
continuously rebreathed a gas mixture (1% Sulphur hexafluoride, 5% Nitrous oxide, and 94% 
oxygen) over 20 seconds with a respiratory rate of 20 breaths/min. Continuous samples of 
expired gases were analysed by an infrared photoacoustic gas analyser (InnoCor; Innovision 
A/S, Chicago, IL, USA) to determine CO and SV. All measurements were taken by myself after 
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I received training from Dr Kaisa Mäki-Petäjä. 
Figure 4.6: Equipment used for the Innocor® inert gas rebreathing technique. 
 






4.4.3.4     Peripheral vascular resistance 
 
Peripheral vascular resistance (PVR) was calculated using supine mean arterial pressure 
within 1 hour of Innocor measurements as follows:  
 
 
4.4.3.5     Heart rate variability 
 
Heart rate variability (HRV) was measured at every visit using the SphygmoCorTM HRV 
System, as previously described. 275 This system utilises a 3-lead ECG to non-invasively 
provide an assessment of sympathetic and para-sympathetic autonomic function in both the 
time and frequency domains, using software that calculates the statistical parameters of the 
normal R–R intervals by excluding ectopic beats of the electrocardiogram (ECG). Participants 
initially had a resting 12-lead electrocardiograph at screening to confirm the presence of 
normal sinus rhythm. HRV was measured at rest in the supine position over a period of 10 
minutes with participants placed in a quiet, darkened room at approximately the same time 
of day at every visit. Participants are asked to maintain a regular breathing pattern during 
measurements. An example of HRV data output on the SphygmoCorTM system is shown in 
Figure 4.8. The variables measured were: 
 
3. power in the low-frequency (LF) range, representing mostly sympathetic activity 
4. power in the high-frequency (HF) range, representing parasympathetic function and 
is considered to be a marker of vagal activity 
5. total power of all frequencies, representing all cyclic components of HRV 
 
The high frequency and low frequency components of HRV were normalized by dividing 
their absolute powers by the sum of high-frequency power and low-frequency power (total 
power), multiplied by 100. I performed all HRV measurements after I received training from 




Fig 4.8: HRV data output obtained using SphygmoCorTM HRV System. As seen above spectral 
analysis of a series of successive R-R intervals provides the frequency domain analysis. This divides 
the heart rate spectrum into different components that quantify sympathetic and vagal influences 
























4.4.4     Biochemical measurements  
 
4.4.4.1     Serum and plasma biochemistry  
 
Serum electrolytes (Na+, K+, Cl- and creatinine), plasma renin and plasma aldosterone were 
measured in an accredited laboratory (Cambridge University Hospitals Department of 
Clinical Biochemistry). Estimated glomerular filtration rate was measured using the 
Modification of Diet in Renal Disease (MDRD) formula. 255  
 
4.4.4.2     VEGF-C and sFLT-4  
 
Plasma VEGF-C and sFLT-4 were measured at each visit. For each participant, a single EDTA 
sample was centrifuged at 4°C (3200 rpm for 15 minutes), and the plasma separated and 
stored at - 80°C prior to analysis for VEGF-C and sFLT-4 (soluble receptor for VEGF-C) by 
sandwich immunoassay. For VEGF-C, in view of the high standard deviation for our previous 
assay, we used an alternative Quantikine ELISA kits from R&D Systems (Abingdon, United 
Kingdom). This was recently used for a similar study on the effect of dietary salt modulation 
on plasma VEGF-C. 159 sFLT-4 was measured by an in-house electrochemical luminescence 
immunoassay on the MesoScale Discovery (Rockville, MA, USA) assay platform using 
antibodies and standards from an R&D Systems DuoSet at the Core Biochemical Assay 
Laboratory (CBAL) in Cambridge.  Reproducibility of the VEGF-C and sFLT-4 assays were 
checked by the team at CBAL by running quality control samples at the beginning and end of 
each batch. 
 
4.4.4.3     24-hour urine biochemistry 
 
The 24-hour urine collections were made for Na+, K+, Cl- , creatinine and albumin within 48 
hours of each visit, starting at 08:00 and discarding the first morning void. Urine electrolytes 
were measured in an accredited laboratory (Cambridge University Hospitals Department of 
Clinical Biochemistry). Samples with a 24-hour urine creatinine value of less than 5.3 mmol, 
the lower limit of normal at the Cambridge University Hospitals Department of Clinical 
Biochemistry, were regarded as incomplete and rejected. Urinary creatinine clearance was 
calculated using the following formula as previously described276: 
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Creatinine clearance (ml/min) = [Urine Creatinine concentration (mmol) x urine volume 
(ml) ]/plasma creatinine (mmol) x 1440 
 
Fractional excretion of sodium (FeNa) is the percentage of the sodium filtered by the kidney 
which is excreted in the urine. This was measured in 24-hour urine collections using the 





4.4.5     Skin biopsy procedure 
 
As described in 2.2, skin punch biopsies of 5mm diameter were taken from the lower back, 
using local anaesthetic (lidocaine) by myself. The first biopsy was done on the right at the 2nd 
visit. The second biopsy was done on the left at the 4th visit in an approximately symmetrical 
position. Any fat obtained with the biopsied tissue was removed. Skin samples were placed 
in cryovials and snap frozen in liquid nitrogen once they were obtained and then stored at 
−80°C until analysis.  As described in 2.5, after 32 participants completed the study, we 
developed Na+-free lidocaine using Dextrose as an excipient (Lidocaine 1% with Dextrose 
3.5%, Tayside Pharmaceuticals, Dundee). This was used in the remaining 16 participants. 
Skin Na+ values for obtained with each type of local anaesthetic were compared at the end 
of the study. 
 
4.4.6     Skin elemental analysis 
 
Skin samples were halved longitudinally with a scalpel under microscopic view, ensuring 
even splitting of the epidermis and dermis, as described in 2.5.3. One portion of each skin 
sample was sent on dry ice to the MRC Elsie Widdowson laboratory to determine Na+, K+ and 
water content by ICP-OES analysis as previously described in 2.2. The remaining portion was 
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stored at −80°C in the EMIT unit for further analysis. The procedures for sample preparation 
for ICP-OES were carried out as outlined in 2.3.2 and 2.3.3.  
 
4.4.7     Expression of skin elemental concentrations 
Skin Na+ and K+ concentrations and water content were calculated and expressed as 
described in 2.3.5. Elemental measurements per wet weight of tissue may have potential 
inaccuracies introduced by changes in sample hydration during sample processing, which is 
why previous animal studies or skin Na+ with dietary modulation expressed skin Na+ and K+ 
concentrations per unit dry weight after samples underwent dry ashing. 134,244,245Therefore, 
Na+Dry was used to compare changes in skin Na+ with salt loading.   
4.4.8     Assessment of drying consistency  
This was assessed as described in 2.3.6. 
4.4.9     Salt taste sensitivity  
Salt taste sensitivity in participants was evaluated using a staircase method with paired 
difference testing, which was originally described by Cornsweet and used in previous studies 
of salt taste sensitivity. 264,265,278,279. Salt (NaCl) solutions of different concentrations were 
made up by dissolving table salt (Waitrose, UK), weighed with a digital weighing scale 
(Mettler PM 400, Hampton) in double distilled deionised water obtained by reverse osmosis 
(ROS) using a Fresenius AquaUNOTM system at the Addenbrookes Hospital Haemodialysis 
unit. 6 solutions of NaCl at concentrations 0.05%, 0.10%, 0.2%, 0.4%, 0.8% and 1.6% were 
used in the test. These were constituted as follows: 
 
1. 0.05% NaCl - 0.05 g NaCl in 100 ml ROS water 
2. 0.1% NaCl - 0.1 g NaCl in 100 ml ROS water 
3. 0.2% NaCl - 0.2 g NaCl in 100 ml ROS water 
4. 0.4% NaCl - 0.4 g NaCl in 100 ml ROS water 
5. 0.8% NaCl - 0.8 g NaCl in 100 ml ROS water 




Salt taste testing was carried out in a single-blind manner by myself.  Each participant was 
presented with a pair of liquids (salt solution and ROS water) in a random order with 
increasing concentrations of NaCl (as shown in Table 4.1), and asked if either solution 
contains salt. A whole-mouth gustatory test procedure was used for the different solutions. 
Participants were asked to apply 1 ml of solution evenly on the tongue using a 5 ml syringe, 
hold the solution for a few seconds and then swallow it. Participants were each given a cup 
of ROS water to rinse their mouths before tasting each solution. The following 2 parameters 
for salt taste sensitivity were assessed: 
 
Salt recognition threshold - This was the lowest concentration of NaCl at which the 
participant recognized the solution as being salty. 280 This is a measure of salt taste 
sensitivity. 
 
Salt detection threshold - This was the lowest concentration at which a participant could 
distinguish between ROS water and salt solution. 281 This is a measure of salt taste acuity. 
 
Table 4.1: Scheme and order of solutions used to test salt taste sensitivity. Participants we given 
solutions in the order A - F with solution 1 and 2 given in random order. 
 
Solution Salt – Y/N  Solution Salt – Y/N  
Solution A1 
0% NaCl 
































Published values for salt detection and recognition threshold have varied in the literature 
with different techniques used. Rabin et al recorded a mean salt detection threshold of the 
0.165 % in 203 normotensive adults. 282 Choe et al recorded salt recognition threshold range 
of 0.045 - 0.285% in 218 healthy adults. 283 Prior to being used in the VARSITY study the 
above solutions were tested on 3 volunteers from the EMIT unit. 2 recorded salt recognition 
thresholds of 0.2 % NaCl and the 3rd recorded a threshold of 0.1 %.On the basis of these 
observations the range of salt concentrations in Table 4.1 were chosen for the VARSITY 
study. Salt recognition and detection thresholds were assessed in all participants in each 
visit after haemodynamic measurements at Visits 1 and 3, and after capillaroscopy at Visits 
2 and 4. 
 
4.4.10    Skin capillaroscopy 
 
Skin capillary density was measured by intravital microscopy following a validated 
technique. 225,284 Participants were studied at approximately the same time between 0900 
and 1100 on visit 2 and 4 and were asked to have an overnight fast from midnight prior to 
these visits. Measurements were carried out in a temperature-controlled room (21 – 24 
degrees Celsius) after at least 20 minutes of acclimatisation. Measurements were performed 
in the morning with participants in the seated position and the left hand supported at the 
level of the heart. Movement of the hand was restricted by placing the hand palm down on 
a table. Video-microscopy was performed on the dorsal skin of the middle phalanx with a 
hand-held digital capillaroscope (OptiliaTM, Sweden), containing a 6500 K LED colour lamp 












Fig 4.9: Equipment and techniques for skin capillary density measurement. A: The OptiliaTM hand-
held digital capillaroscope, showing equipment set up. B: Technique of video-microscopy. C: The 
AccosonTM Duplex Aneroid cuff which was applied to the wrist for venous congestion. 






This device has been previously used to quantity skin capillaries in neonates. 285 A drop of 
liquid paraffin oil was applied to the skin to reduce light reflection. A system magnification 
of 200x was used. Images were processed with OptiPix capillaroscopy research software 
(OptiliaTM, Sweden) and stored as JPEG images, which were analysed offline to count the 
total number of visible (i.e. perfused) capillaries. For each participant, I selected a region of 
interest on the middle phalanx and captured 4 images taken 1 minute apart at baseline. A 
further 4 images were taken from the same point after venous congestion, which was 
achieved using the application of a cuff (AccosonTM Duplex Aneroid Hand Model) to the 
wrist, inflated to 60 mmHg for 2 minutes (Figure 4.9C). Venous occlusion was previously 
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shown to effectively maximise the number of visible capillaries. 284 The increase in capillary 
density during venous occlusion (capillary recruitment) has been noted to be attenuated in 
hypertensives. 228  
 
The number of visible capillaries per 1.0 mm2 field was calculated from each capillaroscopy 
image taken at unoccluded and post venous congestion using a software program developed 
by Dr Stephen Smith from the EMIT unit (Figure 4.10). This novel program was written in the 
Python (version 2.7) programming language and used a Canny edge finding algorithm to 
detect and count visible capillaries per 1.0 mm2. Counted capillaries were highlighted in blue 
(Figure 4.10).  
 
4.10: Examples of skin capillary images. (A)Capillaroscopy image obtained at 200x using the 
OptiliaTM system. (B)Capillaries within a 1.0 mm2 field were identified using the software program. 
.  
The accuracy of the software was tested by a visual inspection by Dr Smith and myself and 
corrections were made if necessary. The average capillary count for 4 images was used to 
obtain the mean capillary density (MCD) per mm2. Capillaroscopy images were reviewed and 
software analysis run by Dr Stephen Smith, who was blinded to the order of treatment. 
Participants were excluded if the images were of inadequate quality and the software was 
unable to detect capillaries, as judged by both Dr Stephen Smith and myself, and if the SD 
for a set of 4 images pre or post cuff exceeded 19/mm2. Capillaroscopy is only possible in the 
lighter pigmented subjects and therefore, only Caucasians were included in this present 
study.  
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4.4.11     Statistical analysis 
 
4.4.11.1     Primary outcome and power calculations  
 
The planned primary outcome measure for which the Varsity main study the change in skin 
Na+ with salt loading, as measured per dry weight (Na+Dry). As published data available on 
changes in skin sodium concentration in response to salt loading in humans were lacking, 
the initial sample size of 48 was based on other salt loading studies of a similar design. A 
planned interim analysis was done after 26 participants completed the study and revealed 
freeze drying was not consistent across samples and Na+Dry values were not reliable. A 
pragmatic approach was taken, and a further analysis was planned after 48 participants 
completed the study. When the study was completed the limitations of freeze drying skin 
samples persisted. For this reason the primary outcome we changed from absolute dry Na+ 
to Na+:K+ ratio.  
4.4.11.2     Main study analysis 
 
Normally distributed data are presented as mean ± SEM and non-normal data as median 
and interquartile range(IQR). Tests for normality were carried out using the Shapiro Wilk’s 
test. Student’s paired t-tests were applied to paired observations after placebo and slow 
sodium for normally distributed data and the Wilcoxon signed-rank test for non-normally 
distributed data. Independent samples t-tests were applied to unpaired observations for 
normally distributed data and the Man Whitney test for non-normally distributed data. 
Correlation coefficients between skin Na+:K+ and putative parameters such as age, sex, body 
mass index (BMI) and haemodynamic variables were calculated using Pearson’s method for 
normally distributed variables and Spearman’s method for non-normally distributed 
variables. I then performed multiple regression analysis to examine the parameters that 
independently influence skin Na+:K+. The presence of carry-over effect for changes in skin 
Na+ was checked using univariate analysis of variance as previously described. 286 A 
probability of < 5% was used to reject the null hypothesis. Statistical analysis was performed 
with the SPSS software (version 23.0). Graph-Pad Prism 7.0 (GraphPad Software Inc., La Jolla, 
CA, USA) was used to construct graphs and figures. 
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4.4.11.2.1     Sex specific analysis  
 
In analysing the data it became apparent that that skin Na+:K+ differed by gender and a post-
hoc gender specific analysis was therefore undertaken. The effects of contraceptive 
treatment on skin biochemistry is unknown. A further analysis of women according to 
contraceptive treatment was undertaken to see if this influenced observed sex differences. 
 
4.4.11.3     Salt taste sensitivity  
 
The Wilcoxon signed-rank test was used to compare salt recognition and detection 
thresholds post placebo and slow sodium treatments. Spearman’s correlation coefficient by 
rank was used to analyse the correlation between the salt recognition or detection 
thresholds and plasma VEGF-C, as well as putative parameters such as age, BMI, BP, plasma 
renin and aldosterone. Multiple regression analysis was then performed to examine the 
parameters that independently influence salt recognition and detection thresholds. P-values 
less than 0.05 were considered significant. 
 
4.4.11.4     Skin capillaroscopy 
 
Mean capillary density at baseline (unoccluded) and after venous occlusion was compared 
using the Student’s paired t test. The relationship between mean capillary density and 
putative parameters such as age, body mass index (BMI) and haemodynamic variables were 
calculated using Pearson’s method for normally distributed variables and Spearman’s 
method for non-normally distributed variables. We then performed multiple regression 






4.5.   Results   
4.5.1     Analysis of whole study population 
 
4.5.1.1     Baseline characteristics 
 
A total of 24 men and 24 women completed the study with a mean age of 30 ± 2 years 
(range 18–49 years). Baseline characteristics are shown in Table 4.2. Our study population 
had a lower baseline sodium intake compared to the current average intake in England 






































































Baseline variables  (n=48) 
Age, years 30 ± 1 
Ethnicity (Caucasian) 45/48 
Body weight, kg 69.2 ± 1.6 
Height, cm 171 ± 1 
BMI, kg ms-2 
 
23.0 (21.9 – 24.4) 
Haemodynamic variables  
Seated SBP, mmHg  120 ± 1 
Seated DBP, mmHg 74 ± 1 
Seated MAP, mmHg 89 ± 1 
Seated HR, BPM 72 ± 1 
Supine SBP, mmHg  118 ± 1 
Supine DBP, mmHg  70 ± 1 
Supine MAP, mmHg 87 ± 2 
Supine HR, BPM 65 ± 1 
24-hr MAP 93 ± 1 
24-hr SBP 118 ± 1 
24-hr DBP 73 ± 1 
Night-time SBP, mmHg 110 ± 1 
Night-time DBP, mmHg 65 ± 1 
Night-time MAP, mmHg 85 ± 1 
Augmentation index, % 9.0 ± 2.0 
PWV m/s    5.3 (4.8 – 5.8) 
Cardiac output, litres/min  6.0 ± 0.2 
Stroke volume, ml 90.8 ± 3.3 
PVR, dynes s-1 cm-5 1166 (997.5 – 1420) 
High frequency powerNormalised, % 77.0 ± 3.9  





eGFR, ml/min/1.72m2 111.6 (95.0 – 122.6) 
Renin, mU/l 13.5 (8.3 – 18.8) 
Aldosterone, pmol/l 121 (80– 209) 
Plasma VEGF C, pg/ml 585.7 (438.6 - 1038) 
sFlt-4, pg/ml 9.6 ± 0.7 
24-hr Urine Na+ 93.8 ± 8.1 
24-hr Urine K+ 69.8 ± 5.1 
24-hr Urine Cl- 108.7 ± 9.0 
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Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR.  
 
4.5.1.2     Assessment of drying consistency  
 
The mean sample weight was 0.015 ± 0.006g. Measured skin sample water content was 
negatively correlated with sample wet weights (Figure 4.11), suggesting that overall, freeze 
drying did not remove water consistently across all samples, with smaller samples recording 
greater proportional water contents because of greater water removal.  Consequently, Na+Dry 
and K+Dry were negatively correlated with sample weights, with a tendency for smaller 
samples to have higher measured Na+Dry and K+Dry content (Figure 4.12). This suggested that 
Na+Dry and K+Dry could not be used in the analysis. For this reason Na+ values expressed as 
Na+:K+ ratios to correct for this variation due to sample weight. 
 
Figure 4.11: Effects of skin sample wet weights on % water content. 
 















4.5.1.2     Primary outcome and skin biochemical variables 
 
The primary endpoint was the change in skin Na+:K+ between the placebo and slow sodium 
phases. Skin biochemical responses to placebo vs. slow sodium are shown in Table 4.3. 
There was an increase in skin Na+:K+ between the placebo and slow sodium phases (from 
2.91 ± 0.08 to 3.12 ± 0.09; p = 0.01; Figure. 4.13). There was a significant increase in skin 
Na+Wet with salt loading with no change in skin K+Wet, in keeping with previous salt loading 
studies in rats. In multiple regression analysis with age, BMI, clinic mean arterial pressure 
(MAP) and sex entered into the model, sex was found to be the only independent factor 
influencing skin Na+:K+ values  (R2 for the model=0.316, P<0.001). This was primarily because 
in women, skin K+ was lower and the Na+:K+ ratio was consequently higher. Therefore, 
subsequent skin analyses were sex-specific. For this thesis, haemodynamic and biochemical 


















Figure 4.13: Skin Na+:K+ response to placebo vs. slow sodium.       
 
 
4.5.1.3     Haemodynamic responses to placebo vs. slow sodium  
 
Haemodynamic responses to placebo vs. slow sodium for the whole study population are 
shown in Table 4.4. There was no significant difference in weight or clinic BP measurements. 
There was a significant increase in ambulatory 24-hr SBP, MAP, day SBP, night SBP and night 
MAP with salt loading. Stroke volume increased with salt loading (97 ± 4 vs. 103 ± 4 ml, p < 
0.05) with no significant change seen in cardiac output or PVR. Pulse wave velocity and 
augmentation index did not change with salt loading. No significant difference was noted in 
normalised high frequency and low frequency components of HRV. 
Variable n = 48 
 Placebo Slow sodium  P-value 
Skin wet weight, mg 0.015 ± 0.001 0.015 ± 0.001 0.70 
Skin Na+, mg/g  2.09 ± 0.04 2.20 ± 0.05 0.04 
Skin K+, mg/g  0.74 ± 0.02 0.73 ± 0.03 0.62 
Skin Na+: K+ 2.91 ± 0.08 3.12 ± 0.09 0.01 
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Variable n = 48 
             Placebo Slow sodium  P-value 
Body weight, kg 68.8 ± 1.6 68.6 ± 1.6 0.07 
Office measurements     
Seated SBP, mmHg  117 ± 1 117 ±   0.92 
Seated DBP, mmHg 72 ± 1 72 ± 1 0.81 
Seated MAP, mmHg 87 ± 1 87 ± 2 0.85 
Seated HR, bpm 73 ± 2 70 ± 1 0.06 
Supine SBP, mmHg  114 ± 1 115 ± 1 0.44 
Supine DBP, mmHg  67 ± 1 67 ± 1 0.83 
Supine MAP, mmHg 83 ± 1 83 ± 1 0.72 
Supine HR, bpm  
 
62 ± 1 60 ± 1 0.06 
Ambulatory BP, mmHg    
24-hr SBP 117 ± 1 120 ± 1 0.01 
24-hr DBP 72 ± 1 72 ± 1 0.36 
24-hr MAP 93 ± 1  94 ± 1 0.03 
Day SBP 121 ± 1 123 ± 1 0.03 
Day DBP 76 ± 1  75 ± 1 0.83 
Day MAP 96 ± 1 97 ± 1 0.12 
Night SBP 109 ± 1    112 ± 1 < 0.01 
Night DBP 64 ± 1 65 ± 1 0.06 
Night MAP 85 ± 1 87 ± 1 0.01 
 
Central haemodynamics  
   
CSBP, mmHg 97 ± 1 98 ± 1 0.26 
CDBP, mmHg 68 ± 1 68 ± 1 0.92 
CMAP, mmHg 82 ± 1  82 ± 1 0.12 
Augmentation index, % 9.1 ± 2 9.5 ± 2 0.67 
PWV ms-1    5.1(4.7 – 5.5) 5.2(4.9 – 5.7) 0.28 
Cardiac output, litres/min 6.1 ± 0.2 6.4 ± 0.2 0.11 
Stroke volume, ml 96.9 ± 3.6 102.8 ± 4.2 0.046 
PVR, dynes s-1 cm-5 1050 ± 46 1128 ± 47 0.57 
    
Heart rate variability    
High frequency powerNormalised,% 48.2 ± 2.8 52.1 ± 3.1 0.27 
Low frequency powerNormalised,% 53.1 ± 2.9 47.9 ± 3.1      0.11 
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Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented as 
median and IQR. Student’s paired t-tests were applied to paired observations after placebo and slow 
sodium for normally distributed data and the Wilcoxon signed-rank test for non-normally distributed 
data. 
 
4.5.1.4     Biochemical responses to placebo vs. slow sodium  
 
Serum, plasma and urine biochemical responses to placebo vs. slow sodium for the whole 
study population are shown in Table 4.5. Slow sodium caused the expected increases in 24-
hour urine Na+ and Cl-, serum Na+ and Cl-, and suppression of plasma renin and aldosterone. 
Serum eGFR and urine creatinine clearance increased with slow sodium, consistent with 
glomerular hyperfiltration as previously seen in salt-loaded healthy adults. 287,288 Fractional 
excretion of sodium (FeNa) was significantly higher after slow sodium, as previously 
described in healthy adults. 288 No significant change in plasma VEGF-C levels or sFLT-4 



















Table 4.5 – Differences in biochemical responses to placebo vs. slow sodium for the whole 
VARSITY study population. 
 
 
Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented as 
median and IQR. Student’s paired t-tests were applied to paired observations after placebo and slow 














Variable n = 48 
 Placebo Slow sodium  P-value 
 
Serum measurements  
   
     Na+, mmol/l 139 ± 0.2 141 ± 0.3 < 0.001 
     Cl-, mmol/l 103 ± 0.3 105 ± 0.4 < 0.001 
     K+, mmol/l 4.3 ± 0.04 4.4 ± 0.05 0.51 
eGFR, ml/min/1.72m2 111.1 ± 3.2 117.2 ± 3.6 0.001 
Plasma measurements     
      Renin, mU/l 20 (14 – 27) 7 (3–11) < 0.001 
     Aldosterone, pmol/l 221 (140 – 344) 70 (69 – 80) < 0.001 
     VEGF-C, pg/ml 672 (396 – 1013) 686 (458 – 1085) 0.85 
      sFlt-4, pg/ml 9.7 ± 0.8 9.8 ± 0.7 0.60 
Urinary measurements    
     Volume, ml/24hr 1741 ± 122 2032 ± 145 0.01 
      Na+, mmol/24hr 72.9 ± 6.3 221.9±16.5 < 0.001 
       Cl-, mmol/24hr 93.4 ± 7.1 236.1 ± 12.7 < 0.001 
       K+, mmol/24hr 60.8 (46.9 – 78.1) 57.3 (41.6 – 78.2) 0.08 
Creatinine clearance, ml/min 112.4 ± 6.0 124.3 ± 5.9 0.02 
Albumin, mg/24h 5.8 ± 1.1 6.8 ± 1.5 0.15 
      FENa , % 0.36 ± 0.03 0.94 ± 0.06 < 0.001 
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4.5.2     Sex-specific analysis 
 
4.5.2.1     Baseline characteristics 
 
Sex-specific baseline characteristics are shown in Table 4.6. Men had higher weight, BP, 
stroke volume, eGFR and renin. Women had higher augmentation index.  
 
Table 4.6 – Differences in demographics and baseline variables for by gender   
 
 
Baseline variables Males (n=24) Females (n=24) P-value 
Age, years 28 ± 2 32 ± 2 0.14 
Ethnicity (Caucasian) 22/24 23/24 - 
Body weight, kg 74.3 ± 2.5 64.1 ± 1.5 < 0.001 
Height, cm 178 ± 2 165 ± 2 < 0.001 
BMI, kg ms-2 22.7 (21.6 – 24.0) 23.9 (22.1 – 25.4) 0.29 
Haemodynamic variables    
Seated SBP, mmHg  123 ± 2 116 ± 2 0.004 
Seated DBP, mmHg 67 ± 2 72 ± 2 0.45 
Seated MAP, mmHg 90 ± 2 90 ± 2 0.89 
Seated HR, BPM 71 ± 2 73 ± 2 0.32 
Supine SBP, mmHg  122 ± 2 115 ± 2 0.03 
Supine DBP, mmHg  67 ± 2 72 ± 2 0.04 
Supine MAP, mmHg 87 ± 2 87 ± 2 0.99 
Supine HR, BPM 64 ± 2 67 ± 2 0.37 
24-hr MAP 95 ± 2 91 ± 1 0.02 
24-hr SBP 122 ± 2 114 ± 1 < 0.001 
24-hr DBP 74 ± 2 72 ± 1 0.43 
Night-time SBP, mmHg 113 ± 2 107 ± 1 0.01 
Night-time DBP, mmHg 66 ± 2 64 ± 1 0.44 
Night-time MAP, mmHg 88 ± 2 83 ± 1 0.05 
Augmentation index, % 2.8 ± 2.0 15.0 ± 2.6 0.003 
PWV m/s    5.3 (4.8 – 5.7) 5.2 (4.8 – 5.8) 0.61 
Cardiac output, litres/min  6.3 ± 0.3 5.6 ± 0.3 0.06 
Stroke volume, ml 101.9 ± 4.7 79.6 ± 3.6 < 0.001 




Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. The values for males and females was analyzed using the unpaired t test with 




4.5.2.2     Skin biochemical variables 
 
Sex-specific skin Na+, K+ and Na+:K+ values are presented in Table 4.7 and Figure 4.14. Men 
showed a significant increase in skin Na+:K+ of 11.2% (p=0.008) from placebo to slow sodium 
phases, whilst women showed a non-significant increase of 4.0% (p=0.31). On formal 
repeated measures ANOVA testing, there was no significant difference between genders 
(p=0.31). Neither sex showed a significant change in skin K+ with a change in salt intake, in 
keeping with previous animal studies. 244,245 Women had a lower skin K+ compared to men ( 
p < 0.01 post placebo and slow sodium) and consequently had higher Na+:K+ ratio than men 
(p < 0.001 post placebo and salt ). No evidence of carry-over effect was seen for skin Na+:K+ 
or skin Na+ for either sex using univariate analysis of variance with order of treatment 




Biochemical variables    
eGFR, ml/min/1.72m2 114.3 (107.7 – 124.4) 97.2 (88.4 - 117.2) 0.01 
Renin, mU/l 18.0 (13.0 – 25.5) 9.0 (7 – 14) < 0.001 
Aldosterone, pmol/l 166.0 (110 – 194) 110.5 (69.0 – 279.5) 0.27 
Plasma VEGF C, pg/ml 542.7 (412.5 - 842.5) 644 (469.7 - 1172.0) 0.22 
sFlt-4, pg/ml 9.1 ± 0.9 10.1 ± 1.0 0.45 
24-hr Urine Na+, mmol/24hr 102.0 ± 12.4 84.9 ± 10.1 0.31 
24-hr Urine K+, mmol/24hr 75.0 ± 8.9 64.2 ± 4.4 0.29 
24-hr Urine Cl-, mmol/24hr 115.4 ± 12.7 101.5 ± 12.8 0.45 
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Table 4.7: Differences in skin biochemical responses to placebo vs. slow sodium by sex. 
 
Student’s paired t-tests were applied to paired observations after placebo and slow sodium for normally 
distributed data and the Wilcoxon signed-rank test for non-normally distributed data. 
 
 
 Figure 4.14: Differences in skin biochemical responses by sex. Responses to placebo vs. slow 
sodium in (A) men and (B) women.  
A.                                                                               B. 
 
 




Variable                  Men (n=24)               Women (n=24) 
 Placebo Slow sodium  P-value Placebo Slow sodium P-value 
Skin wet weight, g 0.014±0.001 0.015±0.001 0.68 0.015±0.001 0.015±0.001 0.35 
Skin Na+, mg/g  2.02±0.06 2.27±0.08 0.02 2.15±0.05  2.14±0.03 0.84 
Skin K+, mg/g  0.80±0.03 0.82±0.04 0.59 0.68±0.03 0.65±0.02 0.28 
Skin Na+:K+ 2.59±0.09 2.88±0.12 0.008  3.23±0.10 3.36±0.12 0.31 
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4.5.3.3     Haemodynamic responses to placebo vs. slow sodium  
 
Hemodynamic responses to placebo vs. slow sodium are shown in Table 4.8. In men there 
were no differences in haemodynamics following salt loading, whilst women had higher 24-
hour systolic BP (SBP), 24-hour MAP, daytime SBP, night-time SBP, diastolic BP (DBP) and 
MAP. Only women had an increase in body weight post slow sodium (63.5 ± 1.6 vs. 64.2 ± 





















Table 4.8 – Differences in haemodynamic responses to placebo vs. slow sodium by sex. 
Variable Males (n=24) Females (n=24) 
 Placebo Slow sodium  P-value Placebo Slow sodium P-value 
Body weight, kg 73.6±2.5 73.6±2.5 0.93 63.5±1.6 64.2±1.6 0.01 
Office measurements        
Seated SBP, mmHg  120±2 119±2  0.85 114±2 114±2 0.72 
Seated DBP, mmHg 71±2 71±2 0.98 73±2 73±1 0.75 
Seated MAP, mmHg 87±1 87±2 0.65 87±2 88±1 0.43 
Seated HR, bpm 72±2 68±2 0.12 74±2 72±2 0.30 
Supine SBP, mmHg  116±2 116±4 0.91 111±2 113±2 0.27 
Supine DBP, mmHg  65±2 65±2 0.72 68±2 69±1 0.55 
Supine MAP, mmHg 83±2 82±1 0.62 83±2 84±2 0.33 
Supine HR, bpm  60±2 58±2 0.15 64±2 63±2 0.23 
 
Ambulatory BP, mmHg 
      
24-hr SBP 121±1 122±2 0.57 114±1 118±1 < 0.001 
24-hr DBP 73±2 73±2 0.46 71±1 73±1 0.05 
24-hr MAP 96±2  96±2 0.89 91±1 93 ± 1 < 0.001 
Day SBP 124±1 125±2 0.32 118±1 121±2 0.02 
Day DBP 76±2  76±2 0.34 75±2 76±2 0.33 
Day MAP 98±2 98±2 0.93 95±1 97±2 0.05 
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Night SBP 114±2    115±2 0.52 105±1 110 ± 1 < 0.001 
Night DBP 65±2 66±2 0.65 63±1 65 ± 1 0.01 
Night MAP 88±2 89±2 0.80 82±1 86 ± 1 < 0.001 
Central haemodynamics        
CSBP, mmHg 99±1 99±2 0.99 95±2 98±2 0.11 
CDBP, mmHg 67±2 66±2 0.21 69±2 70±1 0.22 
CMAP, mmHg 82±2  80±2 0.12 83±2 85±2 0.22 
Augmentation index, % 4.5±2 4.5±2 0.98 13.7±3 14.5±3 0.58 
PWV ms-1    5.2(4.7 – 5.6) 5.3(4.9 – 6.0) 0.10 5.0(4.7 – 5.5) 5.2(4.8 – 5.4) 0.93 
Cardiac output, litres/min 6.6±0.3 7.0±0.4 0.08 5.6±0.3 5.8±0.3 0.10 
Stroke volume, ml 107.9±5.2 116.8±6.5 0.09 86.0±4.0 88.9±3.6 0.29 
PVR, dynes s-1 cm-5 1048±51 1045±64 0.57 1251±72 1212±66 0.46 
 
Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented as median and IQR. Student’s paired t-tests were applied 
to paired observations after placebo and slow sodium for normally distributed data and the Wilcoxon signed-rank test for non-normally distributed data. 
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4.5.3.4     Biochemical responses to placebo vs. slow sodium  
 
Differences in biochemical responses to placebo vs. slow sodium are shown in Table 4.9. As 
expected, in both sexes, slow sodium increased 24-hour UNaV, serum Na+ and Cl-, and 
suppressed plasma renin and aldosterone. There were no significant changes in plasma 


















Table 4.9 – Differences in biochemical responses to placebo vs. slow sodium by sex. 
 
Variable Males (n=24)  Females (n=24) 
 Placebo Slow sodium  P-value Placebo Slow sodium P-value 
 
Serum measurements  
      
     Na+,mmol/l 140±0.4 141±0.3 0.001 139±0.3 140±0.4 < 0.001 
     Cl-,mmol/l 103±0.4 106±0.5 < 0.001 103±0.4 105±0.6 < 0.001 
     K+,mmol/l 4.4±0.06 4.4±0.07 0.97 4.3±0.07 4.3±0.09 0.69 
eGFR, ml/min/1.72m2 114.7 (103.9 – 127.5) 117.1(107.3 – 136.7) 0.24 99.2 (84.1 – 119.2) 105.9 (94.2-127.8) < 0.001 
Plasma measurements        
      Renin, mU/l 24(15–30) 11(4–13) < 0.001 17 (9 – 21) 3 (2 – 7) < 0.001 
     Aldosterone, pmol/l 221(143–318) 80(69–111) < 0.001 240 (137 – 435) 69 (69 – 75) < 0.001 
     VEGF-C, pg/ml 540 (352 – 881) 625 (460 – 1066) 0.20 830 (467 – 1404) 755 (412 – 1130) 0.39 
      sFlt-4, pg/ml 
 
8.9±1.1 9.1±1.0 0.79 10.3±1.0 10.6±0.9 0.57 
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Urinary measurements 
     Volume, ml/24hr 1540±174 1678±203 0.25 1935±166 2299±186 0.004 
      Na+, mmol/24hr 86.3±10.3 221.9±16.5 < 0.001 60.0±6.8 227.1±19.9 < 0.001 
       Cl-, mmol/24hr 103.7±11.6 228.1±14.4 < 0.001 83.8±8.2 241.3±21.5 < 0.001 
       K+,mmol/24hr 63.3(51.2 – 93.5) 55.1(39.9 – 73.8) 0.15 56.9(40.5 – 76.7) 58.7(41.6 – 77.9) 0.49 
Creatinine clearance, ml/min 111.1±9.1 125.3±9.6 0.14 108.1±8.0 122.4±7.6 0.06 











4.5.3.5     Effects of contraceptive use in women  
 
10 women were on contraceptive treatment, of which 6 were on the combined pill and 4 
were on progesterone-only pill or progesterone implants. Contraceptive treatment did not 
seem to affect the skin Na+ or skin Na+:K+ response to dietary salt loading (Table 4.10 and 
Figure 4.15). Women on contraceptive treatment had higher skin K+ levels post slow sodium 
(p = 0.03) but not post placebo (p = 0.11) compared with females not on contraceptive 
treatment. Consequently, females on contraceptive treatment had a trend for lower skin 
Na+:K+ levels post placebo (p = 0.05) and post slow sodium (p = 0.09) compared with females 
not on contraceptive treatment. Baseline characteristics and haemodynamic responses to 
salt loading were similar in women with and without contraceptive use (Table 4.11 and 4.12).  
 
Table 4.10: Differences in skin biochemical responses to placebo vs. slow sodium in women 
according to contraceptive (OCP) use. 
 
Normally distributed data presented as mean ± SEM. The change between placebo and slow sodium for both 









Variables No contraceptive use 
n = 14 
Contraceptive use 
n = 10 
 Placebo Slow sodium P-value Placebo Slow sodium P-value 
Skin Na+, mg/g  2.15 ± 0.07 2.15 ± 0.05 0.92 2.16 ± 0.07 2.12 ± 0.07 0.92 
Skin K+, mg/g  0.65 ± 0.03 0.62 ± 0.02 0.43 0.73 ± 0.05 0.70 ± 0.04 0.50 
Skin Na+:K+ 3.37 ± 0.12 3.53 ± 0.13 0.43 3.04 ± 0.17 3.12 ± 0.20 0.69 
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Figure 4.15: Comparison of skin Na+:K+ responses by use of contraception. Skin Na+:K+ changes with 
salt loading in women not on contraceptive treatment (A ; n=14) and women on contraceptive 
treatment (B ; n=10).  
 




























Age, years 33 ± 3 30 ± 2 0.55 
Ethnicity (Caucasian) 13/14 10/10 - 
Body weight, kg 65.0 ± 2.2 62.9 ± 2.0 0.52 
Height, cm 163 ± 2 166 ± 1 0.31 
BMI, kg ms-2 24.4 ± 0.7  22.8 ± 0.8 0.14 
Haemodynamic variables    
Seated SBP, mmHg  117 ± 2 114 ± 4 0.51 
Seated DBP, mmHg 75 ± 2 76 ± 2 0.80 
Seated MAP, mmHg 89 ± 2 89 ± 3 0.91 
Seated HR, BPM 75 ± 3 71 ± 2 0.36 
Supine SBP, mmHg  115 ± 3 115 ± 4 0.94 
Supine DBP, mmHg  72 ± 2 72 ± 3 0.99 
Supine MAP, mmHg 87 ± 2 86 ± 3 0.96 
Supine HR, BPM 67 ± 2 66 ± 2 0.67 
24-hr MAP 91 ± 1 92 ± 2  0.62 
24-hr SBP 114 ± 2 114 ± 2 0.99 
24-hr DBP 72 ± 1 73 ± 1 0.59 
Night-time SBP, mmHg 106 ± 2 108 ± 2 0.50 
Night-time DBP, mmHg 62 ± 2 66 ± 2 0.59 
Night-time MAP, mmHg 82 ± 1 85 ± 2 0.13 
Augmentation index, % 17.8 ± 3.4 11.0 ± 3.8 0.21 
PWV m/s    5.4 (4.9 – 5.9) 5.0 (4.5 – 5.8) 0.19 
Cardiac output, litres/min  5.3 ± 0.3 6.0 ± 0.4 0.17 
Stroke volume, ml 75.3 ± 4.1 85.7 ± 6.2 0.16 
PVR, dynes s-1 cm-5 1265 (1011 – 1880) 1183(1046 – 1348) 0.22 
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Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as mean and IQR. The values for women with and without contraceptive use was analyzed using the 
unpaired t test with normally distributed data and Man Whitney test for non-normal data. P value < 































   
eGFR, ml/min/1.72m2 95.1 (88.7 – 115.2) 103.7 (87.1 – 151.1) 0.73 
Renin, mU/l 14.1 ± 2.1  7.0 ± 0.8  0.02 
Aldosterone, pmol/l 113 (69 – 247) 87 (70 – 385) 0.83 
Plasma VEGF C, pg/ml 831.9 ± 116.1 840.3 ± 195.9 0.97 
sFlt-4, pg/ml 9.0 ± 1.3 11.8 ± 1.6 0.19 
24-hr Urine Na+,mmol 101.1 ± 14.7 65.4 ± 11.6 0.08 
24-hr Urine K+,mmol 61.6 ± 5.8 67.3 ± 6.9 0.53 
24-hr Urine Cl-,mmol 122.7 ± 19.0 76.1 ± 13.5 0.07 
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Table 4.12 – Differences in haemodynamic responses to placebo vs. slow sodium according to contraceptive use 
 
Variables No contraceptive (n=14) On contraceptive (n=10)) 
 Placebo Slow sodium  P-value Placebo Slow sodium P-value 
Body weight, kg 64.2 ± 2.3 64.8 ± 2.4 0.12 62.4 ± 2.0 63.2 ± 1.7 0.03 
Office measurements        
Seated SBP, mmHg  115 ± 2 116 ± 2 0.48 111 ± 3 111 ± 3 0.85 
Seated DBP, mmHg 74 ± 2 74 ± 2 0.96 71 ± 2 72 ±2 0.63 
Seated MAP, mmHg 88 ± 2 88 ± 2 0.68 85 ± 3  86 ± 2 0.50 
Seated HR, bpm 77 ± 2 75 ± 3 0.42 69 ± 3 68 ± 3 0.55 
Supine SBP, mmHg  111 ± 3 115 ± 3 0.15  111 ± 3 110 ± 2  0.79 
Supine DBP, mmHg  68 ± 2 70 ± 2 0.33 68 ± 2 68 ± 1 0.64 
Supine MAP, mmHg 83 ± 2 85 ± 2 0.18 82 ± 2 82 ± 2 0.74 
Supine HR, bpm  
  
67 ± 2 64 ± 2 0.31  62 ± 3 61 ± 3 0.58 
 
Ambulatory BP, mmHg 
      
24-hr SBP 114 ± 1 118 ± 2 0.02 113 ± 2 118 ± 2 0.004 
24-hr DBP 71 ± 2 72 ± 2 0.54 71 ± 1 74 ± 1 0.03 
24-hr MAP 91 ± 2 93 ± 2 0.07  90 ± 1 94 ± 2 0.001 
Day SBP 119 ± 2 121 ± 3 0.19 117 ± 2 121 ± 3 0.05 
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Day DBP 75 ± 3 75 ± 2 0.95 75 ± 1 77 ± 2 0.17 
Day MAP 95 ± 2 96 ± 2 0.47 94 ± 2 97 ± 2 0.04 
Night SBP 104 ± 2 109 ± 2 0.001 106 ± 2 111 ± 1 0.001 
Night DBP 61 ± 2 64 ± 2 0.10 64 ± 1 67 ± 1 0.07 
Night MAP 81 ± 2 85 ± 2 0.008 83 ± 2 87 ± 1 0.005 
 
Central haemodynamics  
      
CSBP, mmHg 95 ± 2 101 ± 3 0.01 95 ± 3 93 ± 3 0.44 
CDBP, mmHg 69 ± 2 71 ± 2 0.62 69 ± 2 69 ± 2 0.96 
CMAP, mmHg 82 ± 2 87 ± 2 0.01 83 ± 3 81 ± 2 0.44 
Augmentation index, % 15.7 ± 3.6 19.1 ± 3.8 0.10 10.9 ± 4.9 8.1 ± 4.3 0.10 
PWV ms-1    5.6 ± 0.3  5.5 ± 0.2 0.91 5.0 ± 0.1 5.0 ± 0.1 0.95 
Cardiac output, litres/min 5.5 ± 0.3 5.6 ± 0.3 0.46 5.8 ± 0.5 6.2 ± 0.5 0.43 
Stroke volume, ml 82.8 ± 4.7 85.2 ± 4.6 0.42 90.4 ± 6.9 94.0 ± 5.7 0.51 
PVR, dynes s-1 cm-5 1268 ± 91 1278 ± 92 0.79 1229 ± 123 1119 ± 87 0.36 
 
Normally distributed data presented as mean ± SEM. Student’s paired t-tests were applied to paired observations after placebo and slow sodium
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4.5.3.5     Correlations for skin Na+:K+ 
 
Univariate analyses revealed significant correlations between skin Na+:K+ and 
haemodynamic variables in men, as shown in Figure 4.16. Skin Na+:K+ correlated positively 
with supine MAP post placebo (r=0.53, p<0.01) and post slow sodium (r=0.51, p=0.01). Skin 
Na+:K+ was negatively correlated with SV and positively correlated with PVR post placebo 
and slow sodium. Plasma VEGF-C, after logarithmic transformation, showed a positive 
correlation with skin Na+:K+ post slow sodium (r=0.51, p=0.01) but not placebo (r=0.06, 
p=0.79) (fig. 3). These correlations were independent of age and BMI on multiple regression 
analysis.  In women univariate analysis revealed a significant correlation only for skin Na+: K+ 
and PVR post salt (r = 0.49, p=0.02). On multiple regression analysis, this correlation was not 
























Figure 4.16: Correlation between skin Na+:K+ and haemodynamic variables in men. (A) Supine brachial mean arterial pressure (MAP) post placebo. (B) 
Stroke volume post placebo. (C) Peripheral vascular resistance (PVR) post placebo. (D) Supine brachial MAP post slow sodium. (E) Stroke volume post 
slow sodium. (F) PVR post slow sodium.
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Figure 4.17: Correlation between skin Na+:K+ and plasma VEGF-C. A : Post-placebo. B: Post slow 
sodium  
 
4.5.3.6     Effect of lidocaine type 
 
14 male participants received conventional local anaesthetic (Xylocaine 1% with adrenaline, 
Astra Zeneca). 10 male participants received Na+- free lidocaine using Dextrose as an 
excipient (Lidocaine 1% with Dextrose 3.5%, Tayside Pharmaceuticals, Dundee). In view of 
sex differences in skin Na+:K+ a comparison of results was done in males receiving both types 
of lidocaine . Skin Na+:K+ values post placebo and slow sodium were pooled for each group. 
As seen in Figure 4.18, no significant difference to suggest Na+ contamination was evident. 
 
Figure 4.18 : Comparison of skin Na+:K+ by type of local anaesthetic. Skin post-placebo and post-
slow sodium samples from male participants who received conventional local anaesthetic (n = 14) 
and sodium-free anaesthetic (n = 10) in the VARSITY study are shown.  
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4.5.3     Salt taste sensitivity  
Baseline salt recognition and detection thresholds are shown in Figure 4.19. Most 
participants had salt recognition and detection thresholds at 0.05 - 0.10 % NaCl. Univariate 
analyses did not reveal any significant correlations between salt recognition or detection 
thresholds and VEGF-C or other putative variables at baseline (Tables 4.13 and 4.14). These 
findings were similar in men and women (data not shown) 
 
Figure 4.19: Baseline salt recognition thresholds (A) and detection thresholds (B) for the whole 






































Correlations were analyzed using Spearman’s correlation coefficient by rank. 
 
 













Correlations were analyzed using Spearman’s correlation coefficient by rank. 
 
 
The change in salt recognition and detection thresholds with placebo and slow sodium are 
shown in Figure 4.20. A significant change in salt detection threshold was observed, 
Variable Correlation Coefficient  Significance 
Age, years - 0.18 0.22 
BMI, Kg/m2 - 0.11 0.47 
Supine MAP, mmHg 0.05 0.76 
24-hr MAP 0.02 0.91 
Renin, mU/l - 0.01 0.94 
Aldosterone, pmol/l 0.04 0.79 
VEGF-C, pg/ml - 0.11 0.49 
Variable Correlation Coefficient  Significance 
Age, years - 0.18 0.22 
BMI, Kg/m2 - 0.07 0.62 
Supine MAP, mmHg - 0.01 0.97 
24-hr MAP - 0.11 0.47 
Renin, mU/l - 0.06 0.68 
Aldosterone, pmol/l - 0.19 0.20 
VEGF-C, pg/ml - 0.08 0.63 
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indicating rise in the lowest concentration at which participants could distinguish between 
ROS water and salt solution. No change in salt recognition threshold was noted.  
 
Figure 4.20: Response for salt recognition threshold (A) and detection thresholds (B) placebo vs. 
slow sodium for the whole VARSITY study population.                    
 
 
The Wilcoxon signed-rank test was used to compare salt recognition and detection thresholds post 
placebo and slow sodium treatments. 
 
Univariate analyses did not reveal any significant correlations between the change in salt 
recognition or detection thresholds between placebo and slow sodium and the change in 











Table 4.15: Correlation between observed difference (!) in salt detection threshold and putative 
















Correlations were analyzed using Spearman’s correlation coefficient by rank. D represents change 




















Variable Correlation Coefficient  Significance 
Age, years - 0.05 0.77 
BMI, Kg/m2 - 0.16 0.29 
D Renin, mU/l - 0.18 0.24 
D Aldosterone, pmol/l -0.23 0.14 
D VEGF-C, pg/ml - 0.24 0.14 
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4.5.4     Skin capillaroscopy 
 
3 non-Caucasian participants with dark skin were excluded from capillaroscopy analysis. 
Images for 20 participants were excluded as they were of inadequate quality and the 
software was unable to detect capillaries, as judged by both Dr Stephen Smith and myself. 5 
participants were excluded as the SD for mean capillary density (MCD) exceeded 19/mm2. 
The main baseline characteristics of the remaining 20 participants used for analysis are 
shown in Table 4.16. There were 12 men and baseline characteristics were comparable to 
the whole VARSITY study population. The main haemodynamic and biochemical responses 
to placebo vs. slow sodium for the 20 participants are shown in Table 4.17. Skin Na+: K+, 
night MAP and stroke volume were significantly higher post slow sodium compared to 
placebo, as seen in the main study population.  
 



























Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. 
 
 
Baseline variables  (n=20) 
Age, years 31 ± 2 
Ethnicity (Caucasian) 20/20 
Sex (M/F) 12/8 
BMI, kg ms-2 
 
23.2 (22.1 – 25.4) 
Haemodynamic variables  
Supine SBP, mmHg  121 ± 2 
Supine DBP, mmHg  70 ± 2 
Supine MAP, mmHg 87 ± 2 
24-hr MAP 95 ± 2 
24-hr SBP 119 ± 2 
24-hr DBP 75 ± 1 
  
Biochemical variables  
Renin, mU/l 15.9 ± 2.0 
Aldosterone, pmol/l 118 (84– 180) 
24-hr Urine Na+ 113.0 ± 15.6 
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Table 4.17: Main haemodynamic and biochemical to placebo vs. slow sodium by sex for the 20 
participants used in capillaroscopy analysis. 
 
 
Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. Clinic BP refers to supine BP. Student’s paired t-tests were applied to paired 
observations after placebo and slow sodium for normally distributed data and the Wilcoxon signed-rank 
test for non-normally distributed data. 
 
Table 4.18 shows capillaroscopy data obtained at baseline (unoccluded) and after 2 min of 
venous occlusion at 60 mm Hg. Mean capillary density (MCD) at baseline was significantly 








 Placebo Slow sodium  P-value 
 
Haemodynamics  
   
     Weight, kg 72.3 ± 2.7 73.5 ± 2.8 0.28 
     Clinic SBP, mmHg 115 ± 2 117 ± 2 0.29 
     Clinic DBP, mmHg 68 ± 2 68 ± 2 0.82 
     Supine MAP, mmHg 84 ± 2 84 ± 2 0.47 
     24-hr MAP, mmHg 96 ± 1 96 ± 1 0.18 
     Night MAP, mmHg 86 ± 2 89 ± 2 0.03 
     Stroke volume, ml 98.9 ± 5.1  109.5 ± 6.1 0.02 
     PVR, dynes s-1 cm-5 1103 ± 62 1068 ± 79 0.52 
Skin measurements    
    Skin Na+: K+ 2.76 ± 0.08 3.08 ± 0.14 0.01 
Plasma measurements     
      Renin, mU/l 20 (12 – 25) 7 (4 – 13) < 0.001 
     Aldosterone, pmol/l 219 (82 – 361) 80 (69 – 88) < 0.001 
Urinary measurements    
      Na+, mmol/24hr 82.8 ± 11.8 226.0 ± 16.5 < 0.001 
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Table 4.18: Changes in mean capillary density with salt intake in VARSITY methods. 
 
 
Student’s paired t-tests were applied to paired observations after placebo and slow sodium for normally 
distributed data and the Wilcoxon signed-rank test for non-normally distributed data. 
 
 
Figure 4.21: Mean capillary density post placebo vs. slow sodium for the 20 participants. 
 
 




During venous occlusion, MCD increased post slow sodium but not post placebo (Figure 
4.22). MCD post placebo and post slow sodium did not show any independent correlation 
with age, BMI or haemodynamic parameters (BP, stroke volume or PVR).  
 
 n = 20 
                    Variable Placebo Slow sodium  P-value 
Mean Capillary density/mm2     
        Unoccluded 115.2 ± 4.3 106.4 ± 4.1 0.01 
        During venous occlusion  118.8 ± 4.8 121.5 ± 3.7 0.46 
Absolute increase in capillary density/mm2 3.6 ± 3.2 15.1 ± 3.1 0.02 
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Figure 4.22: Effect of venous occlusion on mean capillary density post placebo (A) and post slow 




















4.6     DISCUSSION 
4.6.1     Main study 
 
This study showed that skin sodium increases with dietary salt loading in healthy humans 
and this may occur in a sex-specific way. With dietary salt loading, men had a rise in skin 
Na+:K+ with no rise in BP, while women had a rise in ambulatory BP and no significant rise in 
skin Na+:K+. The dietary salt load used (200 mmol Na+ for 7 days) is within the normal daily 
intakes of many individuals in urban societies, and thus would be clinically relevant. 36 The 
primary endpoint was significant, with skin Na+:K+ increasing between the placebo and slow 
sodium phases for the whole study population. This was mainly driven by men.   
 
Skin measurements showed that women have lower skin K+, as observed in the VARSITY 
methods pilot study (3.4.4) and consequently a higher Na+:K+ ratio (Table 4.7). The epidermis 
has previously found to have a significant K+ content and this difference could be explained 
by the epidermis being thinner in women. 188,260 Therefore changes in Na+:K+ ratio with salt 
loading can be compared, but it is not possible to directly compare values for skin Na+:K+ 
between men and women.  
 
Freeze-drying unfortunately could not remove moisture uniformly in small samples, 
particularly those below 10 mg (Figure 4.11), and it was not possible to use dry weight skin  
Na+ and K+ values as planned.  The observed values for Na+ and K+ per unit wet weight fall 
within the range of previously published values 182,183,186. To correct for sample hydration 
skin Na+ was expressed as a ratio Na+:K+ because it was possible to measure K+ reliably with 
ICPOES and evidence from animal work that skin K+ remains stable with extremes of salt 
intake. 134,244,245 In our study skin K+ did not change with salt loading. Furthermore, the Na+ 
content of injected local anaesthetic did not appear to contaminate our skin samples 
(4.5.3.6).  
Secondary analyses revealed that skin Na+:K+ had a significant interaction with sex and 
hence sex specific analyses were conducted. Unexpectedly the response to salt loading 
appeared to be different between men and women, with only men showing a significant 
increase in skin Na+:K+ . This difference was non-significant with formal ANOVA comparison, 
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and this was most probably due to small sample sizes. Women had a significant change in 
day and night ambulatory BP while men did not. This was associated with a significant gain 
in weight in women. This change in weight in women and lack thereof in men was in keeping 
with a greater sensitivity to dietary sodium in women. 118 Sex differences in baseline 
variables are in keeping with previous studies in healthy young adults. 258,269,289-291. 
Augmentation index is higher in women and this is thought to be due to women having 
shorter stature and higher PVR, when corrected for body surface area. 269,292 Our study was 
not powered to show a difference in PVR, PWV. Or HRV.  
 
There could be several explanations for the sex differences observed with salt loading. Sex 
differences in BP responses to dietary salt modulation (salt sensitivity), have previously been 
observed in large studies of healthy, young normotensive adults, as outlined in 1.5, with 
women showing a greater salt sensitivity. In this study the women had lower 24-hour UNaV 
post placebo than men (60.0 ± 6.8 vs. 86.3 ± 10.3 mmol; p=0.03) suggesting that they were 
more adherent to a low salt diet during placebo phase or ate less per se. This difference was 
statistically significant but modest. There are known limitations of using 24-hour UNaV to 
estimate Na+ intake, with recent evidence showing ± 25 mmol deviations in urinary Na+ from 
recorded Na+ intake. 293 Nevertheless, differences in dietary salt restriction during the 
placebo phase is a possible reason why women had a greater salt sensitivity than men. An 
alternative explanation is that the men did not have BP changes with a short-term change in 
salt intake because they could buffer the additional dietary Na+ with their skin via 
mechanisms described in animal studies, while in women this ability was attenuated. 
 
In animals the skin buffers dietary salt, and a lower capacity to store Na+ in the skin is 
associated with a greater BP rise during acute salt loading. 132 The sex differences could have 
been observed for 2 possible reasons. Firstly,  men have a thicker skin at all ages and higher 
levels of dermal glycosaminoglycans. 261,262 This could imply that the skin is a more effective 
buffer for dietary Na+ in men. In support of this, previous work in rats revealed that male 
rats had a higher capacity for osmotically inactive skin Na+ storage compared to fertile 
female rats on a high salt intake. 132 Secondly, if we compare actual skin Na+ measurements, 
which are not corrected for differences in sample hydration (table 4.7), there is a trend for 
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women to have a higher skin Na+ post-placebo than men (2.15±0.05 vs 2.02±0.06 mg/g, 
p=0.08).  This suggests that men had greater passage of Na+ through the skin than women, 
as opposed to simply higher skin Na+ storage, and the passage of Na+ was protective in short-
term salt loading. As shown in animal studies, the passage of skin Na+ into the skin would 
have resulted in efflux of Na+ via VEGF-C mediated lymphangiogenesis,  which relates to NO 
production by VEGF-C. 133,134. This is consistent with the known adaptation of salt-resistant 
subjects to a salt-load, which is vasodilation concomitant to the increase in cardiac output.  
118,121,122 
 
There were significant correlations between skin Na+:K+ and various parameters in men, 
which were present regardless of salt intake.  This suggests a physiological role for skin Na+ 
or Na+: K+ ratio in regulating normal haemodynamics. Skin Na+:K+ was negatively correlated 
with stroke volume, which could be explained by higher Na+:K+ reflecting increased 
osmotically inactive Na+ binding to glycosaminoglycans, allowing Na+ without commensurate 
water accumulation, and therefore a less pronounced rise in circulatory volume. 64 Skin 
Na+:K+ was positively correlated with BP and PVR. The observations for BP and skin Na+:K+ 
support previous 23Na MRI data, which showed skin Na
+
is positively associated with BP. 197 
The mechanisms for these observations remain to be explained, but several possibilities 
exist. The skin is a rich source of nitric oxide, an important regulator of vascular tone. 211 
Keratinocytes in the skin produce nitric oxide via nitric oxide synthase 2 (NOS-2) under the 
influence of hypoxia-inducible transcription factors, HIF-1a and HIF-2a, and these may be 
involved in modulation of dermal PVR. This is discussed further in 5.3. A further possible 
mechanism is dermal capillary rarefaction, which is discussed in 4.6.3. On univariate 
analysis, the only significant correlation for women was seen for skin or Na+: K+ and PVR post 
salt (r = 0.49, p=0.02). On multiple regression analysis, this correlation is not independent of 
age.  In women contraceptive treatment did not seem to affect skin Na+ or Na+:K+ response 
to salt loading, but skin K+ was higher post salt ,and there was a trend for skin Na+:K+ to be 
lower in women on contraceptives (4.5.3.5). The reasons for this are unclear. Oestrogen 
administration increases epidermal thickness, which could partly explain this. 294 Therefore, 
the Na+:K+ ratio may have been less reliable for assessing correlations in women in our study.  
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No significant changes in plasma VEGF-C or sFLT4 were noted in either sex or the whole 
population between placebo and slow sodium phases. A previous study looking at plasma 
VEGF-C  healthy adults noted no change on dietary salt loading. 159 This may be the first 
study looking at plasma sFLT4. Skin VEGF-C levels were not measured, which may not have 
been reflected by plasma levels, and therefore it may not be possible to make any 
conclusions on skin VEGF-C response. However, plasma VEGF-C in men correlated positively 
with skin Na+:K+  post slow sodium, which suggests increased in the salt-loaded state skin Na+ 
induced VEGF-C production, as seen in animal studies. 133,134 
 
This study has several limitations. The study size was small, but we used a state-of-the art 
technique to measure skin Na+, ICP-OES, which would have been more sensitive than 23Na 
MRI. Our participants were non-resident and the control of Na+ intake was challenging, 
especially in men. Dietary sodium intakes were not normalised for body weight.  Participants 
also did not have their potassium and calorie intakes strictly controlled. Women were not 
salt loaded on the same day of the menstrual cycle. Our skin biopsies were small and taken 
from the lower back, and we had no means of ascertaining if they were representative of 
the whole skin or if skin Na+ varies with region and time.  Cl-could not be measured with ICP-
OES.   The sex differences in BP and skin Na+ are interesting but warrant further investigation 
and confirmation in larger studies. The use of ambulatory blood pressure monitoring made 
the detection of significant BP changes in women possible. Similar studies should also be 
conducted in older people, other ethnicities and hypertensives. In summary, it appears that 
the skin is a buffer for dietary salt, influencing the regulation of salt sensitivity, and this is 









4.6.2     Salt taste sensitivity  
 
This main finding of the salt taste sensitivity study was that salt detection threshold, or the 
lowest concentration at which participants could distinguish between ROS water and salt 
solution, increased with dietary salt loading. This implies that participants were less able to 
identify saltiness on a higher salt intake. No change in salt recognition threshold was noted. 
The observed salt recognition threshold range was similar to Choe et al283. Previous data in 
healthy humans have shown that detection thresholds decrease with dietary salt depletion 
and salt recognition threshold increased with dietary salt loading. 280,295 The methods and 
thresholds used in these studies varied, though they support the view that salt intake 
influences the appreciation of salt taste sensitivity. The mechanisms for this are uncertain. It 
is possible that the abundance of ENaC is altered by dietary salt loading, affecting the 
transduction of the taste of salt in the lingual epithelium. In this study and VEGF-C, renin and 
aldosterone levels did not clearly modulate this process, though lingual ENaC expression 
could have been reduced with decreased aldosterone levels post slow sodium in this study 
(Table 4.5). This would have implications for individuals moving to from rural societies to 
urbanised societies with higher salt intake, who may become less aware of the taste of salt, 
facilitating adaptation to a higher salt intake. There are several limitations for this study. The 
period of dietary salt modulation was short and dietary calorific and sugar intake was not 
controlled.  The participants were presented salt solutions which may not have accurately 











4.6.3     Skin capillaroscopy 
 
The main finding of the skin capillaroscopy study was that mean capillary density (MCD) at 
baseline was significantly lower after slow sodium, suggesting that capillary rarefaction had 
occurred with dietary salt loading (Figure 4.21).This observation is in keeping with data from 
He et al who showed that a significant increase in both basal and post venous occlusion 
MCD with dietary salt restriction in 169 subjects with untreated mild hypertension. 11 In this 
study venous congestion on significantly increased MCD post slow sodium, but not post 
placebo. 
 
The mechanisms for capillary rarefaction are unclear, as outlined in 1.4, and is believed to 
represent a reduction in capillary blood flow and increase in PVR, raising BP. Greaney et al 
showed that high salt intake is associated with impaired dermal NO-mediated vasodilation in 
humans. 296 Helle et al showed that dermal pre-capillary skin vessels in rats on a high salt 
diet had increased vascular reactivity to noradrenaline. 297 These observations suggest that 
dietary salt affects vascular tone and could explain the positive correlation between skin Na+ 
and BP as well as PVR the the VARSITY main study. The measured PVR in this group did not 
show significant change, with a trend for decrease in PVR (Table 4.17). The observation that 
capillary density increased with venous occlusion only post slow sodium suggests that blood 
flow in capillaries was attenuated with high salt intake. It is unknown if changes in PVR can 
occur in resistance vessels independent of systemic PVR.  
 
A major limitation of this study was the significant number of images that were unsuitable 
for analysis, resulting in a small data set. Sub-group analyses were therefore not possible.  
Nevertheless, these findings highlight the possible role of dietary sodium in influencing 







4.6.4     Conclusions 
 
In summary I conclude the following: 
 
1. Skin Na+ increases with dietary salt loading in humans. 
2. The skin may buffer dietary Na+, reducing the hemodynamic consequences of 
increased salt. This may be influenced by sex. 
3. Skin Na+ may influence blood pressure, stroke volume and PVR. 




























Chapter 5     CHANGES IN SKIN GENE EXPRESSION WITH DIETARY SALT 
MODULATION  
 
5.1     INTRODUCTION 
 
In Chapter 4 the change in skin Na+ with dietary salt modulation and its relationship with 
hemodynamic variables were assessed. In this chapter, mechanisms explaining the link 
between skin Na+ and systemic haemodynamics are explored. 
 
Studies in rat models showed that dietary salt intake is directly linked to polymerization and 
sulphation of dermal glycosaminoglycans, providing an additional storage capacity for 
sodium. 130 GAG polymerisation was measured using messenger RNA (mRNA) levels of 
chondroitin synthase and xylose transferase, which are GAG polymerisation enzymes. 130 
Evidence for this occurring in humans in lacking.  Heer et al showed the mRNA expression 
for xeostosin-like glycosyltransferase 2 (EXTL2) (a heparan sulphate polymerisation enzyme) 
and hyaluronidase increased with dietary salt loading in 9 healthy men. The mean 
expression of mRNA for xylosyltransferase 1 (the rate-limiting key enzyme in the 
biosynthesis of the dermatan and heparan sulphate initiation linkage region) and 
chondroitin sulphate synthase 3 was not significantly increased during the high NaCl intake 
period. 298 Fischereder et al showed that skin GAGs content correlated with Na+ 
concentration in renal transplant donors and recipients, suggesting that skin Na+ storage is 
regulated by GAGs in humans. 143 The effect of dietary salt modulation on skin GAGs was not 
assessed.  
 
Studies in rats also showed that macrophages exert a homeostatic function in the skin via 
TonEBP and VEGF-C, regulating clearance of osmotically inactive stored salt via lymphatic 
vessels. VEGF-C also induced expression of endothelial nitric oxide synthase (eNOS), causing 
vasodilation via nitric oxide (NO) production. 133,134 In these studies TonEBP and VEGF-C 
were quantified using western blotting and mRNA using real time polymerase chain reaction 
(rtPCR). eNOS was quantified using indirect immunofluorescence. 133,134 There is a paucity of 
evidence for the relationship between Ton-EBP, VEGF-C, BP and dietary salt in humans. Skin 




The VARSITY study showed that skin sodium, expressed as skin Na+:K+, correlates with both 
MAP and peripheral vascular resistance in healthy humans (4.5.3.5). The mechanisms for 
this are unknown. The hypoxia inducible factor (HIF) transcription system plays a central 
role in a wide range of adaptive responses to changes in oxygenation. 216 As described in 
1.4, the relative concentrations of HIF-1α and HIF-2α ratio in the skin affects MAP in 
humans, with a higher HIF-2α:HIF-1α ratio being associated with hypertension. 217 This 
occurs via differential effects on inducible nitric oxide synthase (iNOS) and regulation of 
nitric oxide (NO) equilibrium in the skin. 217 Furthermore, HIF-1α up-regulates VEGF A, which 
influences NO by upregulating eNOS via VEGFR2 receptors, influencing vascular tone. 219,220 
HIF metabolism may also be related to dietary salt intake. In the rat kidney model, high salt 
intake has been shown to suppress prolyl hydroxylase domain 2 (PHD 2), which hydroxylates 
and degrades HIF-1α and HIF-2α. 299-301 The increase in HIF-1α alpha expression, resulting 
upregulation of heme oxygenase 1 (HO-1) 1 and cyclooxygenase 2 (COX-2), endothelin 1 and 
inducible nitric oxide synthase. This results in pressure natriuresis, counteracting the 
haemodynamic effects of dietary salt. 221,222 It would be plausible for a similar mechanism to 
exist in the skin whereby high salt intake alters levels of HIF isomers, potentially influencing 
















Figure 5.1: A possible mechanism linking dietary salt intake, HIF isomers in the skin and BP. 
Keratinocytes in the skin produce nitric oxide via nitric oxide synthase 2 (NOS-2 or iNOS) under the 
influence of hypoxia-inducible transcription factors HIF-1α and HIF-2α, which act antagonistically. 
HIF-1α induces nitric oxide synthase 2 (NOS-2 or iNOS) which metabolises L-arginine , producing 
NO. HIF-2α induces arginase-1, which catalyses the hydrolysis of L-arginine to l-ornithine and urea, 
thus depleting L-arginine available for conversion to NO by iNOS 218,302,303 HIF-1α up-regulates VEGF 
A, which influences NO by upregulating eNOS via VEGFR2 receptors, influencing PV. The balance of 
dermal HIF-1α and HIF-2α influences BP by altering NO expression, which alters PVR. High salt 
intake suppresses PHD2, which degrades HIF-1a and HIF-2a, thus potentially influencing PVR.  
 
               
 
 
On this background changes in dermal gene expression of GAG-polymerisation enzymes, 
Ton-EBP, VEGF-C and HIF isomers with dietary salt modulation was conducted in a subset of 
VARSITY study participants. As a sex-specific difference in haemodynamic response to 
dietary salt was observed, a comparison was made between gene expression in men and 
women. All procedures involving the analysis of skin gene expression described in this 
chapter were carried out by QIAGEN in their service laboratory in Hilden, Germany. 
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5.2     HYPOTHESES  
 
. Increased salt intake in humans leads to increased dermal gene expression of GAG-
polymerisation enzymes, Ton-EBP and VEGF-C in humans. 
. The dermal hypoxia inducible factor transcription system is altered by dietary salt 
loading and this relates to associated BP changes - an increase HIF-2α expression 
would raise BP while an increase HIF-1α would lower BP. 
. Differences in gene expression in relation to salt intake may explain the sex-specific 
difference in BP response to dietary salt modulation observed in the VARSITY study.  
 
5.3     AIMS 
 
1. The primary aim of this study was to assess the difference in gene expression for GAG-
polymerisation enzymes, Ton-EBP, VEGF-C and HIF isomers with different salt intakes. 
 




















5.4     METHODS 
 
5.4.1     Subjects  
 
20 participants for the VARSITY main study were selected if they had good dietary 
sodium compliance during placebo and slow sodium phases and sufficient skin tissue 
for analysis. These included 10 men and 10 women who were age matched. 
 
5.4.2     Design and protocol  
 
The VARSITY study design and protocol, as described in 4.4.1, was used for all 20 
participants. Skin samples were obtained using methods described in 4.4.5 and 4.4.6 after 
placebo and slow sodium treatments.  The remaining portion of each skin sample was 
stored at −80°C and transferred to the QIAGEN service laboratory in Hilden for PCR analysis 
using a custom quantitative PCR (qPCR) array. This was designed with genes of interest 
selected from QIAGEN’s catalogue and conducted by QIAGEN using their own protocols, 
selected necessary housekeeper and internal control genes.  
 
5.4.3     Custom quantitative PCR array  
 
A brief overview of the custom quantitative PCR array carried out by QIAGEN is summarised 
below.  
 
5.4.3.1     Genes of interest  
 
The genes of interest included in the qPCR array are listed in table 5.1. These included genes 
for the following: 
 
⁃ Key GAG polymerisation enzymes such as chondroitin sulphate synthase (chondroitin 
sulphate elongation), dermatan sulphate epimerase (dermatan sulphate elongation), 
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xylosyl transferase 1 (dermatan or chondroitin sulphate initiation) and xylosyl 
transferase 2 (chondroitin or heparan sulphate elongation).  
⁃ The Ton-EBP - VEGF-C axis, including FLT-4, a tyrosine kinase receptor for vascular 
endothelial growth factor C. 
⁃ The HIF isomers and PHD2, which degrades HIF-1 α and HIF-2α. 
⁃ VEGF-A (a HIF-1 α target gene) and its tyrosine kinase receptor FLT-1. 
⁃ eNOS (NOS3) and iNOS(NOS2). 





































































Vascular endothelial growth factor-A VEGF-A 
Vascular endothelial growth factor-C VEGF-C 
Fms-related tyrosine kinase 1 FLT-1 (VEGFR-1) 
Fms-related tyrosine kinase 4 FLT-4 (VEGFR-3) 
Ton-EBP (NFAT5) Ton-EBP 
Dermatan sulphate epimerase DSE 
Xylosyltransferase I XYLT1 
Xylosyltransferase II XYLT2 
Chondroitin sulphate synthase 1 CHSY1 
Hypoxia inducible factor 1 HIF-1α 
Endothelial PAS domain protein 1 HIF-2α 
Egl nine homolog 1 (C. elegans) PHD2 
Inducible nitric oxide synthase 2 NOS2 
Inducible nitric oxide synthase 3 NOS3 
Housekeeping genes  
Hypoxanthine phosphoribosyl 
transferase 1  
HPRT1 
Ribosomal protein, large, P0 RPLP0 







5.4.3.2     RNA Isolation and quality assessment  
 
Skin tissue samples were first lysed in Buffer RLT and diluted before being treated with 
proteinase K. Debris were pelleted by centrifugation, and the supernatant is removed before 
being mixed with ethanol and then centrifuged through a RNeasy spin column. Traces of 
DNA copurified with the RNA were removed by DNase treatment on the silica membrane. 
DNase and any contaminants were washed away and RNA was eluted in RNase-free water. 
RNA quality and concentration are determined by using a Nanodrop spectrophotometer to 
measure the concentration and optical density (OD) 260/280 values of the samples.  
 
5.4.3.3     cDNA Synthesis and Pre-amplification 
 
The RT2 PreAMP complementary DNA (cDNA) Synthesis Kit (Cat. No. 330451) and RT2 
PreAMP Pathway Primer Mixes (QIAGEN, Maryland, USA) were used to synthesis and pre-
amplification of cDNA from total RNA samples, prior to gene expression analysis using a RT2 
Profiler PCR array.  
 
5.4.3.4     Real-time reverse transcription PCR 
 
cDNA was mixed with a ready-to-use QIAGEN RT2 SYBR® Green qPCR Master Mix. The 
mixture was added into a 96-well RT2 mRNA PCR Array (SABiosciences) that contained 
primers for 84 tests and 5 housekeeping genes according to manufacturer's instruction. 
Thermal cycling was performed using ABI-7900 (Applied Biosystems, Foster, CA, USA).  
 
 
5.4.3.5     Quality control methodologies 
 
Quality control for qPCR was checked by assessing of PCR array reproducibility, reverse 
transcription efficiency and genomic DNA contamination. The Positive PCR Controls (PPC) 
were used to test the efficiency of the polymerase chain reaction using a pre-dispensed 
artificial DNA sequence and the primer set that detects it. Reverse transcription efficiency 
was assessed by testing the efficiency of the RT² First Strand Synthesis Kit (330401) reaction 
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with a primer set to detect template synthesized from the kit's built-in external RNA control. 
The DNA contamination control assay (GDC) was used to determine if genomic DNA was 
present in a skin sample at an amount that may affect PCR results. The GDC primers were 
used to specifically detect non-transcribed genomic DNA contamination, defined as Ct(GDC) 
< 30. In addition, control genes included in the array were used to assess the presence of 




5.4.3.6     Data analysis and statistics  
 
The QIAGEN PCR Array Data Analysis Web Portal 
(http://www.sabiosciences.com/pcrarraydataanalysis.php) automatically performed the 
above calculations and interpretation of the control wells upon including threshold cycle 
data from the real-time instrument (See Figure 5.2). 
 
The threshold cycle (Ct) value is the cycle number at which the fluorescence generated 
within a reaction crosses the fluorescence threshold, which is a fluorescent signal 
significantly above the background fluorescence. At the threshold cycle, a detectable 
amount of amplicon product has been generated during the early exponential phase of the 
reaction. The threshold cycle is inversely proportional to the original relative expression 














Figure 5.2: An example of how QIAGEN PCR Array Data Analysis Web Portal generates cycling 
curves and determines threshold cycle (Ct) value for each gene.  
 
 
qPCR relative expression of genes of interest was determined with the double delta cycle 
threshold (ddCt or ΔΔCt ) method as follows: 
 
4. dCt = (Ct Gene of Interest) – (Ct Average of Housekeeping Genes)  
5. ddCt = dCt (group 2) - dCt (group 1) where Group 1 refers to placebo and Group 2 
refers to slow sodium  
 
Differences in mRNA abundance and gene expression were expressed as fold changes (FC) 
and were calculated using 2−ddCt method. A fold change > 1 represented an upregulation of a 
gene with slow sodium while a fold change of < 1 represented downregulation. Differences 
in gene expression for placebo vs. slow sodium treatments were analysed by Student's t-
test. The p values were calculated based on a Student's t-test of the replicate 2^ (- Delta CT) 
values for each gene in the control group and treatment groups. A P value < 0.05 was 
considered to be statistically significant.  
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5.5     RESULTS    
5.5.1     Analysis of whole study population 
 
5.5.1.1     Baseline characteristics 
 
The 20 participants (10 men, 10 women) had a mean age of 30 ± 2 years (range 18–49 
years). Baseline characteristics are shown in Table 5.2. Our study sub-set had a low baseline 
sodium intake compared to the current average intake in England (approximately 130 
mmol/day) and had similar baseline characteristics to the whole VARSITY study population. 
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Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 






Baseline variables  (n=20) 
Age, years 31 ± 2 
Ethnicity (Caucasian) 18/20 
Sex (M/F) 10/10 
BMI, kg ms-2 
 
24.1 ± 1 
Haemodynamic variables  
Supine SBP, mmHg  119 ± 2 
Supine DBP, mmHg  71 ± 2 
Supine MAP, mmHg 87 ± 2 
24-hr MAP 96 ± 2 
24-hr SBP 120 ± 2 
24-hr DBP 76 ± 2 
  
Biochemical variables  
Renin, mU/l 14.1 ± 2.0 
Aldosterone, pmol/l 110 (70 – 181) 
24-hr Urine Na+, mmol/24hr 80.0 ± 12.2 
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5.5.1.2     qPCR array quality assessment 
 
All gene average threshold cycles were below the limit of 35. All samples passed PCR array 
reproducibility and reverse transcription efficiency tests using the QIAGEN PCR Array Data 
Analysis Web Portal. No significant genomic DNA contamination was detected. 
 
5.5.1.3     Main haemodynamic and biochemical responses 
 
The main haemodynamic and biochemical responses to placebo vs. slow sodium for the 20 
participants are shown in Table 5.3. 24-hr MAP was significantly higher post slow sodium 
























Table 5.3: Main haemodynamic and biochemical responses to placebo vs. slow sodium for the 20 






Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. Clinic BP refers to supine BP. 
 
 
5.5.1.4     qPCR array results 
 
Skin samples had a mean wet weight of 8.9 ± 0.7 mg. qPCR array results showing gene 
expression for slow sodium vs. placebo treatments are shown in Table 5.4. No significant 
changes were noted in gene expression for placebo compared to salt. There were trends for 
Variable n=20 
 Placebo Slow sodium  P-value 
 
Haemodynamics  
   
     Weight, kg 67.9 ± 2.5 68.1 ± 2.4 0.50 
     Clinic SBP, mmHg 115 ± 2 117 ± 2 0.10 
     Clinic DBP, mmHg 70 ± 2 70 ± 2 0.66 
     Supine MAP, mmHg 85 ± 1 86 ± 2 0.27 
     24-hr MAP, mmHg 95 ± 1 98 ± 1 0.04 
     Day MAP, mmHg 99 ± 2 101 ± 1 0.10 
     Night MAP, mmHg 87 ± 2 90 ± 2 0.05 
     Stroke volume, ml 97.1 ± 4.7  103.7 ± 6.7 0.10 
     PVR, dynes s-1 cm-5 1138 ± 67 1106 ± 82 0.36 
Skin measurements    
    Skin Na+: K+ 2.91 ± 0.12 3.14 ± 0.16 0.10 
Plasma measurements     
      Renin, mU/l 219(10 – 27) 4(3 – 11) < 0.001 
     Aldosterone, pmol/l 180 (92 – 407) 70 (65 – 80) < 0.001 
     VEGF-C, pg/ml 632 ± 75 703 ± 90 0.52 
      sFlt-4, pg/ml 10.0 ± 1.2   10.4 ± 1.0 0.55 
Urinary measurements    
      Na+, mmol/24hr 64.8 ± 7.0 261.0 ± 15.2 < 0.001 
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increase in FLT-1 (VEGFR-1), HIF-2a, iNOS and eNOS with slow sodium treatment relative to 
placebo. VEGF-C showed a trend for decreased expression with slow sodium treatment 
relative to placebo (FC 0.59, p = 0.31). No change in gene expression for GAG polymerisation 
enzymes was seen with dietary salt loading. 
 
Table 5.4: Changes in gene expression with placebo vs. slow sodium by sex for the 20 participants 
used in qPCR array. 
 
 
Differences in mRNA abundance and gene expression were expressed as fold changes (slow sodium/ 
placebo) and were calculated using 2−ddCt method. A fold change > 1 represented an upregulation of 
a gene with slow sodium compared to placebo while a fold change of < 1 represented 
downregulation. Fold-change values less than one indicate a negative or down-regulation. The p 
values are calculated based on a Student's t-test of the replicate 2^ (- Delta CT) values for each gene 
for placebo slow sodium treatments. P values less than 0.05 are considered significant.  
Gene of interest Symbol Fold change  P-value 
Vascular endothelial growth factor-A VEGF-A 1.09 0.74 
Vascular endothelial growth factor-C VEGF-C 0.59 0.31 
Fms-related tyrosine kinase 1 FLT-1 (VEGFR-1) 1.32 0.10 
Fms-related tyrosine kinase 4 FLT-4 (VEGFR-3) 0.92 0.42 
Ton-EBP (NFAT5) Ton-EBP 1.06 0.50 
Dermatan sulphate epimerase DSE 0.96 0.68 
Xylosyltransferase I XYLT1 0.74 0.45 
Xylosyltransferase II XYLT2 1.09 0.53 
Chondroitin sulphate synthase 1 CHSY1 1.11 0.30 
Hypoxia inducible factor 1 HIF-1α 1.02 0.93 
Endothelial PAS domain protein 1 HIF-2α 1.21 0.14 
Egl nine homolog 1 (C. elegans) PHD2 1.05 0.53 
Inducible nitric oxide synthase 2 iNOS 1.48 0.11 
Endothelial nitric oxide synthase 3 eNOS 1.30 0.09 
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5.5.2     Sex-specific analysis 
 
5.5.2.1     Baseline characteristics 
 
Sex-specific baseline characteristics are shown in Table 5.3. There were no significant 
differences in age or BMI between sexes. 4 women were on contraceptive treatment. Men 
had higher 24-hr SBP and renin, in keeping with the main VARSITY population. 
 




Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. The values for males and females was analyzed using the unpaired t test with 




5.5.2.2    Main haemodynamic and biochemical responses 
 
Sex-specific main haemodynamic and biochemical responses to placebo vs. slow sodium are 
shown in Table 5.6. Dietary salt compliance and difference in urinary sodium between 
placebo and slow sodium treatments was similar in men and women. In men there were no 
Baseline variables Males Women P value 
 n = 10 n = 10  
Age, years 29 ± 3 33 ± 2 0.33 
Ethnicity (Caucasian) 9/10 9/10 - 
BMI, kg ms-2 
 
23.7 ± 1 24.6 ± 1 0.46 
Haemodynamic variables    
Supine SBP, mmHg  122 ± 2 115 ± 3 0.13 
Supine DBP, mmHg  70 ± 3 73 ± 2 0.42 
Supine MAP, mmHg 87 ± 2 92 ± 2 0.21 
24-hr MAP 100 ± 3 92 ± 2 0.06 
24-hr SBP 126 ± 3 115 ± 2 0.002 
24-hr DBP 78 ± 4 74 ± 1 0.38 
    
Biochemical variables    
Renin, mU/l 20.0 ± 3.0 9.3 ± 2.0 0.002 
Aldosterone, pmol/l 133.4 ± 16.3 134.5 ± 36.2 0.99 
24-hr Urine Na+, mmol/24hr 90.2 ± 20.9 66.2 ± 8.4 0.35 
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differences in BP following salt loading, whilst women had higher 24-hour, day and night 
MAP. Only women had an increase in body weight post slow sodium (62.7 ± 1.4 vs. 63.5 ± 
1.3 kg; p = 0.04). Men showed a rise in stroke volume and a trend for decrease in PVR with 
slow sodium, while in women this was not observed. Men had 9.3 % a rise skin Na+:K+ post 
slow sodium while in women this was 6.7 %, neither of which was statistically significant. In 
men there was a trend for higher plasma VEGF-C (840 ± 150 vs. 567 ± 77 pmol/l, p = 0.07) 
but in women this was not apparent (579 ± 96 vs 698 ± 131 pmol/l, p = 0.63). sFLT-4 did not 



























Variable Men (n=10) Women (n=10) 
 Placebo Slow sodium  P-value Placebo Slow sodium  P-value 
Haemodynamics        
     Weight, kg 73.1 ± 4.2 72.7 ± 4.3 0.32 62.7 ± 1.4 63.5 ± 1.3  0.04 
     Clinic SBP, mmHg 116 ± 2 119 ± 2 0.07 114 ± 3 116 ± 2 0.43 
     Clinic DBP, mmHg 68 ± 2 69 ± 2 0.64 71 ± 2 71 ± 2 0.87 
     Supine MAP, mmHg 84 ± 2 85 ± 2 0.26 85 ± 2 86 ± 2 0.59 
     24-hr MAP, mmHg 99 ± 2 100 ± 2 0.80 92 ± 1 96 ± 2 0.003 
     Day MAP, mmHg 101 ± 2 103 ± 2 0.91 97 ± 2 100 ± 2  0.02 
     Night MAP, mmHg 92 ± 2 93 ± 2 0.67 82 ± 1 87 ± 2  0.006 
     Stroke volume, ml 101.2 ± 7.1 116.4 ± 10.3 0.01 92.9 ± 6.1 91.0 ± 6.7  0.69 
     PVR, dynes s-1 cm-5 1091 ± 88 1006 ± 114 0.08 1185 ± 103.6 1206 ± 115 0.68 
Skin measurements       
    Skin Na+: K+ 2.67 ± 0.15 2.92 ± 0.19 0.16 3.15 ± 0.16 3.36 ± 0.24 0.37 
Plasma measurements        
      Renin, mU/l 23.6 ± 2.8 8.9 ± 1.6 < 0.001 15.2 ± 2.8 4.8 ± 1.2 0.001 
     Aldosterone, pmol/l 180 (93 – 268) 70 (68 – 118) 0.01 235 (69 – 455)  69 (65 – 74) 0.02 
     VEGF-C, pg/ml 567 ± 77 840 ± 150    0.07 698 ± 131 579 ± 96 0.38 
      sFlt-4, pg/ml 7.5 ± 1.8   7.9 ± 1.5    0.83 12.5 ± 1.2 13.0 ± 0.9 0.63 
Urinary measurements       
      Na+, mmol/24hr 67.6 ± 10.7 260.1 ± 25.8 < 0.001 62.0 ± 9.6 261.9 ± 17.7 < 0.001 
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Normally distributed data presented as mean ± SEM. Non-normally distributed data are presented 
as median and IQR. Student’s paired t-tests were applied to paired observations after placebo and 
slow sodium for normally distributed data and the Wilcoxon signed-rank test for non-normally 
distributed data. Clinic BP refers to supine BP.
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5.5.2.3     qPCR array results 
 
Sex specific qPCR array results showing gene expression for slow sodium vs. placebo 
treatments are shown below Table 5.7 and Figure 5.3. Women had a significant rise in HIF-
2A gene expression with slow sodium compared to placebo (FC 1.43, p = 0.046) while in 
men this was attenuated (FC 1.17, p = 0.14). In men there was a trend for increase in iNOS 
and eNOS gene expression, in keeping with a trend for decrease in PVR with slow sodium 
compared to placebo. Both sexes showed a trend for decreased VEGF-C expression with 
slow sodium compared to placebo, though this was associated with wide 95% confidence 
intervals - (FC 0.67; CI 0.05, 1.29; p = 0.90) for men and (FC 0.54; CI 0.06, 1.02; p = 0.31) for 
women.  In women there was a trend for increase in FLT-1 (FC 1.71, p = 0.11) with slow 
sodium treatment relative to placebo, while this was not seen in men (FC 1.07, p = 0.41). 
There was a trend for FLT4 expression to increase in men (FC 1.32, p = 0.26) and decrease in 
women (FC 0.64, p = 0.78). No change in gene expression for GAG polymerisation enzymes 























Differences in mRNA abundance and gene expression were expressed as fold changes (slow 
sodium/ placebo) and were calculated using 2−ddCt method. A fold change > 1 represented an 
upregulation of a gene with slow sodium compared to placebo while a fold change of < 1 
represented downregulation. Fold-change values less than one indicate a negative or down-
regulation. The p values are calculated based on a Student's t-test of the replicate 2^ (- Delta CT) 




  Men (n = 10) Women (n = 10) 





Vascular endothelial growth factor-
A 
VEGF-A 1.21 0.38 0.91 0.45 
Vascular endothelial growth factor-
C 
VEGF-C 0.67 0.90 0.54 0.31 
Fms-related tyrosine kinase 1 FLT-1 
(VEGFR-1) 
1.07 0.41 1.71 0.11 
Fms-related tyrosine kinase 4 FLT-4 
(VEGFR-3) 
1.32 0.26 0.64 0.78 
Ton-EBP (NFAT5) Ton-EBP 1.07 0.35 1.00 0.97 
Dermatan sulphate epimerase DSE 0.91 0.54 0.97 0.92 
Xylosyltransferase I XYLT1 0.86 0.75 0.26 0.35 
Xylosyltransferase II XYLT2 0.97 0.79 1.26 0.48 
Chondroitin sulphate synthase 1 CHSY1 1.03 0.77 1.17 0.31 
Hypoxia inducible factor 1 HIF-1A 1.06 0.84 0.94 0.81 
Endothelial PAS domain protein 1 HIF-2A 1.07 0.48 1.43 0.046 
Egl nine homolog 1 (C. elegans) PHD2 1.17 0.34 0.93 0.66 
Inducible nitric oxide synthase 2 iNOS 1.43 0.24 1.24 0.53 
Endothelial nitric oxide synthase 3 eNOS 1.45 0.16 1.13 0.38 
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Figure 5.3: Illustration of changes in gene expression for men and women for slow sodium vs. 
placebo. The diagrams show the mean fold changes and SEM.   
A: HIF isomers and PHD-2. 
 
B. INOS and eNOS. 




5.6     DISCUSSION 
 
 
This analysis of specific dermal gene expression changes was carried out in a sub-set of 20 
participants with characteristics and sex-specific differences similar to the main VARSITY 
study population. In analysis of all 20 participants an increase in 24-hr MAP was seen with 
salt loading and this was not associated with any clear change in GAG polymerisation, Ton-
EBP, VEGF-C, VEGF-A or HIF isomers. In sex-specific analyses, women had a BP rise and 
increase in body weight with higher dietary salt while men did not, despite similar urinary 
sodium excretions in both groups. This sex-specific difference in haemodynamic response 
was associated with differences in dermal gene expression for HIF-2 and trends for 
differences in expression for eNOS, iNOS and FLT-1. There was no clear evidence that 
differences in the Ton-EBP-VEGF-C axis or polymerization and sulphation of dermal 
glycosaminoglycans explain the sex-specific difference in haemodynamic response. 
Previous studies showing activation of the Ton-EBP-VEGF-C axis in rats used high salt intake 
of 4-8% NaCl over 4 weeks. 133,134 This represents an increase in salt intake of up to 15-fold 
compared to rats receiving a normal intake of 0.4% NaCl. 304 In the VARSITY study, 7 days of 
high salt intake (approximately 16 g of NaCl a day) were used, which is less than twice the 
average salt intake in current average intake in England (approximately 130 mmol/day). 256 
This was a more relevant level of salt intake, but it may not have caused an adequate 
increase skin hypertonicity to induce Ton-EBP. In men there was a trend for increase in 
plasma VEGF-C and a trend in both sexes for a decrease in VEGF-C gene expression. Reasons 
for these observations are unclear and both plasma ELISA quantification and mRNA 
quantification showed significant variability, limiting the ability to observe trends. In rats 
both gene expression and protein quantification of Ton-EBP and VEGF-C was increased with 
higher salt intake. Skin tissue obtained in the VARSITY study were insufficient for protein 
analysis and therefore this could not be achieved. 
In the only previous study of salt intake on GAG polymerisation enzymes, Heer et al showed 
the mRNA expression for xeostosin-like glycosyltransferase 2 (EXTL2) and hyaluronidase 
increased with dietary salt loading in 9 healthy men. These genes were not tested in this 
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qPCR array. In this study expression of xylosyltransferase 1 and chondroitin sulphate 
synthase 3 was not significantly increased, which concurs with the finding of this analysis. 298 
GAG enzymes are a surrogate for GAG protein expression and may not reflect actual changes 
in GAG. The duration of salt loading in this study was shorter than previous work in rats (4 
weeks) showing upregulation of GAG polymerisation enzymes. 130 
In this analysis, women had an increase in HIF-2α and an increase in ambulatory BP with 
increased salt intake while men showed no increased in either HIF-2α or BP. As described in 
5.1, increased HIF-2α activity would induce arginase-1, which catalyses the hydrolysis of L-
arginine to l-ornithine and urea, thus depleting L-arginine available for conversion to NO by 
iNOS 218,302,303 No difference in HIF-1α expression was seen, though it should be noted that 
HIF-1α mRNA has a relatively short half-life, while HIF-2a RNA has a remarkably longer half-
life. 218 This could mean that changes in gene expression of HIF-1α could have been missed 
at 7 days. Both VEGF-A and its receptor FLT-1 (VEGF-1) are involved in regulating 
vasculogenesis and angiogenesis. 305 FLT-1 variants are increased in preeclamptic placentas 
compared with normotensive placentas. 306 In this analysis men had a modest trend for 
increase in VEGF-A (a target gene for HIF-1α) expression with salt loading (FC 1.21, p = 0.38). 
This could suggest increased HIF-1α expression or a reason for the trend for increase in 
eNOS expression. The basis and relevance for the trend for increase in in FLT-1 in women 
with slow sodium treatment relative to placebo is unclear and merits further study. In men a 
trend for decrease in PVR and increase in both eNOS and iNOS expression was seen. This 
could potentially explain why they did not have a rise in BP while women did. It is possible 
that differences in HIF-2A expression could partly account for this, but clearly further work 
would need to be done. 
In summary, this qPCR analysis provides a unique insight into changes in gene expression 
with dietary salt loading. Results have to be interpreted with caution and are not conclusive 
as this is a small sample size and mRNA quantification in only a surrogate for protein 





Chapter 6     ELEMENTAL PROFILES AND THE EXISTENCE OF ENaC IN 
THE SKIN  
 
6.1     INTRODUCTION 
 
In Chapters 3 and 4 the functions of the skin as a repository for body sodium and a buffer 
for dietary sodium were explored using ICP-OES, which quantified skin sodium and 
potassium content. This technique could not be used to evaluate skin Cl- concentrations or 
the distribution of elements in different layers or structures of the skin. In this chapter the 
development of techniques for analysing elemental distributions in the skin and the 
distribution of the epithelial sodium channel (ENaC) in keratinocytes are described. These 
would facilitate an understanding of mechanisms involved in sodium flux within the skin, a 
possible reason for the apparent sex-specific skin changes described in 4.5.2, potentially 
illuminating novel roles for skin Na+. 
 
The skin is a large, complex organ with a variety of structures and cells, including hairpin-like 
lymphatic and blood capillary structures (Figure 6.1). The distribution of sodium within 
these are largely unknown, as outlined in 1.3.4.  
 
Figure 6.1: Structure of the skin and the different layers of the epidermis. The epidermis consists of 
continually keratinizing or cornifying, stratified non-vascularised epithelium terminating at 
mucocutaneous junctions such as the mouth. 178. The stratum basale consists of keratinocytes, 
which are columnar epithelial cells on a basement membrane, undergoing cell division. The next 
layer, the stratum spinosum, consists of polyhedral cells connected by desmosomes, becoming 
progressively flatter upwards. Above this layer, the stratum granulosum, consists of flattened cells 
with numerous basophillic granules. Above this lies the stratum lucidum, consisting of packed 
squamous cells that lack organelles or nuclei. The outermost layer, the stratum corneum, is made 
of dead, anucleate cornified cells. 307 
 








Few studies have analysed the distribution patterns of sodium and other elements in the 
skin. Over 30 years ago, electron probe analysis and X-ray microanalysis revealed sodium 
distribution patterns in the epidermis, with high levels in the keratinocytes of the lower 
epidermis. 308-310 The relevance of these patterns was unknown. Recently, 23Na-MRI analysis 
of the skin at 7 tesla revealed an age-dependent increase in skin Na+ content directly under 
the keratinocyte layer of the skin in humans. 199 This has given rise to notion that a kidney-
like countercurrent system functions in the skin, whereby a Na+ concentration gradient, 
believed to be generated by active transport in keratinocytes, forms an osmotic barrier. 
208,209 It has been recently proposed that epithelial sodium channels (ENaC) are responsible 
for generating sodium gradients in keratinocytes. 135,311 
 
In the kidney, the amiloride-sensitive epithelial sodium channel (ENaC) plays a major role in 
the regulation of sodium transport in the collecting duct and is a well-known determinant of 
sodium homeostasis and BP. 312 The function of ENaC in human skin is unclear. Reptilian skin 
is known to be possess α , β and γ ENaC subunits in the apical membranes of keratinocytes 
within the stratum granulosum and the stratum spinosum, where they facilitate Na+ 
transport and are believed to enable osmoregulation. 313,314 Mice having keratinocyte- 
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specific deletions of ENaC-α subunits have epidermal hyperplasia, suggesting a role for ENaC 
in in normal epidermal differentiation. 315,316 Studies assessing blood pressure and sodium 
homeostasis in these animals have not been published. Recently, ENaC-α subunits were 
localised in all epidermal layers in human skin except stratum corneum using confocal 
microscopy, as well as in the sebaceous glands, eccrine glands, arrector pili smooth muscle 
cells, and intra-dermal adipocytes. 317 It is unclear if sodium flux in the skin during periods of 
high salt intake is facilitated by ENaC. The distribution of chloride and potassium in the skin 
are poorly understood, with 1 previous study showing high potassium concentration in the 
epidermis as measured using flame photometry. 188 
 
In this chapter I will explore the feasibility of using SEM-EDX to show Na+, K+ and Cl- patterns 
in the skin and how ENaC transporters are located relative to these patterns.  
 
6.2     Hypotheses 
 
On this background I propose the following hypotheses: 
 
1. Skin sodium has distribution patterns in the epidermis and dermis, forming a barrier to 
water loss to the external environment. 
 




6.3     Aims 
The aims are to determine the following:  
 
1. The feasibility of studying skin sodium distribution profiles using scanning electron 
microscopy with energy dispersive X-ray spectroscopy (SEM-EDX) 
 
2. The feasibility of immunohistochemical localisation of ENaC in human skin.  
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6.4     Methods 
 
6.4.1     Assessment of skin elemental distribution 
 
6.4.1.1     SEM-EDX  
 
Scanning electron microscopy with energy dispersive X-ray spectrometry (SEM–EDX) is a 
powerful tool for simultaneously examining the morphology and the elemental composition 
of solid structures, showing chemistry and morphology of particles as small as a few tenths 
of a micrometer. 318 It has been employed in the analysis of bullet wounds in forensic 
science and skin disease in dermatology. 319,320 The scanning electron microscope (SEM) is a 
type of electron microscope that creates images of the sample surface by scanning it with a 
high-energy electron beam, focussed on a field of interest.  The electrons interact with the 
atoms that are in the sample to generate secondary electrons and backscattered electrons. 
Secondary electrons are emitted from the atoms occupying the top surface and produce a 
readily interpretable image of the surface which is three dimensional. Backscattered 
electrons show the distribution of different chemical phases in the sample and have less 
resolution.  In the SEM EDX technique, the SEM image generated by secondary electrons is 
used to select the area of interest while an energy dispersive detector is used to measure 
the energies of emitted x-rays which are characteristic of the elements present. The energy 
of the primary electron beam is termed the accelerating voltage, which is adjustable to 
control image detail. The interaction between the primary electron beam and atoms in the 
sample causes inner electron shell transitions, which result in the emission of X-rays. A 
fraction of these X- rays are collected and analysed by means of an energy dispersive X-ray 
spectrometry. This detects and measures the characteristic X-ray energies, yielding an 
analysis of the elements present in the feature. Energy dispersive X-ray spectrometry can 
give a rapid, qualitative analysis, or, with adequate standards, quantitative analysis of 
elemental composition with a sampling depth of 1–2 μm. X-rays can be acquired in 
synchronization with the image-forming electron beam to form two-dimensional maps 
showing the distribution of elements in a sample surface. 318  
 
Thus, SEM-EDX can be used to derive elemental distribution patterns in solid structures, 
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including human tissue. The instruments and expertise for using this technique were 
available at the Cambridge Nanoscience Centre and Graphene Centre. For these reasons 
SEM-EDX was chosen for this thesis.  
 
 6.4.1.2     SEM-EDX instruments 
 
The work in this thesis was developed initially at the Cambridge Nanoscience Centre and 
continued at the Cambridge Graphene Centre. Instruments were operated by Dr Yury 
Alaverdyan, Research Facilities Manager at Cambridge Graphene Centre, who developed 
the SEM-EDX techniques with me for this thesis. The first analysis was performed on the LEO 
GEMINI 1530VP FEG-SEM system at the Cambridge Nanoscience Centre (Figure 6.2).  This 
consists of a scanning electron microscope coupled with an energy dispersive X-ray 
spectrometer (Inca Energy MX from Oxford Instruments Nanoanalysis). INCA software 
(version 4.02, Oxford Instruments) was used to process EDX outputs. The second analysis 
was performed at the Cambridge Graphene Centre on the on the FEI Magellan 400 XHR SEM 
coupled with a Bruker X-Flash EDX detector. OIM Analysis™ software (version 7, AMETEK) 
was used to process EDX outputs. (Figure 6.3) 




Figure 6.3: The FEI Magellan 400 XHR SEM coupled with a Bruker X-Flash EDX detector at 




6.4.1.3     Samples  
 
SEM-EDX analysis was performed on 2 remaining skin portions from the Tissue Bank 
samples, described in 2.5. These were healthy breast reduction surgical resections and were 
numbered sample 1 and 2. Skin Na+ and K+ had previously been determined by ICP-OES, as 
described in 2.5.3. The measures values for these elements using ICP-OES and the age of 
skin donors are shown in Table 6.1.  
 









Tissue Bank skin sample  Age Skin Na+Dry, mg/g  Skin K+Dry, mg/g 
1 47 5.57 0.76 
2 45 4.06 1.66 
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6.4.1.4    Sample processing 
 
Skin samples were stored at - 80 °C before undergoing cryosectioning in a Bright Clinicut 
cryostat in the EMIT unit. I cut Sample 1 at 30 micrometers (µm) at a chamber temperature 
of - 20 °C using O.C.T. Compound (Tissue-Tek, VWR) mounting medium. A frozen section of 
mounting medium was previously analysed using the LEO GEMINI 1530VP FEG-SEM system 
and found to have no sodium, potassium or chloride content. Samples were viewed with a 
light microscope (OLYMPUS 2467) under 20 x magnification to ensure intact epidermis and 
dermis portions were present. Sample 2 was sectioned at 35 μm at the Addenbrookes 
Hospital Tissue Bank using the same techniques. Frozen skin sections were mounted on 10 x 
10 x 0.5 mm pre-cut undoped silicon slides obtained from the Cambridge Nanoscience 
Centre and stored at - 80 °C in the EMIT unit. Sample 1 was subsequently transferred to the 
Cambridge Nanoscience Centre and sample 2 to the Cambridge Graphene Centre on dry ice 
for SEM-EDX analysis. Sample thicknesses of 30-35 μm were chosen as it was felt this would 
include intact keratinocytes and samples were able to resist the damaging effects of 
freezing and thawing.  
 
Figure 6.4: Skin sample preparation for SEM-EDX analysis. A: Sample 1 being cryosectioned in a 







6.4.1.5     SEM-EDX procedure for skin analysis   
 
Each skin section was placed in a drying cupboard at 60-70 °C for 1 hour to remove water 
content and prevent charging artefact (Figure6.4A). Sections were then viewed under a 
digital light microscope (OLYMPUS BX 51) at 20 x magnification to define an area of interest 
which included both the epidermis and dermis. An image of the area of interest was 
captured and used to guide the positioning of sections on sample holders and establishing 
starting fields X-ray microanalysis on the LEO GEMINI 1530VP FEG-SEM and FEI Magellan 
400 XHR SEM (Figure 6.4B). Images were acquired over 1 hour. All analyses were run at an 
acceleration voltage of 15kV, a current of 100pA and an integration time of 100s. EDX 
spectra were used to ascertain elemental distributions for sodium, potassium or chloride in 
skin sections (Figure 6.5). For both samples, spectra were mapped to digital microscopic 
images of skin sections on silicon slides. For sample 2, in addition, a 4µm H&E section was 
cut at the Addenbrookes Hospital Tissue Bank and compared with elemental maps for 
sodium, potassium and chloride obtained from the FEI Magellan 400 XHR SEM. 
 
Figure 6.4: Procedures prior to SEM-EDX. A: Skin sections on silicon slides were placed in a drying 
cupboard to remove moisture. B: Skin sections were then placed in the FEI Magellan 400 XHR SEM 





Figure 6.5: Examples of EDX spectra output. A: Output from the LEO GEMINI 1530VP FEG-SEM 
showing a SEM image of a sample and the area of interest in the yellow box and the elemental 
spectra detected within it.  B: Output from the FEI Magellan 400 XHR SEM with SEM image of a 









6.4.2.1     Samples 
 
Tissue bank skin sample from a 23-year-old woman and skin samples post-placebo and slow 
sodium for a 20-year-old male Caucasian VARSITY participant were used to assess the 
feasibility of immunohistochemical localisation of ENaC α subunits. 
 
6.4.2.2     Paraffin embedding 
 
4 µm sections were cut from 3 skin samples and embedded in paraffin by the Tissue Bank 
using their unit procedures. 
 
6.4.2.3     Skin ENaC staining procedure 
 
Staining procedure was carried out with DAKO Envision® Plus Kits (Denmark) by Miss 
Nichola Figg, Laboratory Manager at the EMIT unit using the following procedures. 
 
Slides with skin sections from the Tissue Bank were deparaffinized through three changes of 
Histoclear, incubating slides for 10 min in each change. Slides were then rehydrated by 
dipping them decreasing strengths of ethanol followed by distilled water. Slides were placed 
in a microwave slide dish and covered with citrate buffer. Antigen retrieval was performed 
using the Prestige Medical 2100 Retriever and slides were allowed to cool for a minimum of 
30 minutes before being rinsed in distilled water and placed in phosphate-buffered saline 
(PBS). Endogenous peroxidase activity was blocked using a pre-prepared solution from the 
DAKO kit and before rinsing in PBS. The primary antibody against ENaC α or negative control 
solution was then applied at a concentration of 1:10,000 and incubated for 2 hours at room 
temp. Rabbit anti-human epithelial sodium channel gamma antibody (ab3468, Abcam, UK) 
was used as the primary antibody against ENaC α. A rabbit IgG control antibody (DAKO, 
Denmark) was used for the negative control solution. Slides were then rinsed again with 
PBS. Counterstaining with haematoxylin (DAKO S3309) was carried out for 10 seconds.  
Slides were dipped five times in dilute ammonia water and then rinsed in tap water. Slides 
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were dehydrated in 95% ethanol followed by three changes of 100% ethanol. Slides were 
cleared in Histoclear and coverslips applied.  
 
Skin sections were reviewed by myself under a digital light microscope (OLYMPUS BX51). 
Findings were confirmed with Dr George Meligonis, Consultant Pathologist at the 


































6.5     RESULTS 
 
6.5.1     SEM-EDX 
 
EDX spectra from the LEO GEMINI 1530VP FEG-SEM system for Sample 1 are shown below in 
Figure 6.5. Sample 1 was 3.72 mm long on its longitudinal axis. The intensities for sodium, 
potassium and chloride are given in keV and these show variations from epidermis to dermis 
layers. Sodium intensities were significant in the dermis and lower epidermis. Potassium 
intensities showed it was present in both layers. Chloride intensities were generally lower 
than sodium and potassium, and its distribution was mainly in the dermis. 
 
 
Figure 6.6: EDX spectra for Sample 1 showing elemental intensity. The violet lines represent 
sodium, potassium and chloride elemental intensities along the epidermis and dermis, which are 
separated by the dotted green line. The 30 μm section used is shown on the right.  
 
 
Elemental maps generated from the EDX spectra from the FEI Magellan 400 XHR SEM for 
sample 2 are shown below in Figure 6.7. Sample 2 was 1.5 mm long on its longitudinal axis. 
The colour intensities show elemental concentrations in the epidermal and dermal layers, 
separated by the dotted yellow lines. Sodium distribution was significant in the dermis and 
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lower epidermis. Distribution of potassium was decreased moving up the epidermis and 
generally lower than sodium in the dermis. Chloride did not show any clear variation in 
distribution in the epidermis or dermis.  
 
 
Figure 6.7: EDX spectra for Sample 2 showing elemental maps sodium, potassium and chloride. 
Elemental intensities are denoted by intensity of colour. The epidermis and dermis are separated 
by the dotted yellow line. The 35 μm section used is showed second from the left, with skin layers 
identified and the defined area of interest shown in the red box. A corresponding H&E section for 




In both analyses, skin sections had to be replaced several times because of damage during 
the thawing procedure, resulting in skin tissue folding back off the silicon slide. This was 
detrimental for the structural integrity of the epidermis for analysis of elemental 
distributions.   
 
6.5.2     Skin immunohistochemistry 
 
Results for skin immunohistochemical localisation of ENaC-α are shown in Figures 6.8 - 6.10. 
In Figures 6.8 and 6.9, ENaC-α staining in breast skin appeared to be present mainly in the 
lower epidermis, corresponding with the stratum basale, stratum spinosum and granulosum 
in Figure 6.9. Under 20x magnification staining appeared to be nucleolar or cytoplasmic 





Figure 6.8: ENaC-α staining in a 4 µm section of breast skin in a 23 year-old woman under 10x 
magnification. ENaC-α is distributed in the lower layers of epidermis. The corresponding negative 





Figure 6.9: The same breast skin section under 20x magnification. ENaC-α staining (red arrow) 





ENaC-α staining in the 20 year-old male Caucasian VARSITY participant is shown in Figure 
6.10. Staining was evident in most of the epidermis and appeared to be more prominent on 
the low salt diet.  
 
Figure 6.10: ENaC-α staining in a 4 µm section of lower back skin from a 20 year-old male 
Caucasian VARSITY participant under 20x magnification. ENaC-α distribution in the epidermis is 

















6.6     DISCUSSION 
 
This study demonstrated that SEM-EDX can be used to study skin elemental patterns in 
human skin and that ENaC α immunohistochemical localisation is possible, showing 
significant ENaC presence in the epidermis.  
 
In the SEM-EDX technique described, sodium, potassium and chloride distributions were 
seen in the epidermis and dermis. It was not possible to show the distribution of these 
elements in each layer of the epidermis as maintaining structural integrity of the epidermis 
was challenging and cryosections of less than 30µm repeatedly proved unsuccessful due to 
structural fragility during thawing. Sample 1 had a higher concentration of Na+ as 
determined by ICP-OES, with evidence of a high ‘band’ of sodium in the epidermis which 
probably corresponded with the stratum basale, stratum spinosum and granulosum. This is 
in keeping with previous studies done with electron probe analysis and X-ray microanalysis 
in human skin. 308-310 In Sample 2 it was not possible to see a similar band using element 
intensity maps, which were less precise at showing the variation in element intensity. 
Samples 1 and 2 had a significant difference in skin K+ as determined by ICP-OES (0.76 vs. 
1.66 mg/g respectively). Sample 2 appeared to have a high potassium content in the 
epidermis as reflected in the element intensity map, while in Sample 1 potassium appeared 
to decrease moving up the layers of the epidermis, which could potentially occur with 
damage to the keratinocytes, releasing intracellular potassium during the skin sample 
preparation. Chloride levels appeared to be lower than sodium in both epidermis and 
dermis with no discernible pattern seen. The respective elemental intensity readings shown 
in Figure 6.6 correspond with animal data on skin Na+, K+ and Cl- using atomic spectrometry. 
This showed that skin Cl- was around 50-60% of skin Na+ while skin K+ was 60-70 % of skin 
Na+. In Chapter 3, skin K+ appeared to be lower in women than in men (Table 3.4) and lower 
in the Tissue Bank breast skin samples compared to VARSITY methods (Table 3.7). This could 
be explained by sex differences in  epidermal thickness if there is a high concentration of K+ 
in the epidermis, which is more cellular than the dermis. 188,260 This difference significantly 




The findings for immunohistochemical localisation of ENaC are preliminary and inconclusive 
but show that ENaC α has a significant presence in the epidermis. Several studies have 
assessed the presence of ENaC in human skin, yielding little insight into its function. 
311,316,317,321,322 Recently Honukoglu et al mapped the sites of localization of ENaC α in the 
human skin by confocal microscopy using polyclonal antibodies generated against human 
ENaC α. They showed that ENaC α exists in all epidermal layers except stratum corneum, 
and also in the sebaceous glands, eccrine glands, arrector pili smooth muscle cells, and 
intra-dermal adipocytes. In the comparison of skin ENaC α staining during different salt 
intakes, there was an impression that ENaC expression was lower with high salt intake. This 
would concur with the decrease in aldosterone levels during high salt seen in the VARSITY 
study. The relevance of this to sodium homeostasis and BP is unclear. Hanukoglu et al 
observed that ENaC α had a cytoplasmic distribution, as seen in this analysis,  the nature of 
which is not understood. 317 It would also be relevant to study the effects of increased ENaC 
activity in in humans with Liddle’s syndrome to see the effects on skin sodium distribution.  
 
In conclusion, this work shows that skin elemental distributions can be mapped out using 
SEM-EDX and immunohistochemical localisation of ENaC is feasible. Further development of 
these techniques to show better definition of epidermis elemental distribution patterns 
through better tissue preservation techniques and the possible use of confocal microscopy 
to ascertain the location of ENaC in the skin should be attempted. There were no conclusive 
findings regarding any possible underlying countercurrent system functioning in the skin, 
though was is a suggestion of high sodium distribution in the lower epidermis coinciding 
with the presence of ENaC α. Further work would be needed to confirm if ENaC is relevant 









Chapter 7     Conclusions and Future Directions 
 
7.1 SUMMARY AND CONCLUSIONS 
 
Excessive dietary sodium, principally as the chloride salt, has long been considered a pivotal 
factor in development of hypertension, an important modifiable risk factor for 
cardiovascular disease. 1,3,4,28 However, the haemodynamic response to salt intake is 
variable, with only some individuals showing salt sensitivity of blood pressure. 43,44 Current 
knowledge of the relationship between dietary sodium and BP fails to explain this 
heterogeneity in human response to sodium intake. We are now witnessing a paradigm shift 
away from the traditional nephrocentric view that pressure natriuresis exclusively 
determines salt sensitivity. The skin is now emerging as a potentially important site of extra-
renal sodium homeostasis and BP regulation. Studies in rodent models have highlighted the 
relevance of interstitial electrolytes and the roles played by GAGs, the lymphatics and cells 
of the mononuclear phagocytotic system in buffering the haemodynamic effects of dietary 
salt. 133,134,152 It has been proposed that sodium in the skin may have certain distribution 
patterns that facilitate water conservation. 208 On this background, the principle hypothesis 
of this thesis is that the skin functions as a buffer for dietary sodium and modulates its 
haemodynamic effects.  
  
In Chapters 2 and 3 the feasibility of measuring skin Na+and K+ concentrations using ICP-OES 
was shown using skin samples obtained from the Tissue Bank and skin biopsies in healthy 
volunteers. The values obtained for skin Na+and K+ were similar to previous studies of direct 
chemical measurements in full thickness human skin. The observed skin Na+: water ratios 
support the existence of non-osmotic sodium storage in the skin, as seen in previous studies 
in rodents. 132,133,244,245 In Chapter 3 the observed average skin Na+ concentration value of 
2.15 mg/g of wet weight approximates to 10 - 14 % of total body sodium, suggesting that 
the skin is a reservoir for sodium in humans. 263 The water content in skin was found to be 
62%. Thus, in a 70 kg human with 4.2 kg of skin, this would approximate to 2.6 litres of 
water. Skin Na+ was not seen to increase with age, as shown in previous  23Na-MRI studies, 
and this could have been due to the study size and narrow age rage in the study. 197,204 The 
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observed skin Na+ values in mmol/l were lower than seen with 23Na MRI. 195,197-204  It is 
possible that Na+ bound to GAGs and ionised Na+, as well as intracellular and extracellular 
sodium are detected differently by 23Na MRI. This could lead to a discordance between 
direct chemical measurements and 23Na MRI measurements or observed correlations. There 
was a trend for lower skin Na+ in women in VARSITY methods, in keeping with the findings in 
23Na MRI data. This could be because men have a thicker epidermis and dermis at all ages 
and may have higher levels of dermal glycosaminoglycans, leading to sex-specific difference 
in skin Na+ storage 261,262 Skin K+ was lower in women and this be due to the epidermis being 
thinner in women. 188,260  
 
In Chapter 4 skin Na+ and K+ was measured in 48 healthy volunteers in the VARSITY study, 
using the techniques developed in Chapters 2 and 3, to observe the effects of varying salt 
intake on skin electrolytes alongside haemodynamic and biochemical measurements. In 
addition, the effects of varying salt intake on plasma VEGF-C, salt taste sensitivity and skin 
capillary density were examined. Skin sodium was expressed as the Na+:K+ ratio due to non-
uniform water removal from samples. Skin Na+:K+ increased with dietary salt loading and 
showed a significant interaction with sex because women had lower skin K+ and higher 
Na+:K+ ratios. Post-hoc sex-specific analyses showed that with dietary salt loading, men had 
a rise in skin Na+:K+ with no rise in BP, while women had a rise in ambulatory BP and no 
significant rise in skin Na+:K+. This supports the hypothesis that the skin buffers increase in 
body sodium and the degree of change in skin sodium with dietary salt loading relates to the 
BP change. In this study this occurred in a sex-specific manner. Possible explanations include 
sex-specific skin structural differences, as described above, and greater sodium flux in men, 
enabling skin in men to function as a more effective buffer in men.  Plasma VEGF-C did not 
show change with dietary salt modulation and the relevance to skin VEGF-C are unclear. 
Correlations were seen between skin Na+:K+ and MAP, stroke volume and PVR during high 
and low salt intakes. Skin Na+:K+ correlated positively with plasma VEGF-C during high salt 
intake. These correlations were only observed in men, possibly because of the effects of 
contraceptive use on skin K+ in women. A distinction should be made between the role of 
skin Na+ in influencing BP in short term and long-term high-salt intake. In short-term salt 
loading, as in the case of the VARSITY study, dermal Na+ storage may have buffered the BP 
response to salt. Long-term (months), the ability to maintain normal BP in the face of high 
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salt intake is dependent on the ability to decrease PVR. 323 The positive correlation seen 
between skin Na+:K+ and PVR suggests that skin Na+ accumulation may, in the long-term, 
lead to higher BP by increasing PVR. This is supported by cross-sectional 23Na MRI data 
showing that skin Na+ storage higher in hypertensives and positively correlates with BP. 
197,204 VARSITY was a short-term study and a salt loading over a longer period may not have 
been ethical. Chronic skin electrolyte changes in response to changes in salt intake may be 
different.  
 
In the analysis of salt taste sensitivity, salt detection threshold, or the lowest concentration 
at which participants could distinguish between ROS water and salt solution, increased with 
dietary salt loading. Thus, participants were less able to identify saltiness on a higher salt 
intake. No change in salt recognition threshold was noted. This would suggest that 
individuals became less aware of the taste of salt with greater salt intake or adapted to a 
higher salt intake, supporting the role of habituation in determining salt intake, as previously 
described. 324 
 
In Chapter 4, skin capillary density was assessed in a group of 20 participants and appeared 
to decrease with dietary salt loading. This would imply that high salt intake decreases 
capillary blood flow in the skin. The observation that capillary density increased with venous 
occlusion only post slow sodium further supports the theory that blood flow in capillaries 
was attenuated with high salt intake. This could be explained by an increase in PVR in the 
skin due to increased arteriolar tone in the dermis. The measured PVR in this group did not 
show significant change, with a trend for decrease in PVR (Table 4.17). It is unknown if skin 
PVR changes can occur independent of PVR elsewhere in the body. The observation that 
blood flow in the skin is highly dynamic in mediating thermoregulation, ranging from as low 
as 1% rising to as high as 60-70%, may support this. 211,212The finding that salt intake is linked 
to dermal vasculature is interesting and possible mechanisms would need to be explored in 
more detail in further studies.  
 
In Chapter 5 specific skin gene expression changes were assessed in a sub-set of 20 
participants with characteristics and sex-specific differences similar to the main VARSITY 
study population. This study found that women showed an increase in HIF-2α and an 
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increase in ambulatory BP with increased salt intake, while men showed no increase in 
either HIF-2α or BP. This would concur with studies in rodents, showing opposing effects of 
HIF-1α and HIF-2α on NO availability, with greater HIF-2α expression causing higher BP. 217 
Changes in gene expression of HIF-1α and PHD2 could have been missed at 7 days. It is 
unknown if changes in skin Na+, skin hypertonicity or systemic factors altered by dietary salt 
intake could have influenced PHD2 activity and consequently increased HIF-2α gene 
expression. It is also unclear if the difference in HIF-2 gene expression with salt loading 
represent sex differences or differences in salt sensitivity. Previous work on skin HIF isomers 
in rodents involved male animals and sex differences were not assessed. Very recent work in 
mice and humans in the MARS 500 study have shown that increased salt intake increases 
urea genesis by the liver and this accumulates in the renal medulla, acting as a driving force 
to facilitate renal water reabsorption. 325,326 This novel mechanism has been proposed as a 
means to limit water loss through natriuresis during dietary salt loading. Increased dermal 
HIF-2α expression with high salt intake would induce arginase-1, which catalyses the 
hydrolysis of L-arginine to l-ornithine and urea, increasing urea levels in the skin. 218,302,303 In 
support of this, recent work in rodents has shown that the urea gradient from the epidermis 
to dermis increased with salt loading, suggesting that high salt intake increases ureagenesis 
in keratinocytes. 327 This would reduce water loss in the skin and limit hypertonicity in the 
skin during periods of high salt intake. Thus, dermal HIF-2α could potentially complement 
the TonEBP - VEGF-C axis in addition to the haemodynamic response to salt loading. (Figure 
7.1)  No changes were observed in gene expression for GAG polymerisation, Ton-EBP or 
VEGF-C, which were shown in studies in rodents. 133,134,152 Possible explanations would 
include discordance between gene expression and protein expression for these factors in 
humans and the significantly greater duration and extent of salt loading in rodents 
compared to humans in the VARSITY study, implying that similar degrees of skin 








Figure 7.1: The Ton EBP-VEGF-C axis and HIF-isomers in the skin responding to high salt intake. 
VEGF-C secretion expands dermal lymphatics, allowing movement of water and electrolytes from 
the skin to the systemic circulation. PHD2 inhibition by high salt intake results in increased 
expression of HIF-1α and HIF-2α. HIF-1α increases NO expression via action on iNOS while HIF-2α 
increases urea genesis. Urea causes an osmolyte gradient that could potentially limit water loss 




Chapter 6 addressed the feasibility of using SEM-EDX to study how sodium, potassium or 
chloride are distributed in the skin. The feasibility of immunohistochemical localisation of 
ENaC sodium transporter in the skin was also analysed with a view to assessing whether this 
is involved in skin sodium distribution. Using the LEO GEMINI 1530VP FEG-SEM and FEI 
Magellan 400 XHR SEM systems, skin distributions for sodium, potassium or chloride in skin 
sections were evaluated. Sodium appears to be present in the lower epidermis, where 
immunohistochemical localisation of ENaC was found. Adequate structural detail of sodium 
distribution in the epidermal layers was not possible and further work developing methods 
for skin section structural preservation during freezing and drying is required. It is possible 
that ENaC facilitates sodium flux between the epidermis and dermis. Sex steroids have 
recently been found to influence ENaC expression in animal models in various tissues and 
could potentially explain sex differences in sodium flux within the skin. 328-330 Chloride 
appears to exist within the dermis while potassium may be concentrated in the epidermis, 
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potentially explaining observed sex differences in skin potassium.  
 
7.2     FUTURE WORK   
 
There are several further studies that should be done to confirm and build on the findings of 
this thesis.  
 
A study of dietary salt loading, similar to the VARSITY study, should be done with greater 
numbers to enable sex comparisons and comparisons between women on and without 
contraceptive treatment. Similar studies should also be conducted in older people, other 
ethnicities and hypertensives.  
 
Currently, there is an ongoing study at the EMIT unit looking at the effects of sodium 
depletion with thiazide use on skin sodium. This study plans to validate a new 23Na MRI 
technique in Cambridge by comparing sodium measurements obtained by direct chemical 
measurements (ICP-OES) and 23Na MRI. Upon validation, this 23Na MRI technique can 
eventually be used in larger cohorts such as the AIM-HY study, a multi-centre study running 
at the EMIT unit with the aim of identifying differential responses to antihypertensive drugs 
by ethnicity. This would show the effects of antihypertensives, diuretics in particular, on skin 
sodium and the relevance to BP response to treatment. This would potentially also show the 
effects of race on skin Na+ responses.  
 
Chloride could not be measured with ICP-OES, and techniques to evaluate skin chloride 
changes and how they relate to BP changes and other haemodynamic measurements are 
required.   
 
The relevance of HIF isomers in modulating the effects of salt intake on systemic BP should 
be evaluated by salt loading keratinocyte-specific mutant mice with HIF-1α and HIF-2α 
deletions respectively, to see if the latter show greater salt sensitivity. Previous work by 
Cowburn et al could be repeated to include mice of both sexes, to see if HIF-1α or HIF-2α 
responses differ by sex.  
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Skin electrolytes, BP and response to dietary salt loading should be examined in the skin of 
mice in which the keratinocyte epithelial sodium channel alpha subunit had been deleted, 
to ascertain the influence of epidermal ENaC on these parameters. 315,316 SEM-EDX analysis 
of skin sodium distributions should be done in patients with Liddle’s syndrome and 
compared to healthy volunteers, to observe the effects of increased ENaC activity on skin 
Na+ quantity and distribution. This could reveal whether humans with this sodium 
channelopathy have extra-renal mechanisms for hypertension.  
 
In summary, it appears that the skin is a buffer for dietary salt, influencing the regulation of 
salt sensitivity, and this is affected by sex. The skin has yet undefined pathways and 
mechanisms for sodium homeostasis and regulation of the vasculature that merit 
investigation. Some of these may explain sex differences in the haemodynamic response to 
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